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5 
1. Introduction 
 
“Taste is more than a sensual experience: it is a signal of nutritional value or danger. It has 
evolved as a vital survival mechanism in mammals and driven epic periods of human history — it 
was, after all, the quest for spices that helped launch the age of exploration1,2. Yet our 
understanding of how taste works has lagged behind the other senses.”  
 
With this fascinating sentence begins the editorial of Herbert Brody for the recent issue of Nature 
dedicated to taste. It highlights the centrality of this experience which finds countless implications 
in history, art, science, food industry, and obviously cooking, and which can also have beneficial 
therapeutic implications with relevant outcomes in drug discovery. 
The way by which food is experienced is not limited to the mouth — odour, vision, hearing and 
even touch can profoundly change the taste thus affecting food preference. All starts before birth, 
since amniotic fluid contains glucose, fructose, fatty acids and amino acids, and newborns prefer the 
sweet taste of mother milk to other flavours. 
The basic tastes include sweet, bitter, sour, and salty, even though this exclusive club might admit 
new members. After umami, the glutamate-dependent tastefulness, other recognized tastes include 
carbonation, metallic and fattiness. 
Notably, taste is a whole-body experience since taste receptors, besides being located in the taste 
buds, are also found in non-sensory tissues, like the gut or the airways, playing still not completely 
known roles, for example, in glucose metabolism as well as in energy homeostasis.  
Synthetic ligands for “taste” receptors can found several potential applications as both nutritional 
and therapeutic agents. With regard to medicinal perspectives, one may hypothesize that metabolic 
syndrome and diabetes can be treated by artificially activating the taste receptors so as to trick the 
body, which, believing it had eaten, would initiate the release of hormones from the gut, pancreas 
and fat tissues. Not to mentioned that the ability to modulate the taste receptors of fatty acids should 
reduce the natural preference for fatty foods, resulting in new anti-obesity strategies. From a 
nutritional standpoint, taste receptors have received great interest in designing new artificial 
sweeteners, taste enhancers, synthetic flavours and, more in general, a detailed knowledge of taste 
receptors should allow the rational design of new ingredients (ranging from foods stabilizers to drug 
excipients) with an enhanced palatability avoiding (or masking) bitter and sour tastes.   
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1.1 Taste sense. 
 
Taste is the sensory impression of food or other substances on the tongue and is one of the five 
senses. It is produced when a substance interacts with taste receptor cells (TRC) located on taste 
buds. Along with smell (olfaction) and trigeminal nerve stimulation (experiencing texture, pain, and 
temperature), it determines flavours.  
In humans, taste receptors are located on taste buds (gustatory calyculi) and on other areas including 
the upper surface of the tongue and the epiglottis.3 The tongue is covered by thousands of small and 
clearly visible bumps, called papillae. Within each papilla, there are hundreds of taste buds, except 
for the filiform papillae that do not contain taste buds. Moreover, thousands of (between 2000 and 
5000) are located on the back and front of the tongue. Other taste buds are located on the roof, sides 
and back of the mouth, and in the throat. Each taste bud contains from 50 to 100 taste receptor cells. 
Taste buds are able to differentiate among the five basic tastes (i.e., sweetness, sourness, saltiness, 
bitterness, and umami as deeply described later) by detecting interaction with different molecules or 
ions. Relying on this capacity of distinction, the German scientist D.P. Hanig proposed in 1901 the 
so-called “tongue map” hypothesis, according which there are different area on the tongue assigned 
to detect a unique taste. Only first in 1942, with Edwin Boring, and then in 1974, with Virginia 
Collings, this theory have been refuted and replaced by the fact that all tastes are equally detected 
across areas of the tongue. 
From a physiological point of view, a functional distinction can be based on the nature of the 
receptors involved in taste signaling. Sweet, umami, and bitter tastes are triggered by G protein-
coupled receptors (GPCR), on the cell membranes of taste buds, while saltiness and sourness are 
perceived through ion-channels which are activated by alkali metal or hydrogen ions, respectively.4 
 
 
1.1.1 Sweetness. 
 
Sweetness is regarded as a pleasant experience. Foods rich in carbohydrates are commonly 
associated with sweetness, although there are other natural and synthetic compounds which induce a 
sweet sensation at very low concentrations, and as such they can be exploited as non-caloric 
surrogates. Examples of non-sugar sweet substitutes include saccharin, aspartame, acesulfame 
potassium, sucralose, xylitol, erythritol, and stevia. Other compounds, such as miraculin, may alter 
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perception of sweetness itself. The molecular basis for detecting sweetness varies between both 
individuals and species and has only begun to be understood since the late 20th century.  
Studies indicate that sensitivity to sweetness has a very ancient evolutionary beginning, since it is 
present as chemotaxis even in motile bacteria, such as E. coli5. Newborns also prefer high sugar 
concentrations and solutions including sugars sweeter than lactose, the sugar found in breast milk6,7. 
The perception of sweetness is based on the multipoint attachment theory, which involves multiple 
binding sites between a sweetness receptor and a sweet substance. Sweetness shows the highest 
taste recognition threshold, as it is detectable at around 1 part in 200 of sucrose in solution. 
Bitterness has the lowest detection threshold, about 1 part in 2 million of quinine in solution. 
During the evolution, a sweet food was related to an energy source, while bitterness indicates 
toxicity. The high detection threshold for sweetness and low detection threshold for bitterness 
would have predisposed our ancestors to prefer energy-rich foods while completely avoiding bitter-
tasting foods. Even leaf-eating primates prefer immature leaves, which are higher in proteins and 
sugars and lower in fibers and (potentially toxic) secondary metabolites than mature leaves. Thus 
the 'sweet tooth' has an ancient evolutionary origin and, while food processing has changed 
consumption habits, human physiology remains essentially unchanged. 
About the mechanism of sweet sensing and among the involved GPCRs, T1Rs (taste receptor type 
1) is the most important sub-family, followed by T2Rs one. They belong to the C type GPCRs, 
which are characterized by a large extracellular Venus flytrap domain (VFT) harboring the 
orthosteric binding site and which are organized in homo- and hetero-dimers.  
T1R family consists of three members: T1R1 and T1R2 (identified in 19998) and T1R3 (discovered 
in 20019), that dimerize to reach a functional structure. The T1R2-T1R3 heterodimer is the actor of 
the sweet taste sensing10, while the T1R2-T1R3 is responsible for the umami taste11. They are 
expressed in the TRC type II cells as well as in the testis and in small intestine12. 
To prove that the T1R2-T1R3 heterodimer functions as a sweet taste receptor, studies were 
conducted on knockout mice without the genes for T1R2 and/or T1R3. Mice lacking one of the 
genes (T1R2 or T1R3) showed a reduced response to sugars, sweeteners, and D-amino acids, thus 
confirming that the T1R2-T1R3 heterodimer is the main sweet taste receptor in vivo. 
However, knockout mice showed very low, but still measurable responses to very high 
concentrations of natural sugars (>300 mM). This suggests that there may be additional sweet taste 
receptors the activation pathway of which is independent of T1R, or that T1R2 and T1R3 can 
function as sweet receptors also in the absence of their heteromeric partners. In knockout mice 
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lacking both genes, i.e., T1R2 and T1R3, the response to sweeteners has been completely 
eliminated13.  
T1R2-T1R3 heterodimer recognizes a wide variety of sweet substances ranging from natural sugars 
(sucrose, fructose, glucose, maltose), sweet amino acids (D-tryptophan, D-phenylalanine, D-serine), 
the sweeteners (aspartame, cyclamate, saccharin) and sweet proteins (monellin, brazzein, 
thaumatin)14. Humans and mice have different ability to identify sweeteners and sweet proteins. For 
example, mice do not respond to aspartame or monellin, even though the introduction of human 
T1R2 gene into mouse genome assimilated their taste preferences to those seen in humans. 
The sweet signal transduction occurs via two distinct pathways. The first one involves cAMP and 
the second one involves inositol 1,4,5-trisphosphate (IP3). It was shown that sugars cause an 
increase of cAMP, while sweeteners stimulate the production of IP315. 
Briefly, sugars bind the T1R receptor and activate the adenylate cyclase (AC) through Gs protein 
thus converting ATP to cAMP. cAMP can directly cause the influx of cations through cyclic 
nucleotide-dependent ion channels, or it can activate protein kinase A (PKA) that causes them to 
shut down through phosphorylation of the K+ channels of the basal membrane. This leads to TRC 
cell depolarization resulting in the Ca++ influx through voltage-gated calcium channels and 
neurotransmitter release16. Expression of cyclic nucleotide gated ion channel in TRC cells may also 
contribute to membrane depolarization and influx of calcium as induced by an increase of cAMP17.  
Differently, sweetener bind to the T1R receptor and activate Gq proteins. Dissociated subunits Gqα 
or Gqβγ stimulate phospholipase C β2 (PLC β2) that hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacylglycerol (DAG) and IP318. Elevated IP3 levels cause the release of 
calcium ions from intracellular compartments leading to the depolarization of the TRC cell 
membrane and release of neurotransmitter19. Different signaling pathways to sugars and sweeteners 
were found in rat model. Notably, the cAMP level in rat cells after stimulation with sweeteners is 
significantly lower than after sucrose, while the level of IP3 is higher in response to sweeteners than 
in response to sucrose. In response to sugars and sweeteners, TRC cells showed elevated Ca++ level, 
although with high sweetener concentrations the Ca2+ level is independent of the extracellular Ca2+ 
concentration and ruled by the Ca2+ release from intracellular compartments20. 
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1.1.2 Bitterness.  
 
Bitterness is the most sensitive taste and is usually perceived as unpleasant and sharp, even though 
it can be sometimes desirable and intentionally added by various bittering ingredients. Common 
bitter foods and beverages include coffee, unsweetened cocoa, South American mate, bitter gourd, 
olives, citrus peel, many plants in the Brassicaceae family, dandelion greens, wild chicory, and 
escarole. The ethanol confers a bitter taste to alcoholic beverages21, which also contain other bitter 
ingredients such as hops in beer and orange in bitters. Quinine, a typical ingredient of tonic water, is 
also known for its bitter taste. 
Bitterness is particularly relevant to study evolution and has clear toxicological implications since 
many natural bitter compounds are known to be toxic. The ability to detect bitter and toxic 
compounds at low thresholds provides an important protective function22. Various food processing 
techniques able to detoxify otherwise inedible foods, rendering them safe and tasty23. Furthermore, 
use of fire, changes in diet, and avoidance of toxins has led to evolution in human bitter tasting 
resulting in a reduced sensitivity when compared to other species24.  
Several studies have shown that T2Rs, such as T2R38 which is coupled to the G protein gustducin, 
are responsible for the human ability to taste bitter substances25. They were identified by their 
ability to detect known bitter ligands as well as by their morphology since they are surface bound 
and monomeric receptors26. The human T2R family comprises about 25 different taste receptors, 
some of which can recognize a wide variety of bitter compounds. Over 550 bitter molecules have 
been identified, and for about 100 ligands one or more specific receptors have been identified. T2Rs 
are located in the TRC cells of tongue and palate as well as in extra-oral tissues, including the 
airways and upper respiratory tract, where they cause bronchodilation and influence host 
susceptibility to infection. They are also expressed in the gastrointestinal tract, where they play a 
role in the emetic reflex, thus emphasizing their potential therapeutic relevance, although their exact 
non-sensing functions remain partially unknowns27. 
Recent pharmacological studies on T2Rs led to the identification of constitutively active mutants 
(CAMs)28, useful for the identification of new bitter taste blockers, as well as for elucidating the 
mechanisms of T2R activation and their physiological pathways. 
In contrast to the T1Rs, T2R receptors have shorter extracellular N-terminal domain29. Likewise 
T1Rs, these receptors should be able to form dimers, even though there are no clear evidence 
supporting this hypothesis30. T2Rs are coupled with gustducin and are characterized by both highly 
conserved motifs in cytoplasmatic loops and transmembrane domains and variable extracellular 
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regions, structural features which are required for the recognition of structurally heterogeneous 
ligands31. The binding site of the tastants corresponds to the first and the second extracellular loop 
and transmembrane domains TM 1, 2, 3, and 732. 
Although TRC cells express either T1R or T2R receptors in the same taste buds, the T1R and T2R 
receptors are not co-expressed in the same cell33. Most T2Rs are co-expressed in the same subtype 
of TRC cells, which recognize a huge variety of bitter substances, but without distinguishing them. 
Initially, it was thought that bitter substances stimulate all cells expressing T2R receptors, even 
though successive studies have shown that each TRC cell recognizes one or more, but not all bitter 
ligands. These results are explained by Behrens and co-workers, who revealed that human TRC 
cells sensitive to bitter substances express only some T2Rs, and not the entire T2R family34. 
Ligands for T2R receptors are amides, such as denatonium (phenylmethyl-[2-[(2,6-
dimethylphenyl)amino]-2- oxoethyl]-diethylammonium benzoate), alkaloids, such as strychnine, 
caffeine, and quinine, amino acids, urea, fatty acids, phenols, amines, and even potassium, 
magnesium, and calcium salts. Depending on their substrate specificity, T2R receptors can be 
activated by many heterogeneous bitter substances or by a few homogeneous ligands only35. The 
T2R family includes many orphan receptors, for which ligands have not yet been identified. 
 
 
1.1.3 Umami. 
 
The Japanese term umami was proposed by Kikunae Ikeda and can be translated as "pleasant 
savoury taste". Umami taste is detected by receptors for glutamate, which is a common food 
additive added in its salt form as the monosodium glutamate (MSG)36. Hence, umami has to be 
considered as distinct from saltiness, even though there was a long debate whether umami is a basic 
taste since its existence was proposed in 1908. Finally, umami is now recognized as the scientific 
term to describe the taste of glutamates and nucleotides such as guanosine monophosphate (GMP) 
and inosine monophosphate (IMP)37. It is a pleasant long lasting and mouth-watering taste giving a 
coating sensation over the tongue. Umami taste is perceived only in presence of other aroma and is 
acribable to the detection of the glutamate carboxylate anion by specific cells present on the 
tongue38. Its effect is to balance the overall flavour of a dish by enhancing the palatability of many 
foods. Glutamic acid imparts little umami taste, whereas its salts, known as glutamates, give the 
characteristic umami taste. GMP and IMP amplify the effects of glutamate39. Glutamate has a long 
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history in cooking and foods rich in glutamate were used widely in ancient Rome, in medieval 
Byzantine and Arab cuisine, and in China. 
Many foods are rich in ingredients conferring umami taste. Glutamates are found in meats and 
vegetables, whereas inosinate comes mostly from meats and guanylate from vegetables. Thus, foods 
rich in umami taste include fish, shellfish, cured meats, mushrooms, vegetables (e.g., ripe tomatoes, 
Chinese cabbage, spinach, celery, etc.) or green tea, and fermented and aged products (e.g., cheeses, 
shrimp pastes, soy sauce, etc.). The first food rich in umami taste is the breast milk, which contains 
roughly the same umami taste as broths. 
Taste buds on the tongue and other regions of the mouth can detect umami taste, regardless of their 
location. Biochemical studies revealed that the taste receptors responsible for the sense of umami 
are modified forms of mGluR4, mGluR1 and of taste receptor type 1 (T1R1 + T1R3), which are 
expressed in all regions of the tongue bearing taste buds40. 
The mGluR1 and mGluR4 receptors specifically recognize glutamates, whereas T1R1 + T1R3 are 
responsible for the mentioned synergism, although the specific role of each receptor in taste buds 
remains unclear. These GPCRs involve similar signaling pathways includin G proteins beta-gamma, 
PLC β2 and PI3 which mediate release of calcium from intracellular stores41. In turn, Ca2+ activates 
the selective cation channel transient receptor potential melastatin 5 (TRPM5, see Chapter 4) that 
leads to membrane depolarization and the consequent release of ATP and secretion of 
neurotransmitters including serotonin42. 
Cells responding to umami taste do not possess typical synapses, but ATP conveys taste signals to 
gustatory nerves and in turn to the brain that interprets and identifies the taste quality43. mGluRs are 
activated are not sensitive to nucleotides, while T1R1+T1R3 are activated by a broad range of 
amino acids and shows a strongly potentiated response in the presence of nucleotides. Loss of the 
T1R1 or T1R3 genes depresses but not eliminates responses to umami. When mammalian taste 
buds are apically stimulated by umami tastants, their functional responses do not resemble to that of 
a single umami receptor. Thus, umami taste may involve multiple receptors expressed in different 
taste cells. This receptor diversity may emphasize the complex perception of umami taste, with 
different mixtures of amino acids, peptides, and nucleotides producing subtly distinct tastes44. 
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1.1.4 Sourness. 
 
Sourness is the ability to taste acidity. The sourness of a given compound is rated by using an index 
by which all compounds are compared to dilute hydrochloric acid, which stays as reference with a 
sourness index of 1.  
The most common sour foods are fruits, such as lemon, grape, orange, tamarind, and sometimes 
melon. Wine also usually has a sour flavour, and  milk, if not kept correctly, can generate a sour 
taste. Children usually show a greater preference for sour foods than adults, as exemplified by very 
popular sour candies, mostly containing citric acid. 
Various mechanisms have been proposed to detect sour taste. These include acid-sensing ion 
channels (ASICs), hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, and two 
pore domain K+ channels (K2P). Sour taste is detected by a small subset of cells distributed across 
all taste buds, which can be identified by the expression of PKD2L1, Polycystic kidney disease 2-
like 1 protein, (transient receptor potential polycystic 3, TRPP3), although this protein is not 
involved in sour tasting.  
Protons that are abundant in sour foods can directly enter into the taste cells, thus triggering an 
electrical response. Also weak acids, such as acetic acid, which are not fully dissociated at 
physiological pH, can have a similar effect penetrating taste cells and eliciting an electrical 
response. After their intracellular penetration, hydrogen ions inhibit K+ channels, which normally 
hyperpolarize the cell. The combination of these two depolarizing effects fires action potentials and 
releases neurotransmitter within the taste cell.  
 
 
1.1.5 Saltiness. 
 
The saltiness is mostly produced by the sodium ions, even though other metal ions group can also 
confer a taste salty, depending on their similarity to Na+ in terms of size and charge. Similarly to 
what was described for sourness,  also the saltiness of substances is described by an index by which 
each ingredient is compared to sodium chloride (NaCl), which has an reference index value of 145. 
The apical amiloride-sensitive epithelial sodium channel (ENaC) is the major player involved in 
salty sensation as also confirmed by animal experiments. Deletion of ENaC gene causes animals to 
die early, as this channel plays a critical role in the kidneys, lungs, and other organs and this 
hampers the studies concerning the ENaC role in saltiness. To tackle this problem, Zuker and co-
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workers developed an animal model lacking functioning ENaC receptors only in their taste receptor 
cells46. The so engineered mice responded normally to sweet, umami, sour, and bitter tastants with 
no taste for sodium chloride. Even when depleted of salt, mice without ENaC in their taste cells 
showed little interest in saline solutions. “While this result was largely expected, it’s very satisfying 
to validate the theory,” Zuker says.  
The influx of Na+ ions through the EnaC channel directly depolarizes the taste cell and releases 
neurotransmitter onto the afferent nerve fibers (10, 12). ENaC in expressed in TRCs as well as in 
other epithelia where it is essential for salt and water balance. Regardless of expressing tissue, it 
shows some common features including small conductance (∼5 pS), Na+ ∼ Li+ >> K+ ion 
selectivity, regulation by extracellular Na+ (self-inhibition) and intracellular Na+ (feedback 
inhibition), and it is modulated by hormones (e.g., aldosterone, vasopressin, atrial natriuretic 
peptide)47,48
.
 In detail, aldosterone and arginine-vasopressin (AVP) increase ENaC-mediated 
currents, while atrial natriuretic peptide and oxytocin reduce these currents. Clearly, ENaC plays 
key roles in regulating blood pressure and extracellular fluid volume. 
 
 
1.1.6 Fattiness. 
 
Fattiness is the last discovered basic taste and is involved in the natural preference for caloric end 
nutrient foods, thus supporting a primordial instinct by which humans and animals tend to eat foods 
that can improve their survival chances.  
Interestingly, fatty foods send signals to the brain not only through receptors on taste buds but also, 
once they are ingested and absorbed in the gastrointestinal tract, at a systemic level though 
unknown mechanisms. Signals from both taste buds and peripheral tissues are integrated by the 
brain and further reinforce the preference for fatty foods via a reward system.  
Fat tasting is mediated by the free fatty acid receptors (FFAR), a GPCR type A subfamily activated 
by free fatty acids (FFAs), which play important roles not only as essential nutritional components 
but also as signaling molecules in numerous physiological processes. In the last decade, FFARs 
have been derived from the human genome database and identified by the GPCR deorphanization 
strategy. To date, several FFARs have been identified and characterized as critical components in 
various physiological processes. FFARs are classified according to the chain length of their ligands.   
FFA2 and FFA3 are activated by short chain FFAs, GPR84 is activated by medium-chain FFAs, 
whereas FFA1 and GPR120 are activated by medium- or long-chain FFAs. FFARs act as 
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physiological sensors for FFAs contained in food and derived by digestion in the gastrointestinal 
tract. Moreover, they are involved in the regulation of energy metabolism as mediated by insulin 
and incretin as well as by sympathetic system, taste preferences, and inflammatory responses 
related to insulin resistance. Therefore and because FFARs play key roles in relevant 
pathophysiological processes, it comes as no surprise that FFARs represent promising therapeutic 
targets for the treatment of metabolic disorders including type 2 diabetes and metabolic syndrome. 
 
 
1.2 Transient Potential Receptors (TRPs): a general introduction. 
 
Besides the above described main tastes and their signaling pathways, a lot of additional sensations 
(such as pungency, spiciness, coolness, numbness, astringency, metallicness),  mediated by many, 
much less known mechanisms, cooperate to give a 360° taste experience. 
Among the proteins involved in perception of these additional tastes, the Transient receptor 
potential ion channel (TRPs) represent the most involved and physio-pharmacologically interesting 
family. The interest for such ion-channels also derives from the observation that the really few is 
known about their tridimensional structure as well as their mechanism of action and tissue-
dependent roles49,50. 
They are mostly non-selective cation channels, characterized by a low voltage dependence. TRP 
channels are polymodal receptors since they respond to a variety of activation and modulation 
stimuli and are involved in diverse functions such as thermosensation, pheromone reception, and 
regulation of  blood flow and cellular osmotic pressure.  
The first TRP channel was cloned from the fly drosophila. To date, more than fifty diverse genes 
have been individuated among different species, twenty-eight of which have been cloned in 
humans. They are commonly classified in six subfamililies, according to their aminoacidic 
sequences similarity: (i) the “canonical” TRPC (TRPC1-7), (ii) “vanilloid” TRPV (TRPV1-6), (iii) 
“melastatin-related” TRPM (TRPM1-8), (iv) “polycystin-related” TRPP, (v) “mucolipin-related” 
TRPML and (vi) “ankyrin” TRPA51.  
All members have in common the same three-dimensional architecture made of six transmembrane 
segments (S1–S6) , and cytoplasmic N- and C-termini. The six membrane spanning helices can be 
grouped into two functionally different blocks: the first, made of S1-S4, that acts as sensor module 
and hosts the ligand binding domain, and the second, the pore module, made of S5-S6 and the 
relative linker loop, that brings the residues involved in both cations attraction and selectivity.  
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Similarly to the highly homologous Kv channels, a functional TRPs channel appears to be in a 
tetrameric conformation. In detail, a highly conserved segment of 25 amino acids, containing the 
TRP box motif, located in the C-terminus domain, immediately following the last transmembrane 
segment, is thought to stabilize the entire multimeric protein52.  
As anticipate above, TRP channels are characterized by a polymodal behavior which involves a 
variety of activation and regulatory mechanisms, some of which are still not completely known. 
Among the different physical stimuli, one may cite light, temperature, osmolality, mechanical force, 
while chemical factors include pH and endogenous and/or exogenous agonists. These stimuli may 
directly activate the channels or may open them through a indirectly-mediated pathway often 
involving PLC-coupled receptors. Moreover, some TRP channels are constitutively active because 
they are not activated by an identified stimulus.  
Moreover, the polymodal profile is further complicated by the wide localization of TRP channels 
among all the human body. TRP are found not only in sensory tissues, where they play crucial roles 
in sensing pathways, but in non-sensory tissues as well. They are expressed in gastro-enteric 
systems, airways, bladder, pancreas, brain or even genitals, where they are involved in many 
physiologic mechanisms such as homeostasis, glucose metabolism and energy balance or synaptic 
activity, pain feelings and tissues suffering. 
On these grounds, they clearly appears not only as interesting target for sensing modulation, but  
also as potential multi-therapeutic target for the treatment of many pathologic conditions. 
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Aim of the here reported Ph.D studies 
 
As described in the Introduction, taste perception plays a central role and may have relevant (and 
industrial) implications in food-related researches but also in medicinal chemistry and nutraceutical 
science. In these contests, in silico studies can have manifold roles. They can be exploited both in 
rational drug design to optimize already existing ligands and in virtual screening campaigns to find 
new ligands possibly exhibiting new chemotypes. The so designed ligands can found applications 
as synthetic tastants but also they can have a medicinal role since the number of therapeutic 
implications of the taste receptors is exponentially growing. Moreover, computational studies can 
also have a mechanistic role allowing a better understanding of the receptor recognition processes 
and consequently of the activation mechanism at a molecular level. Hence, the numerous 
computational studies recently reported in literature concerning taste receptors come as no surprise.  
Notably, the hitherto published studies involve almost exclusively GPCR proteins involved in taste 
signaling. For example, the bitter receptors have been extensively studied in silico for the relevance 
of predicting the bitter taste of excipients and food additives. Most studies involved homology 
modeling and docking simulations as clearly exemplified by the study of Goddard and co-workers, 
who generated the 3D structure of TAS2R38 bitter receptor and modeled its binding to well-known 
reference agonists53. In some studies, the computed complexes are then validated by targeted MD 
simulations and the so refined models were utilized to suggest key residues whose role was then 
verified by mutagenesis54. 
By considering the richness of already available studies on taste GPCR proteins, we decided to 
focus the here described studies on a completely different family of transmembrane receptors 
variously involved in taste signaling, namely the TRP ion channels. This choice has a three key 
reasons. First, TRP channels play relevant roles in taste perception and in particular TRPM5 (see 
Chapter 4) acts a general door for taste transduction in the gustatory system of bitter, sweet and 
umami tastes, thus suggesting that TRPM5 ligands can have a modulating role for all taste 
perception.  
Second, TRP ligands have notable medicinal roles in analgesia as well as in metabolic related 
diseases such as obesity, diabetes and metabolic syndrome. Moreover, TRPM8 ligands can have a 
relevant therapeutic application in treatment of prostate cancer and recently studies revealed that 
testosterone is a potent endogenous agonist for TRPM8 which thus can play notable roles in many 
testosterone induced effects including psychosomatic traits.  
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Third, a reliable homology model was already generated using a fragmental approach by the group 
where the here reported studies have been conducted. Such a model has already been validated by 
docking simulations and MD simulations which allowed the TRPM8 mechanism of activation to be 
hypothesized at an atomic level.  
On one hand, this model represents a satisfactory starting point for new studies on TRPM8 
including rational design of novel agonists and virtual screening campaigns aimed at finding novel 
potent and selective antagonists (see Chapter 3). On the other hand, the encouraging results already 
obtained by the TRPM8 homology model emphasize that the exploited fragmental approach may be 
conveniently utilized to model other relevant TRP members. Thus, the present thesis describes the 
generation by fragments and the following validation by docking simulations for the TRPM5 (see 
Chapter 4) and TRPV4 (see Chapter 5). Notice that the latter shows a clearly poorer homology 
degree with the TRPM8 and thus its modeling represents a more challenging task compared to that 
of TRPM5 for which the computational strategy already used for TRPM8 could be closely used. 
Lastly, the thesis describes the modeling of TRPV1 as performed using a simple global approach 
based on the use of previously generated TRPV4 model as the template (see Chapter 6). Such a 
simplified strategy has the primary objective to verify whether less computationally demanding 
procedures can be exploited to obtain satisfactory results at least when the two involved models 
show a high degree of similarity (as in the case of TRPV1 and TRPV4). Nevertheless and 
considering the unavoidable approximations introduced by such a simplified approach, more 
TRPV1 homology models were generated and a tailored filtering strategy was applied.  
As a preamble, the here reported studies deserve two major considerations. The first concerns their 
industrial profile which is reflected in the kind of objectives pursued and in the major computational 
strategies adopted. Starting from the key collaborations with Axxam s.p.a. and Dompé s.p.a. which 
inspired and contributed to the computational studies on TRPM8, the same general approach was 
maintained in the following reported studies which were primarily aimed at validating homology 
models and computational protocols to be exploited in virtual screening campaigns. The second 
more technical considerations concern the organization by which the results are here described 
which follows a chronological order. Such an approach might perhaps mix methods and results but 
gives a clear idea of how the here reported studies were developed during the Ph.D period.  
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2. Computational strategies  
 
At the time I started my doctoral activity, among the TRPs family, only the three-dimensional 
structure of the TRPM8 member was already been modelled, by homology techniques55, and 
validated, through molecular docking and molecular dynamics studies56, in the group where I spent 
my Ph.D. course. Hence, the here described TRPM8 studies exploited such a homology model, 
while the studies concerning all others TRP members started from the generation of reliable three-
dimensional models. Indeed and as trans-membrane proteins, the 3D structures of such receptors are 
not easily resolved by crystallographic methods and, thus, their in silico construction was performed 
by homology modelling. 
 
 
2.1 Homology modelling. 
 
Known also as comparative modelling, it is a computational technique which allows the generation 
of  the three-dimensional structure for a given protein (target) by exploiting its amino acid sequence 
similarity with one or more proteins (templates), the structures of which have already been 
experimentally resolved. This method is based on the assumption that two proteins with high 
sequence similarity have similar secondary and tertiary structure. This hypothesis is supported by 
experimental evidence in which denatured proteins, placed in renaturating conditions, quite similar 
from the physiological point of view of pH and ionic strength, assume always the original folding. 
Furthermore, chaperones, proteins capable of favouring certain forms of hydrophobic folding, are 
able to recognize specific amino acid sequences, inducing particular arrangements of the protein 
chains. From these lines of evidence, it is clear that the information about the secondary and tertiary 
structure are intrinsically encoded in the primary one (the so-called Anfinsen’s principle). 
Another aspect to be considered is that, often, proteins with high sequence similarity are 
homologous, namely evolutionarily derived from the same ancestral gene: homologous proteins 
often retain the same physiological functions of the ancestor protein. All these considerations 
further corroborate the basic assumption leading to the comparative modelling approaches. 
In daily practice, a choice can be made in terms of which homology modelling program to use, 
since there are many available as online or free downloadable tools. One of the driving reasons to 
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prefer one program rather than another one is, often, the availability of reliable templates and their 
degree of homology with the target protein.  
Highly homologous templates allow the whole protein to be easily modelled. Contrarily, the lower 
is the homology between target and templates, the greater is the need to resort to alternative 
approaches. A convenient example of these different methods involve the subdivision of the 
primary sequence into structural segments that are then aligned and modelled separately. This 
strategy is known as “fragmental approach” and allow to valorise the local homology in order to 
obtain more reliable models. 
Concerning the here reported studies, four different homology modelling programs have been 
utilized depending on the homology level of the available templates.  In the case of low homology, 
I-TASSER and FUGUE were used, while in the case of high homology the choice fell on SWISS-
MODEL or MODELLER. The specific protocols utilized will be detailed in the following charters, 
here a general description of the mentioned methods will be briefly given.  
In detail, I-TASSER57 server is an integrated platform for automated protein structure and function 
prediction based on the “sequence-to-structure-to-function” paradigm. Starting from an amino acid 
sequence, it generates three-dimensional atomic models from multiple threading alignments and 
iterative structural assembly simulations. I-TASSER guarantees a reliable product, quite complete 
and optimized, that needs just a final refinement. On the other hand, among the programs mentioned 
above, it is the most demanding in terms of time of calculation (days or weeks) and doesn’t allow to 
queue more than one request; this makes it a powerful tool to be cautiously used only if opportune. 
Beside I-TASSER, FUGUE58 as well represents a valid alternative for modelling studies depending 
on templates with medium-low homology. In particular, considering its quick feedback, it is useful 
specially for the fragment approach, since it allows to model many small fragments in a short time. 
It can be used as stand-alone solution or, and this is the way I often used it, as optimizing tool for a 
protein modelled by a more detailed and time demanding program, such as I-TASSER, in order to 
improve not correctly modelled local regions. In detail, FUGUE has three key features: (1) 
improved environment-specific substitution tables. Substitutions of an amino acid in a protein 
structure are constrained by its local structural environment, which can be defined in terms of 
secondary structure, solvent accessibility, and hydrogen bonding status. The environment-specific 
substitution tables have been derived from structural alignments in the HOMSTRAD59 database. (2) 
Automatic selection of alignment algorithm with detailed structure-dependent gap penalties. 
FUGUE uses the global-local algorithm to align a sequence-structure pair when they greatly differ 
in length and uses the global algorithm in other cases. The gap penalty at each position of the 
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structure is determined according to its solvent accessibility, its position relative to the secondary 
structure elements (SSEs) and the conservation of the SSEs. (3) Combined information from both 
multiple sequences and multiple structures. FUGUE is designed to align multiple sequences against 
multiple structures to enrich the conservation/variation information. The combination of these three 
key features implemented in FUGUE improves both homology recognition performance and 
alignment accuracy. 
This in case of low homology templates, while in the opposite situation, when the target protein do 
align with high homology a template, SWISS-MODEL60 or MODELLER61 were the preferred 
tools. 
The first is a good compromise between the required time and reliability of the model and indeed it 
is widely used in standard modelling studies. The program compares the target sequence to a single 
template, that can be suggested by the user as well as chosen by the program, and this clearly 
justifies the need of highly homologous templates.  
Lastly, when highly homologous three-dimensional structures are available, the homology 
modelling can be performed by using Modeller, that aligns the sequences and build the models by 
satisfying spatial restraints. The restraints can operate on distances, angles, dihedral angles, pairs of 
dihedral angles and some other spatial features defined by atoms or pseudo atoms. Presently, 
MODELLER automatically derives the restraints only from the known related structures and their 
alignment with the target sequence thus resulting in generated models which are very similar to the 
template structures as long as their sequences are conserved. The so generated models are then 
optimized by exploiting molecular probability density functions (pdf). The molecular pdf for 
comparative modelling is optimized with the variable target function procedure in Cartesian space 
by conjugate gradients minimizations. 
Regardless of the utilized method, homology models are often incomplete because of possible local 
reduced homologies by which it is not possible to generate reliable three-dimensional structures. If 
these local unpredicted regions are not particularly large, simplified ab initio methods can be used 
to remedy the problem. Otherwise, a second homology modelling run, using the same or different 
approaches, should be performed in order to model the missing regions and so to complete the 
predicted structure.  
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2.2 Model Validation. 
 
Once the complete model is generated, it is subjected to a set of refinement processes in order to 
optimize its structure, by minimizing intra-molecular repulsions, which may to arise from the 
substitution of amino acids different from those of the template. The refinement of the highly 
conserved segments, such as the transmembrane helices, involved energy minimizations often 
keeping the backbone atoms fixed to preserve the predicted folding, while the optimization of loop 
segments was markedly more difficult and required specific procedures depending on their length 
and complexity as well as on the availability of reliable templates. To this end, MD runs of the 
protein embedded in suitable environments were utilized to gain a better relaxation and a more 
correct arrangement of whole models. The specific protocols utilized in these refinement phases 
will be detailed in the following chapters. 
Lacking reference structures with which to compare the obtained models, the so generated models 
require a careful validation and their reliability was assessed by two kinds of analysis: (1) a 
structural validation which involved a set of checks through which the model was evaluated by 
using well-known structural parameters (see below) and (2) a functional validation which is focused 
on the binding site(s) and was performed by suitably designed docking simulations with a view to 
assess the predictive power of the analyzed model. 
With regards to structural validation, a first preliminary check had the objective to avoid unphysical 
occurrences such as cis peptide bonds, wrong configurations, improper bond lengths, non-planar 
aromatic rings or colliding side-chains. Then the model underwent to a set of conformational 
analyses which afford an  assessment of the overall quality of the model as compared with well-
refined resolved structures and which also highlight regions that may need further refinement. By 
using specific programs, such as Procheck, this analysis involved the calculation of the percentage 
of residues falling in the allowed regions of the Ramachandran Plot, of the chi-space concerning the 
correct conformation of the side-chains, of the optimal planarity of the aromatic rings. These checks 
involved also the analysis of all non-bonded interactions between different pairs of residues as well 
as of all main-chain bond lengths and bond angles in the model. The analyses produced detailed 
residue-by-residue results thus revealing the protein regions requiring further refinement.  
    
 
 
 
  
 
 
 
22
2.3 Docking set-up. 
 
Since the ligand binding domain (LBD) of the studied receptors was known as were the key 
residues involved in the ligand recognition, the generated models were also validated by analysing 
the binding modes and the interaction features of the complexes obtained by molecular docking.  
As the studies were focused on the competitive antagonism, molecules with antagonist activity were 
collected from literature and patents, following each time appropriates criteria of selection, but at 
the same time maintaining a common thread. In order to ensure statistically significant results and 
considerations, several tens of ligands (from 30 up to 150 molecules) per each receptors have been 
collected with the wider as well as equally represented range of potency as possible. Chemical 
diversity were also take into account, providing challenging test sets. 
Once selected, all test set libraries were prepared by using an automatic script of the VEGAZZ62 
suite of programs which performs the following tasks for each compound: (i) generating the 3D 
structure; (ii) adding the hydrogen atoms; (iii) assigning the atom types and the Gasteiger’s atomic 
charges; (iv) for ionizable molecules, selecting the predominant form at physiological pH; (v) for 
undefined chiral molecules, generating all possible stereoisomers; (vi) minimizing the so obtained 
molecules combining steepest descent and conjugate gradient algorithms. So optimized molecules 
are then ready for molecular docking calculations.  
 
 
2.4 Molecular Docking. 
 
Among so many available docking programs, the present studies mostly involved three programs, 
namely Autodock, PLANTS and LiGen, that represent conceptually different approaches and, as 
such, allow the ligand-protein interaction to be explored from different points of view. 
Autodock63 is a well-known example of stochastic docking program, based on genetic algorithm. 
Relying on grids of interaction energies, pre-calculated in batch mode by the internal tool AutoGrid, 
and based on the macromolecular target and on each type of atom in the ligand, including 
dispersion/repulsion forces and hydrogen bonding energies, AutoDock performs the docking 
calculation exploring the space driven mostly by polar interactions, according to the AMBER force 
field. It allows the flexibility of the ligand, while maintaining the protein atoms fixed. It was 
considered for long time as a landmark in the field of molecular docking, even though it has been 
recently outclassed by a new generation of docking programs, which are characterized be less time-
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demanding calculations, parallel architectures, flexibility of both ligand and protein target and more 
refined scoring functions, which are able to equally account for polar and hydrophobic interactions 
that suitably contribute to the total energy of the so generated complexes.  
Differently, PLANTS64 is a “knowledge-based” molecular modelling program, since it places and 
scores the ligand-protein interactions by comparing them to an internal pattern of interactions and 
evaluating the recurrence. It introduces an innovative approach, based on ACO technique, for 
sampling the search space. in detail, the heuristic search is based on the MAX-MIN Ant System 
(MMAS) algorithm, through which it is possible to calculate the probability of each “ant” to choose 
an appropriate value of the degree of freedom relying on both the heuristics information derived 
from the calculation of potential through the force field, and the influence of “pheromones” 
previously deposited. Since the MMAS algorithm requires that only one solution for iteration can 
be used to deposit a pheromone, by convention, PLANTS uses only the best pose. The update of a 
generic pheromone depends on the score which is calculated for the best solution found for a 
specific iteration: only in cases in which the score has a negative value and that corresponds to a 
situation of high affinity between ligand and receptor, the pheromone is deposited. 
Plants includes two types of docking scores. The first one involves the so-called Piecewise Linear 
Potential (PLP). In this score function, atoms are classified into the following four types: H-bond 
donor, H-bond acceptor, H-bond donor/acceptor, and nonpolar. Each pair of interacting atoms is 
then assigned one of the three interaction types: a H-bond interaction between donors and acceptors, 
a repulsive interaction for donor-donor and acceptor-acceptor contacts, and a dispersion for other 
contacts. The energy of each interaction type is represented by a piecewise linear function, with 
different parameters for different types of interaction. Total PLP Energy is then the sum of 
corresponding energy of each pair of ligand and protein heavy atoms. 
The second Plants score function (CHEMPLP) consists of two parts: the first uses a modified 
version of the PLP function, which includes the estimation of the steric complementarity between 
ligand and receptor, while the second part implements the function CHEMSCORE of the program 
GOLD, that is particularly optimized in estimating the contribution of hydrogen bonds. Differently 
from AUTODOCK score, these scoring account for both electrostatic and hydrophobic interaction, 
equally. 
Since PLANTS can generate multiple solutions very similar following different paths, a specific 
algorithm based on the calculation of the RMSD is able to identify the redundant poses and to keep 
only the most significant one, thus greatly simplifying the analysis of the obtained results. 
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Third, LiGen65 is a “pharmacophore-based” molecular modelling program. It is less known than the 
previous ones since it was released very recently. It consists of a set of modules that work 
sequentially or as standalone tools, according to the user’s need: LiGenPass for binding site 
recognition, LiGenPocket for binding site analysis and structure-based pharmacophore definition, 
LiGenDock for docking and virtual screening, and LiGenBuilder for de novo design. Thus, 
LiGenPocket and LiGenDock are the two modules that constitute the docking engine of LiGen. 
First, LiGenPocket computes volume, shape, and physicochemical properties (donor, acceptor, 
hydrophobic,etc.) of the binding pocket and proposes a pharmacophore model based on these 
characteristics. Then, LiGenDock uses such pharmacophore scheme as the driving force for the 
docking procedure. It strongly depends on the quality of the pharmacophore, but it can perform 
even better than the other utilized programs and it requests much less time for the calculation, 
especially if compared to AutoDock, that requires more than thirty times the time taken by 
PLANTS. 
LiGen scoring function, LiGebScore, for the evaluation of binding free energy in receptor-ligand 
complexes, derives from the well known X-SCORE66 function. It is an empirical scoring function 
that computes the binding free energy as the sum of the van der Waals interactions, hydrogen 
bonding, deformation penalty, and hydrophobic effects between receptor and ligand. Moreover, it is 
able to provide a clear physical meaning of the suitable features for the ligand recognition, such as 
number of hydrogen bonds, hydrophobic zones, or frozen rotatable bonds during the binding 
process.  
 
 
2.5 QSAR and Virtual screening. 
 
Scoring structural and physicochemical properties of so obtained complexes allow us to validate the 
reliability of our homology model in different ways. First, certainly, the canonical QSAR studies. 
By exploiting tens of docking scores, as well as extended sets of ligand-dependent and complex-
related descriptors, it is possible to develop correlative equations with the experimental activities 
that, besides permitting to predict the putative bioactivity of unknown ligands in an hit search 
context, act as benchmark to assess the goodness of the involved model, supporting its reliability 
with their statistical parameters.  
Beside the QSAR analyses, the virtual screening campaigns are raising as effective validation tools 
to assess the reliability of the generated homology models. Virtual screening involves databases 
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made of active compounds dispersed among thousands of “decoy” molecules, performed in order to 
verify the capacity of the receptor to “select” for its ligands. Such a validation strategy appears to be 
particularly effective in the here reported studies which have as primary objective the screening of 
proprietary libraries. 
Virtual screening (VS) is a computational technique used in drug discovery to search libraries of 
small molecules in order to identify those structures which are most likely to bind to a drug target, 
typically a receptor or an enzyme. 
It has been defined as the "automatically evaluating very large libraries of compounds" using 
computer programs. As this definition suggests, VS has largely been a numbers game focusing on 
how the enormous chemical space of over conceivable compounds can be filtered to a manageable 
number of molecules that can be synthesized or purchased, and tested. Although searching the 
entire chemical universe may be a theoretically interesting problem, more practical VS scenarios 
focus on designing and optimizing targeted combinatorial libraries and enriching libraries of 
available compounds from in-house compound repositories or vendor offerings. As the accuracy of 
the method has increased, virtual screening has become an integral part of the drug discovery 
process67.There are two broad categories of screening techniques: ligand-based and structure-based 
approaches. 
In the former, given a set of structurally diverse ligands that binds to a receptor, a pharmacophore 
model of the receptor can be built by exploiting the collective information contained in such set of 
known ligands. A candidate ligand can then be compared to the pharmacophore model to determine 
whether it is compatible with it and therefore likely to bind. 
A different strategy is to develop logic-based rules describing features of substructures and 
chemical properties related to bioactivity using support vector inductive logic programming. These 
logic-based features provide insights into bioactivity which can be understood by medicinal 
chemists. Support vector machine integrate the features to yield QSAR models which are then used 
to screen molecular databases. This approach is well suited for scaffold hopping to identify novel 
active molecules and is implemented in the package INDDEx. Another approach to ligand-based 
virtual screening utilizes 2D chemical similarity analysis methods to scan molecular databases 
against one or more active ligand structures. A popular approach to ligand-based virtual screening is 
based on shape similarity analysis by searching molecules with shape similar to that of known 
actives, considering that such molecules will fit the target's binding site and hence will be likely to 
bind the target. The interested reader can find several prospective reviews of this class of 
approaches in literature. Ligand-based methods typically require a fraction of a second for a single 
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structure comparison operation. A single CPU is enough to perform a large screening within hours, 
even though several comparisons can be made in parallel in order to accelerate the processing of 
very large databases of compounds. 
Contrarily, the structure-based virtual screening involves docking simulations of candidate ligands 
into a target protein followed by a scoring function to evaluate the likelihood that the ligand will 
bind to the protein with high affinity. The size of the task requires a parallel computing 
infrastructure, such as a cluster of Linux systems, running a batch queue processor to handle the 
work, such as Sun Grid Engine or Torque PBS. A means of handling the input from large 
compound libraries is needed. This requires a form of compound database that can be queried by 
the parallel cluster, delivering compounds in parallel to the various computer nodes. Commercial 
database engines may be too ponderous, and a high speed indexing engine may be a better choice. 
Furthermore, it may not be efficient to run one docking simulation per job, because the ramp up 
time of the cluster nodes could easily outstrip the amount of useful work. To solve this problem, it 
is necessary to process batches of compounds in each cluster job, aggregating the results into a log 
file. A secondary process, to analyse the log files and extract high scoring candidates, can then be 
run after the whole calculation has been run. 
Virtual screening (VS) techniques are well established tools in the modern drug discovery process 
and an almost unmanageable number of different VS techniques are available today68. Along with 
that, a plethora of comparative performance assessments has been published in recent years in order 
to support computational chemists in finding the best approach, particularly in the field of structure-
based VS. However, the specific needs and aims of the VS campaigns differ considerably69, and so 
do the fields of application of the different algorithmic approaches. Therefore, comparing different 
VS algorithms is a challenging task, particularly in case of those approaches involving protein–
ligand molecular docking. 
The performance of VS approaches is mostly measured in terms of their ability to discriminate 
between active and inactive compounds. Actives and inactives are thereby injected to the VS 
workflow either as one mixed library or as two dedicated collections. In the latter case, the resulting 
hit lists are combined before the actual analysis of the results. The collection and preparation of 
these compounds at the very beginning of an investigation represents the Achilles’ heel of any 
evaluation of VS protocols. 
About actives, a crucial aspect during the selection for our VS studies is the common mechanism of 
binding of the ligands to the target protein. Since the pharmacophore models in general are able to 
represent only one specific binding mode, one has to make sure that either all compounds of the 
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active set share the identical binding mode or that all possible binding modes are accounted for by 
specific pharmacophore models in a parallel screening. Moreover, the performance assessments of 
the scoring functions and of their ability to predict the protein–ligand affinity require reliable 
bioactivity information. In the best case, all data should be obtained by the same bioassay and 
preferably also by the same laboratory. 
For what concern the inactive compounds, it is common practice to collect the so-called decoys (i.e. 
molecules presumably inactive against the examined target) from structural pools or to create them 
by using virtual combinatorial library generators such as, for example, Ilib Diverse70 and SmiLib 71. 
It has been confirmed by several studies that the characteristics of the known inactive compounds or 
of the decoys molecules chosen for VS assessments have a significant impact on the performances 
of the utilized VS approaches. Both known inactive molecules and decoys are required to meet 
some essential prerequisites in order to achieve meaningful results. The most important need for 
decoys is the similarity of their physicochemical properties to the set of the active compounds.  
Probably one of the best examples for the hidden impact of decoy characteristics on the 
performances of VS techniques is the direct dependence of docking scores on the molecular weight 
of the ligands. It is known that the bigger is the ligand the higher is the computed score of the 
complex, since the number of functional groups and the related interactions grows proportionally.  
In the here reported studies at least three physicochemical properties were utilized in order to design 
unbiased decoy sets. Mass, volume and charge are always taken into account because their 
combination well frame the key features of the simulated ligands, along with descriptors such as 
virtual logP72, number of rotors, and Lipole (encoding for the separation between hydrophobic and 
hydrophilic functional groups within a given molecule), which are checked to better define the 
physicochemical properties of the set. 
Last but not least, an adequate ratio of actives and decoys is necessary for both statistical reasons 
and to be compatible with real-life scenarios73. Only evaluations performed using ‘high-quality 
haystacks’ allow robust conclusions on the performance of the VS methods.  
About this, all collected decoy sets have from 10000 up to 15000 molecules, with a percentage of 
actives toward the target of interest between 1 and 1.5%, a range of values normally used by the 
scientific community since it approximates the random value of actives in non-focused large 
libraries. 
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2.6 Virtual screening validation tools. 
 
Many metrics are currently used to evaluate the performance of ranking methods in virtual 
screening (VS), for instance, the area under the receiver operating characteristic curve (ROC), the 
area under the accumulation curve (AUAC), the average rank of actives, the enrichment factor (EF), 
and the robust initial enhancement (RIE). 
ROC, AUAC, and all averaged rank metrics show the same drawback, called “early recognition 
problem”, since they are unable to evaluate whether the active compounds are focused on the first 
positions of the ordered list and thus they appear to be poor metrics for analysing VS campaigns 
whose purpose is to rank actives very early. Even though their use has often been questioned for the 
arbitrariness of the defined thresholds, the enrichment factors appear to be meaningful when 
comparing virtual screening campaigns performed by using the same ligand dataset, the same 
receptor and different computational approaches (as here performed). The major concern in using 
the enrichment factors in comparative studies is that they are focused on the top-ranking molecules 
and unavoidably ignore what happens in the remaining part of the ranking. 
The goal of virtual screening method is to detect more true positives from a compounds database  
respect to those that would be selected using a random approach. In detail, as schematized in Figure 
2.1, a VS can be seen as a strategy to select a group of molecules (n) among a starting set (N) that 
would contain both active compounds (true positive, TP) and inactive compounds (also called 
decoys, false positive, FP); among the non selected molecules there will be as well active 
compounds (false negative, FN) and decoys (true negative, TN). In order to evaluate the 
performances of such a VS method, by assessing the enrichment of actives from a mixed database, 
several descriptors have been developed.   
Two important values are usually considered in developing these enrichment descriptors: (i) the 
sensitivity74, accounting for the true positive rate (Eq. 1) and (ii) the specificity, that accounts for 
the ratio of  discarded inactives respect to the entire decoys population (Eq. 2).   
 
 
 
  
 
 
 
29
 
 
Figure 2.1 Selection of n molecules  
from a database containing N entriesby a VS protocol. 
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Most enrichment descriptors do not include a weight for the rank that is assigned to the active 
molecules by the VS algorithm, considering only the fraction of selected and not the relative 
positions within the ranking, thus giving rise to the so-called ‘early recognition problem’. 
The relevance of this problem depends on the percentage of the molecules retrieved by a VS 
campaign which will be investigated, e.g., by biological testing. Clearly, this problem becomes a 
crucial issue when only a very restricted fraction of the top-ranked compounds (e.g. 0.1 % or less) 
will be tested and then one needs that these small fraction includes some active compounds. 
Therefore, it is not only important to have a VS protocol that performs well in discriminating 
actives from decoys, but also to have a VS workflow that is able to rank the active compounds at 
the beginning of a rank-ordered list. 
Selectivity and specificity can be utilized to plot the receiver operating characteristic (ROC) curve, 
the area under which is a widely reported metric to evaluate VS performances, since it possesses 
suitable statistical characteristics. For example, it appears to be independent of the ratio of active 
compounds and decoys, even though this aspect was questioned by recent studies; it can be 
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interpreted as the probability that an active compound will be ranked before an inactive molecule; it 
has a value between 0 (worst performance attainable) and 1 (best performance) with 0.5 which 
corresponds to a random picking. 
However, recent works have shown that the area under the ROC curve is clearly completely unable 
to tackle the early recognition problem because it does not depend on the specific ranking of the 
active compounds. Hence, some metrics have been recently proposed which are conceptually 
related to ROC curves but introduce weighting functions to account for the position of the active 
compounds. As an example, the Boltzmann-enhanced discrimination of receiver operating 
characteristic (BEDROC), which is derived as a generalization of ROC, but which addresses the 
“early recognition” problem by incorporating an exponential function to weight the contribution of 
the rank to the final score. 
Another frequently used metric is the enrichment factor EF (Eq. 3). This descriptor takes into 
account the improvement of the hit rate by a VS protocol compared to a random selection75. 
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A flaw of the EF descriptor is its marked dependency on the ratio of active compounds contained in 
the considered set, thus limiting its use in comparing more VS methods only when dealing with the 
same databases of active compounds and decoys. Another disadvantage is that all active compounds 
contribute equally to the measured value, not considering their position within the analyzed subset.  
Thus, also the EF descriptor do not consider the ‘‘early recognition problem’’.  
In relation to EF, the statistical significance of the enrichment (Eq. 4) is used to assess VS 
performance. It describes the probability that a random selection of molecules contains an equal or 
higher number of active compounds than a molecule selection derived by a VS protocol. 
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To grasp a complete picture of all the distribution, avoiding to take blunder considering what 
happens in the best ranked cluster only, in the here reported VS campaigns the results of an 
enrichment study was and represented by an histogram plot as obtained by subdividing the ranking 
into 100 bins. Ideally, the active compounds should be included in the first bins, decrease gradually 
in the following bins and be absent from the last bins. By contrast, a virtual screening which evenly 
distributes the active compounds throughout the ranking should be considered as ineffective 
regardless of how many active ligands are placed in the first bins.  
 
 
 
 
 
 
Figure 2.2 Exemplificative distribution plot derived from (a) a satisfactory 
 and (b) an  unsatisfactory virtual screening, respectively. 
 
 
 
a. 
b. 
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As examples, the first graph (Figure 2.2a) reports a satisfactory screening, since all active 
compounds take place on the left of the plot, falling in the best-ranked bins. Conversely, the second 
one (Figure 2.2b) describes a totally unsuitable screening, since the active compounds fall evenly in 
all bins, including the worst-ranked ones. 
Besides a graphical support for the analysis of virtual screening analyses, these distributions can 
also be exploited to derive a novel parameter which quantitatively describes how much the active 
compounds are focused in the first bins and thus which can be exploited to tackle the “early 
recognition problem” . In detail, this parameter corresponds to the skewness of the distribution 
which is a measure of its asymmetry and is computed by Eq. 5 as the third standardized moment76. 
In a suitable distribution the parameter has to be the largest possible positive number.  
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3.  Computational studies concerning the hTRPM8 ion channel 
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3.1  hTRPM8 and its mechanism of action: an introduction 
 
3.1.1 TRPM8 structural features. 
 
Located on region 2q37.1 of chromosome 2, the human Trpm8 gene spans 102,124 bases, contains 
25 exons and codes for a protein of 1104 amino acids. Several shorter isoforms have been 
described, but they are poorly characterized.  
Structural details about the TRPM8 protein are still quite limited. Like the rest of the TRP channels, 
it has an overall topology similar to that of voltage-gated potassium (Kv) channels, with six 
transmembrane segments (S1–S6) flanked by large amino- and carboxy-termini located 
intracellularly. Charge-neutralizing mutations along segment S4 and S4–S5 linker region have been 
proved to reduce the channel gating, suggesting they are part of the voltage sensor77. The putative 
pore loop is formed by the segment between helices S5 and S6, while within the segments S1-S4, 
referred to as “sensor module”, stays the orthosteric ligand binding domain.  
TRPM8 subunits are thought to tetramerize into functional channels78,79. Oligomerization process of 
TRPM8 is still cloudy, it has been related to a coiled-coil domain at the C-terminal end of the 
protein, even if mutants missing the entire C-terminus have been proved to be able to tetramerize as 
well and to localize to the plasma membrane. The TRP domain, a 25 amino acid motif containing 
the TRP box (EWKFAR), also located within the C-terminal region (within residues 990–1025), is 
known to be important in PIP2 regulation and in the energetics of channel opening, i.e., translating 
drug binding into channel opening80.  
The C-terminus of TRPM8, as well as the TRPV1 one, have proved to contains structural elements 
involved in temperature-dependent gating within several functional studies on chimeric channels81. 
Moreover, the C-terminus accommodates critical sites for the activation of TRPM8 by 
phosphatidylinositol 4,5-bisphosphate (PIP2)82. Actually, little is known about the function of the 
long intra-cytoplasmic N-terminus of TRPM8. It contains four conserved regions, TRPM family 
homology sequences (MHR)83. Several studies showed so far that removing till the first 39 amino 
acids of the protein does not affect channel activity, but larger deletions do give rise to non-
functional channels84.  
Bioinformatic tools predict the presence of five putative phosphorylation sites on the N-terminal 
domain (Ser9, Thr17, Thr32, Ser121, and Ser367), some of which are confirmed protein kinase A 
(PKA) phosphorylation sites85. A short, leucine-rich conserved sequence among TRPM channels, 
  
 
 
 
35
known as the ICF region (indispensable for channel function), has been characterized in some 
detail. TRPM8 proteins lacking this region are still expressed in significant, even if reduced, 
amount at the cell surface but do not constitute functional channels themselves86.  
As discussed later, the main binding sites for chemical agonists and antagonists have been mapped 
within the sensor module of the monomer. In particular, residueTyr745 in the S2 segment is 
involved in channel activation by menthol and also mediates inhibition by SKF9636587. In contrast, 
the agonist effects of icilin require specific residues within the helix S3. 
TRPM8 channels is also subject to post-translational modifications able to affect its function. For 
example, the channel is glycosylated on an asparagine residue in position 934, near the putative 
vestibule of the ion channel pore. This change is not critical for channel assembly or function but it 
modulates the channel activity88. Moreover, glycosylation of TRPM8 affects its association to lipid 
rafts89. Flanking this glycosylation site, two cysteine residues, namely Cys929 and Cys940, are 
proved to be essential for channel function with their disulfide bond90. A recently observed 
modification of TRPM8 consists in the covalent linkage of the protein to repeated units of R-3-
hydroxybutyrate, giving rise to the attachment of large polymeric chains of poly-(R)-3-
hydroxybutyrate (PHB)91. Mutants lacking specific PHB-binding sites showed highly reduced 
response to menthol or cooling.  
 
 
3.1.2 TRPM8 functional features. 
 
TRPM8 is a non-selective cation channel, with modest calcium permeability. The relative 
permeability for Ca2+ versus Na+  (PCa/PNa) has been estimated at 1–3.392. At the single-channel 
level, the current versus voltage relationship of TRPM8 channels is approximated linear with an 
estimated conductance of ~60–70 pS at 20°C, increasing to ~95 pS at 30°C93.  
In sensory neurons and their terminals, TRPM8 is thought to monitor fine changes in ambient 
temperature. In agreement with this physiological role, the gating of TRPM8 shows steep 
temperature dependence, with Q10 estimates around 30–4094. 
Cold activation is accompanied by wide changes in both enthalpy and entropy but leads to relatively 
small changes in free energy95. The molecular mechanism(s) underlying TRPM8 thermal sensitivity 
is still quite unknown. About that, experimental evidences that TRPM8 channels purified from 
bacterial expression system and then reconstituted into planar lipid bilayers can be gated by 
temperature96, in addition to evidences about the thermally sensitive modules identified in TRPM8 
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structure, as well as in other TRP members97, clearly support an intrinsic thermal sensitivity of the 
channel98 . 
A functional feature shared by TRPM8 with other TRP channels is the polymodal activation, that 
makes them signal integrators. Beside chemical stimuli (e.g., menthol), TRPM8 is also gated by 
voltage. In order to better understand the function of the channel it has to be explained how the 
different sensors within the protein communicate with the pore to induce its opening and closing. 
Both low temperature and menthol increase probability of TRPM8 opening99. Moreover, menthol 
sensitizes the activation of TRPM8 by temperature and vice versa.  
The voltage dependence of TRPM8 shows a characteristic outward rectification at depolarized 
transmembrane potentials and a rapid and potential-dependent closure at negative membrane 
potentials. TRPM8 gating charge is reasonably small compared to that of classical voltage-gated 
potassium channels (about 0.6–0.8 e). As a result, small changes in the Gibbs free energy of the 
channel can cause large shifts (>100 mV) in the voltage-activation curve100; while, the shallow 
voltage dependence curve implies a wide gating window, enabling a precise fine-tuning of the 
extent of channel activation rather than an all/none type of response. Charge-neutralizing mutations 
in the TRPM8 domains S4 and the S4–S5 linker, namely on Arg842 and Lys856, have proved to 
reduce the gating charge, suggesting that this region is part of the voltage-sensing domain, as 
happens in voltage-dependent potassium channels (Kv). 
A detailed characterization of both voltage- and temperature-dependent gating of TRPM8 channels 
at the single-channel level showed an intricate gating mechanism. The observed increased channel 
open probability, caused by cooling or membrane depolarization, appeared to be mainly due to a 
decrease in closure intervals duration time, showing only a modest increase in mean open times. 
This behaviour would fit much more to a multi-state gating model, in which would exist at least two 
open and five closed states. Coherently, expression of short TRPM8 isoforms in prostate 
downregulated the channel activated by cold or menthol, but did not lead to any change if activated 
by icilin101.  
At the single channel level, the effect of short isoforms co-expression mimicked the effects of high 
temperature (i.e., long closures). In native channels, the apparent temperature activation curve of 
TRPM8 is shifted to temperatures warmer then the ones related to recombinant TRPM8 channels 
expressed in hippocampal neurons102. This shift is in line with an apparent shift in voltage-
dependent activation toward more negative potentials. Altogether, this would explain the important 
difference in thermal threshold observed between cold thermo-receptor fibers expressing TRPM8 
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and recombinant channels. In line with this behaviour, static warm ambient temperatures have 
proved to shift the temperature threshold of TRPM8 to warmer values103 .  
The TRPM8 polymodal activation has stimulated the development of several models aiming to 
describe the relation between chemicals binding and channel gating. In 2004, Nilius and colleagues 
proposed that cooling and menthol activate TRPM8 through a shift in the voltage dependence of 
activation (V1/2). In more detail, both agonists would shift the TRPM8 voltage-activation curve  
towards more negative potentials, so increasing the probability of channel openings and 
encouraging inward currents at physiological membrane potentials. A two-state gating model, with 
a direct coupling of temperature and voltage, reproduced the macroscopic G/V curves correctly and 
could adequately predict the temperature dependence of TRPM8 whole-cell currents at different 
potentials. However, the complexities of the gating of single TRPM8 channel indicate that multi-
state models would better explain the gating mechanisms104.  
Differenty, Latorre and collegues proposed an allosteric model in which TRPM8 gating activation 
by voltage and temperature lead to augment the open probability of the channel both separately and 
in concert. In this view, sensors for voltage, chemical agonists, and temperature would be located in 
different protein domains. In this direction, Matta and Ahern found that very high agonist 
concentrations are able to activate TRPM8 in a totally independently from voltage, while voltage 
alone cannot completely activate TRPM8105, which would be the case if voltage was the final gate 
in channel activation (two-state model). While the allosteric model would seem to reproduce 
experimental data, the independence of the many fit parameters is not obvious at all. 
As highlighted by Zhu106, it is a challenging issue to understand the key differences between the 
allosteric model and the two-state model, since this mechanisms can be influenced by experimental 
factors such as desensitization or voltage clamp errors. In a more recent publication, Voets 
etcelleagues generated a Monod–Wyman–Changeux (MWC)107 model explaining the combined 
effects of voltage, temperature, and menthol on TRPM8 gating. The model was proved to faithfully 
reproduce experimental data, predicting the menthol-related shifts in both the voltage-activation 
curves and the temperature activation threshold. Practically, without the ligand, the MWC channel 
is reduced to a two-state model. In practice, the MWC model appears to be able to predict voltage- 
and time-dependent kinetics, while being more simple than the allosteric one. Nevertheless, this 
model cannot accommodate data which point to a menthol-induced increase in the maximum open 
probability. 
Finally, Yang et colleagues, working on the TRPM8 thermodynamics, reformulated the allosteric 
model idea, proposing that activation of TRPM8 by temperature, voltage, and menthol constitutes 
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three stand-alone mechanisms. It remains to be clarify how this view can be consolidated with the 
existing data of agonist-induced effects on TRPM8 voltage dependence. In a recent publication, 
Jara-Oseguera and Islas introduced a novel hypothesis about the allosteric modulation of the 
temperature-dependent TRP channels activation. In a MWC-type model, they showed that a large 
decreasing of the coupling constant between temperature sensor activation and channel gating could 
reverse the sign of the temperature sensitivity108. Practically, TRPM8 channel would bring a heat 
sensor negatively coupled to the gate that during cooling would cause the opening of the channel. 
 
 
3.1.3 TRPM8 expression. 
 
TRPM8 channel was originally cloned from prostate tissue109 and named Trp-p8, before being 
detected in a subpopulation of small-diameter cold-sensitive peripheral sensory neurons110. 
Following investigations using knockout mice lacking functional TRPM8 led to attest that it plays a 
crucial role in detecting cold temperatures in the environment111. 
Moreover, TRPM8 was proved to be strongly upregulated in several tumoral conditions, originally 
in testis and prostate, but recently even in many other cancerous tissues112. In prostate, healthy or 
cancerous as well, TRPM8 gene expression is regulated by androgen receptors, but the precise 
subcellular localization of TRPM8 in this tissue is somewhat controversial, apparently depending 
on the oncogenic status. 
 
 
3.1.4 TRPM8 physiology. 
 
Relying on the detection of TRPM8 in a subclass of thermo-sensitive peripheral sensory neurons, 
early studies investigated its putative role in temperature perception and pain.  
Diverse sensations can follow to cold temperature sensing, going from pleasant to painful as 
temperature decreases. These sensations are thought to derive from activity in sensory fibers with 
different thermal thresholds. 
Exposing the skin to mild cold temperatures excites a subset of peripheral somatosensory neurons. 
In the same fibers, menthol appears to sensitize the response to low temperatures, behaviour known 
as “cooling mimetic action”. Both cooling and menthol are able to generate inward depolarizing 
currents which in turn depolarizes the cell and releases the chemical signal113. Evidences from 
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several experimental studies run on cold-sensitive neurons showed how the non-selective cation 
current (Icold) reports physical/chemical properties in line with TRPM8-dependent currents in 
transfected cells114. Furthermore, it was evidenced how several peripheral cold-sensitive neurons 
does not express TRPM8, which on contrary was proved to be expressed within the most part of 
such cold sensing tissues115, suggesting the need of an additional cold sensor. 
The role of TRPM8 in detecting noxious cold stimuli have been increasingly studied during the 
recent period, approaching it in diverse physio/pathological contest, such as, just to mention one, 
the hypersensitivity to cold (known as cold allodynia) and its treatment with TRPM8 antagonists116.  
Notably, the variable presence of potassium channels has proved to modulate the sensory fibers 
sensitivity to temperature changing, further demonstrating how variable the operating range of cold 
receptors could be.  
Receptors sensitive to cold temperature in peripheral neurons are known to be constitutively active 
at neutral skin temperatures as well, generating a steady neural signal that reaches the brain and 
maintains constant all related processes. When exposed to a lower temperature, cold receptors 
activity increases leading to spontaneous thermoregulatory responses, among which include 
decrease of superficial vessels volume as well as increase in thermogenesis from fat, by directly 
increasing the expression of thermogenin (uncoupling protein 1). 
In line with this physiological behaviour, cooling agents acting on TPRM8 lead to response in body 
temperature, which increases in defence of the organism; while, contrarily, TRPM8 blockers have 
been proved to inhibit this reflex, leading the body temperature to decrease of about 1 °C 117.  
 
 
3.1.5 TRPM8 related pathologies.  
 
To date, TRPM8 expression profile variations as well as its incorrect functionality have been related 
to several pathologic conditions, most of which, further supported by the relatively confined  
presence of TRPM8 in sane organs, have been identified as cancerous diseases, often prostate 
related. This clearly makes it a promising target for both diagnosis and, hopefully, for therapeutic 
treatment too, reason why the pharmacological interest in it keeps growing.  
As an example of a diagnostic use, TRPM8 expression profile can be analysed  to determine the 
prostate tumor progression, since directly proportional to the androgen hormone. Furthermore, 
TRPM8 mRNA has recently been reported to be tracked in blood and urine as well118. Here, it can 
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be used as metastasis prognosis detector since its level was proved to be much higher in this 
condition than in both subjects sane and patients with tumor still localized at organ level. 
Unfortunately, from the pharmacological targeting point of view things get more complicated, since 
TRPM8 role in prostate cancer is still unknown.  
Beside prostate tumor, TRPM8 over-expression have been detected in other different kind of 
cancers, in which it passes from being virtually undetected in physiological conditions to be 
considerably increased in tumoral environment.  
To mention just few examples, cooling agent TRPM8 triggering in melanoma cells would reflect 
into sustained calcium influx and reduced cell viability119; while, in breast adenocarcinoma, it is 
mainly detected with abnormal frequency in small, level I cancers, suggesting how it would be 
related to low proliferative diseases.  
Cancer is not the only big issue with which TRPM8 has been related so far. 
The neural mechanisms underlying the cold-related pain are quite intricate, involving both 
activation of nociceptors via low temperature and several interdependent afferent inputs in the 
central nervous system, where finally the sensory experience takes place120.  
In order to better understand these mechanisms, several studies have been conducted on TRPM8 
antagonism in animal models of neuropathic pain. For example, not only cold allodynia was proved 
to be sensibly alleviated by treating the animal with a TRPM8 antagonist, the Capsazepine121, but 
also TRPM8 knockout models showed no response to temperature variation in neuropathic cold 
pain conditions.  
On the other hand, cold is also known to have analgesic effects on pain and so TRPM8 agonists as 
well are object of interest in pain alleviation, specially when inflammatory conditions are existing, 
in line with the common practice of cooling the sore skin to receive a lenitive sensation. The 
intricate paths underlying this analgesic effect are still far from being completely clears. 
 
 
3.1.6 TRPM8 ligands. 
 
For convenience, it is usual to refer to TRPM8 ligands subdividing them into two main categories 
depending on their chemical structure: (i) the first one hosts the so called para-menthane based 
compounds, while (ii) the second one contains the non-para-menthane based ones. Among the first 
one, clearly united by the shared isopropyl-methylcyclohexan structure, both agonists and 
antagonists take place; while, contrarily, except for icilin, an agonist twenty time more potent then 
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menthol, the second class mostly accounts for antagonists only. To date, several TRPM8 ligands 
with diverse chemical structures have been individuated, mostly discovered through HTS of 
proprietary in-house chemical libraries in several pharmaceutical companies. 
 
 
3.1.6.1 Para-menthane-based TRPM8 ligands: agonists. 
 
l-(–)-Menthol is the classic menthane-based TRPM8 agonist. It is a common and popular flavoring 
and cooling additive in household remedies (topical pain gels, throat lozenges, toothpaste) and 
foods (gum, candies, teas), and is known to produce its cooling effects by activating the TRPM8 ion 
channel. Menthol binds to TRPM8 with an EC50 of 66.7±3.3µM in Xenopusoocytes or 30µM in 
transfected CHO cells, however; this monoterpenoid also non-selectively activates TRPV3 (EC5020 
mM), inhibits mouse TRPA1 (IC5068µM) but activates human TRPA1. 
Menthol is also known to have anesthetic, analgesic and counter-irritant  properties, most of which 
are now linked to its TRPM8 agonist activity. During a wide mutagenesis study, Tyr745, placed in 
the middle of segment S2, was identified as crucial for the menthol sensitivity of mouse TRPM8122. 
Residues Tyr1005 and Leu1009 situated in the TRP box of the intracellular C-terminus were also 
found to participate in channel activation by menthol, but were postulated to be involved in events 
downstream of menthol binding. Using tandem tetramers of mutant TRPM8 channels with low 
affinity for menthol, Janssens and Voets estimated that each channel can bind up to four menthol 
molecules123. 
Starting from the individuation of both TRPM8 gene and mRNA in normal and malignant prostate 
cells, TRPM8 ligands have been investigated for efficacy in prostate cancer and benign prostatic 
hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. Among these agonists, for 
exemple, the benzimidizalone D3263124 was advanced to Phase I clinical trials in diseased patients 
and appeared to be well-tolerated, showing preliminary efficacy for disease stabilization in three out 
of eight male patients with advanced prostate cancer. 
The expression of TRPM8 in prostatic tissue is regulated by androgen and is upregulated in 
androgen-responsive tumors125 till its lost when reaching the androgen independence condition, 
making TRPM8 expression a valid prognostic marker for cancer progression.  
Clearly, TRPM8 agonists may have therapeutic potential for treatment of early-stage prostate 
cancer and prevention of tumor progression.  
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3.1.6.2 Para-menthane-based TRPM8 ligands: antagonists. 
 
Among para-menthane-based TRPM8 antagonists, Ortar and colleagues have reported a series of 
(−)-menthylamine-based molecules which TRPM8 affinity and selectivity was obtained by 
installing substituents found in TRPV1 ligands such as BCTC onto the TRPM8 (−)-menthylamine 
scaffold126. 
 
 
3.1.6.3 Non para-menthane-based TRPM8 ligands: agonists. 
 
Among non-menthane-based ligands for the TRPM8 ion channel, Icilin is a well characterized 
potent agonist and “potent cooling agent”, acting as TRPM8 agonist with 200-fold greater efficacy 
(EC500.36µM) than menthol127. To date, icilin seems to be the only one non-p-menthane based 
TRPM8 agonist. The structural dissimilarity between TRPM8 agonists icilin and menthol seems to 
point to different binding sites and/or different activation mechanisms, further supported by the fact 
that activation of TRPM8 by icilin and cold (17°C) is modulated by intracellular pH, whereas the 
same is not true for menthol.  
Icilin activation of TRPM8 seems to require the concomitant elevation of intracellular calcium, with 
TRPM8 acting as a coincidence detector of two different stimuli. A comparative analysis of rat 
TRPM8 and icilin-insensitive avian TRPM8 based on the analysis of chimeras and mutant channels 
revealed the critical residues for icilin sensitivity to be Asn799, Asp802, and Gly805 in the 
transmembrane domain128. 
 
 
3.1.6.4 Non para-menthane-based TRPM8 ligands: antagonists. 
 
There has been a significant effort by the pharmaceutical industry in discovering TPRM8 
antagonists for various therapeutic applications, particularly pain. By and large, most TRPM8 
antagonists reported in the journal literature and patents are non-p-menthane based antagonists, 
obtained by optimizing high-throughput screening hits. Little commonality other than the presence 
of perhaps two phenyl rings, one of which usually contains a fluoro- or trifluoro-substitution, is 
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seen in these compounds. Some well-characterized TRPM8 antagonists have been used as tools by 
other laboratories to understand the pharmacology of TRPM8 in pain models. 
Among this class, 4-benzyloxyphenylmethylamides, 4-benzyloxybenzoic acid amides, 2-benzyloxy-
benzoic acid amides (AMTB), benzyloxy-phenylmethylcarbamates (PBMC), 3-Chloro-2-pyridinyl-
N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide (BCTC) and 
benzyloxyphenylmethylureas have been found to possess nanomolar activity.  
High affinity antagonists, such as AMTB and PBMC have been used by both academia and industry 
as selective pharmacological probes of TRPM8 to explore the range of therapeutic applications 
resulting from blockade of this receptor, such as the regulation of deep body temperature (Tb)129, 
treatment of urological disorders130 and cold hypersensitivity associated with inflammatory and 
neuropathic conditions131.  
A focused high-throughput screen of in-house chemical libraries, followed by further structural 
elaborations, leads Calvo et al. to identify 2-vinyl cycloalkyl-substituted benzimidazoles as 
moderately potent TRPM8 antagonists132.  
As well, Parks et al. run into a series of  heteroatom-substituted spiro[4,5]dec-2-enes substituted at 
the 2-position of a benzimidazole core and optimizing studies culminated in the identification of a 
trifluoro-substitute, revealed an orally bioavailable, potent, and selective TRPM8 antagonist 
exhibiting antiallodynic properties in in vivo pain models133.  
Janssen has also developed an extensive series of benzothiophenephosphonate esters134 and 
pyrrolidines135, including JNJ-39267631, active in various models of allodynia associated with 
neuropathic pain and hyperalgesia associated with inflammatory pain. Compound JNJ-39267631 is 
also active in the WDS model, has potent antagonist activity against icilin, menthol and cold-
induced TRPM8 responses, and is selective versus TRPV1, TRPV2 and TRPA1 channels.  
The actions of TRPM8 blockers on native thermo-receptors are still relatively unexplored, with only 
a few studies addressing the antagonism of TRPM8 in sensory neurons136,137,138 and sensory nerve 
terminals139. 
Malkia and colleagues showed that several antagonist compounds (e.g., BCTC and SKF96365) act 
as negative allosteric modulators of channel gating, shifting the voltage activation of TRPM8 
towards more positive potentials, suppressing the depolarizing effects of temperature and chemical 
agonists140. They showed that co-application of different concentrations of an agonists and an 
antagonist could be used to titrate the voltage-activation curve of TRPM8 to any desired value, 
leading to changes in thermal activation threshold. Tyrosine residue 745 at the menthol binding site 
is critical for inhibition mediated by the compound SKF96365. In contrast, the inhibition by BCTC 
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is unaffected suggesting that at least one other binding site exists on the TRPM8 channel from 
where this drug exerts its negative allosteric modulation. 
 
 
3.1.7 TRPM8 computational background. 
 
As mentioned before, at the time I started my PhD course, a homology model of the hTRPM8 was 
already obtained and validated by the group141. Briefly, the construction of the monomeric structure 
of TRPM8 channel was achieved in three steps, here resumed. The first part involved the modeling 
of the vast cytoplasmic N-terminus by the classical homology techniques, basing on the structure of 
importin-β (PDB: 1QGR). The second step concerned the generation of the TM bundle by 
fragments using the structure of Shaker channel Kv1.2 (PDB: 2A79) to guide the final assembly. 
Lastly, the C-terminus was modelled using the experimental structure of HCN2J pacemaker (PDB: 
1Q43). Once assembled, structurally optimized and energetically minimized, the obtained monomer 
was used to build the corresponding quaternary structure through protein–protein automatic docking 
using the EscherNG142 program, via a two sequential steps strategy. In the first step, two TRPM8 
monomers were docked in order to obtain the corresponding homo-dimer, and then two dimmers 
were docked together to generate the final TRPM8 tetramer.  
Then, several docking calculations of representatives agonists and antagonists were performed on 
both monomeric and tetrameric protein, allowing to validate the reliability of the model and, in 
particular, of its ligand binding domain. 
Relying on several studies emphasizing the key role of S4 helix and S4–S5 linker which act as a 
voltage sensor integrating thermal and chemical stimuli in TRPM8143, and, considering the recently 
demonstrated critical role of S4 helix in a voltage-dependent phosphatase144, in which a 
conformational shift during the channel activation range from the standard α-helix to a more 
elongated 3–10 helix, our group hypothesized a three steps activation mechanism. 
Moreover,  mutagenesis studies revealed that the neutralization of the positively charged residues, 
which characterize the S4 and S4-S5 linker, alters voltage dependence and thermal sensitivity and 
affects menthol binding and activation, supporting a general activation mechanism based on 
conformational shifts happening in this region. The proposed role of S4 is also in line with the 
evidence that opening of the pore does not require conformational changes in S5 or S6 but is based 
on a rigid-body movement of the entire module145. 
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3.1.8 Proposed activation mechanism for TRPM8. 
 
Analysing the geometric relations between menthol binding cavity, the segment S4 and S4–S5 
linker, one can note that Arg842 is placed between Glu802 and Asp835 and probably it can interact 
with such negative residues changing the conformation of its side chain. Moreover, the ion-pair 
between Arg842 and Glu802 may be influenced by Tyr745 and then by the interaction between this 
latter and ligands. The particular arrangement of these residues seems to suggest that Arg842 can 
move between Glu802 and Asp835 depending on ligand binding and/or voltage and such a 
transition may influence the S4 structure. Considering our model, one can suppose that the ligand 
binding breaks the interaction between Tyr745 and Glu802 favoring that between Arg842 and 
Glu802, which implies a down movement of Arg842 and the shift of S4 segment to 3–10 helix. This 
may mean that the menthol binding induces a local change in S3 which approaches Asp802 to S4 
promoting the contact between Arg842 and Asp802. Globally, these considerations may suggest 
that: (i) the close state is characterized by S4 in canonical αhelix, while the open state requires its 
elongation to 3–10 helix; (ii) in the close state Arg842 interacts with Asp835 stabilizing the αhelix 
conformation in the S4 helix; (iii) in the close state Glu802 is turned towards S2 and interacts with 
Tyr745; this interaction is broken when the ligand interacts with Tyr745; (iv) the open state requires 
a transition of Glu802 towards S4, so that it can attract Arg842 which, in turn, leaves Asp835; (v) 
such a shift of Arg842 unblocks the S4 conformation, which assumes the elongated 3–10 helix. 
Such observations propose that the open state involves an elongation of S4 which induces a joint 
movement of S4–S5 linker and, more importantly, the opening of S5–S6 pore. The described 
mechanism could be triggered also by voltage, which can influence the arrangement of charged 
residues and/or by pH of milieu which can change the ionization state of considered charged 
residues.   
 
 
3.1.9 Molecular Dynamics study. 
 
With a view to substantiating the hypothesized mechanism, a molecular dynamics (MD) 
simulations study involved the TRPM8 monomer alone and in complex with selected ligands. To 
avoid too long simulations, the MD runs were intentionally targeted so as to focus the attention on 
the conformational shifts directly induced by ligand binding (namely, the approaching of S3 
towards S4 and the shifts of the latter). 
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In detail, the study involved four MD simulations considering the TRPM8 alone and in complex 
with menthol, icilin and AMTB, a known TRPM8 antagonist. While the choice of the representative 
agonists (namely, menthol and icilin) was quite obvious involving the most known natural and 
synthetic compounds, AMTB was chosen considering that a recent mutational analysis suggested 
that some hydrophobic inhibitors (such as capsazepine and BCTC) interact in a lateral binding 
cavity which only marginally overlaps with the orthosteric binding site146, whereas the more polar 
AMTB should occupy the orthosteric cavity in a competitive manner. 
The MD simulations lasted 5 ns and involved TRPM8 alone and bound to menthol, icilin and 
AMTB. To simplify the simulation space, the MD runs involved a single monomer and all atoms 
were kept fixed apart from those within a sphere of 15 Å radius around the bound ligand. This 
sphere was chosen to include the lower region of the transmembrane voltage sensor (S1–S4) plus 
the S4–S5 linker.  
Figure 3.1.1 reports the dynamic profiles for the distance between Tyr745 and Asp802 showing that 
the starting conformation of all simulated complexes is similarly stabilized by a close contact 
between Tyr745 and Asp802. Nevertheless, the four simulations show quite different behaviours. 
Indeed, while the free TRPM8 (Figures 3.1.1-3, blue plot) and the channel bound to AMTB 
(Figures 3.1.1-3, yellow plot) conserve the contact during the whole simulation, the binding with 
menthol and icilin disrupts this interaction and the monitored distance progressively increases 
during the simulation. Moreover, Figure 3.1.1 shows that menthol (Figures 3.1.1-3, red plot) 
induces a slower but more pronounced conformational shift compared to that exerted by icilin 
(Figures 3.1.1-3, green plot). The monitored differences could be somewhat explained by a visual 
comparison of the first and last frames of the monitored simulations. During the simulation time, 
both agonists reinforce their interaction with Tyr745 through the hydroxyl function for menthol and 
through the nitro group and the pyrimidinone ring for icilin. Due to its small size and hydrophobic 
nature, menthol appears to be wedged in the binding site physically distancing Tyr745 from Asp802 
and explaining the significant increases as seen in Figure 3.1.1. Despite its polarity, AMTB, 
conversely, engages the TRPM8 binding site mainly stabilizing p-p stacking and charge transfer 
interactions and it never contacts Tyr745 or Asp802 during all the monitored simulation.  Taken 
together, these results seem to confirm that TRPM8 agonists are characterized by ability to strongly 
engage Tyr745, thus liberating Asp802 which in turn can approach Arg842, while the antagonists, 
irrespective of their polarity, occupy the binding site or block the entrance, as recently proposed by 
Malkia147, without contacting Tyr745 nor influencing its interaction with Asp802. This result shows 
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that the performed simulations can clearly discriminate between agonists and antagonists and 
affords an interesting confirmation for the first triggering step of the proposed mechanism.  
 
 
 
 
 
Figure 3.1.1 Dynamic profile of the distance between Tyr745 and Asp802 
 within a 5ns MD simulation. 
 
 
Concerning the approaching of Asp802 towards Arg842, Figure 3.1.2 reports the distance between 
these residues as monitored during the MD runs. One may note that all complexes are characterized 
by an initial distance of about 10–12 Å which indicates a lack of significant interactions between 
them. As already seen in Figure 3.1.1, also Figure 3.1.2 shows marked differences between the 
performed simulations. Indeed, while the distance between Asp802 and Arg842 remains constantly 
above 10 Å during the entire simulations of the TRPM8 free and bound to the AMTB antagonist, 
the simulated agonists induce a clear approaching characterized by a distance between Asp802 and 
Arg842 of about 5 Å thus indicating a relevant ionic interaction between them. Remarkably, the 
timing of the approaching of Asp802 towards Arg842 as seen for the agonist complexes is in line 
with that of moving away between Tyr745 and Asp802 as reported by Figure 3.1.1. This 
observation seems to confirm that the two monitored structural changes can be seen as related steps 
of a concerted mechanism activated by agonists and leading to the channel opening. 
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Figure 3.1.2 Dynamic profile of the distance between Asp802 and Arg842 
 within a 5ns MD simulation. 
 
 
The last analysis involved the conformational shifts which happen in the S4 segment due to the 
agonist binding. To simplify the analysis and considering that the imposed constraints could alter 
the exact movements of this segment, the attention was simply focused on the atomic fluctuations as 
described by RMSD values computed taking into account only the S4 atoms and irrespective of the 
conformational shifts underlying such fluctuations. Figure 3.1.3 depicts the dynamic profile of the 
RMSD values showing interesting differences between the monitored simulations. Indeed, after a 
common starting equilibration phase, the S4 segment evidences a clearly greater mobility when the 
channel is bound to agonists compared to TRPM8 alone or bound to AMTB. Yet again, there is an 
evident synchronization between the RMSD variations induced by the simulated agonists and the 
conformational shifts as analyzed by Figures 3.1.1 and 3.1.2. Indeed, the RMSD increase occurs 
almost immediately with icilin and after about 3 ns with menthol. This further confirms that the 
monitored structural variations can be seen as sequential steps of the same activation mechanism 
selectively induced by the agonist binding. 
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Figure 3.1.3 RMSD fluctuations of S4 helix 
 within a 5ns MD simulation. 
 
 
The comparison of the three plots for menthol complex evidences how all main transitions occur at 
the same time (black  circle) thus suggesting that they are concatenate steps of  an unique concertate 
mechanism (Figure 3.1.4).  
 
 
 
 
 
Figure 3.1.4 Summary of the three steps mechanism for the TRPM8-menthol complex.  
 
 
  
 
 
 
50
3.1.10 Here presented computational studies. 
 
As anticipated above, the studies focused on TRPM8 and carried out during my Ph.D activity were 
thus based on this reasonably reliable homology model, the validation of which culminated in the 
above described MD study to which I contributed before beginning my Ph.D course. These studies 
can be roughly subdivided in four parts as schematized below: 
1. Virtual screening study performed combining ligand-based and structure based approaches 
on a rather large proprietary database, which led to the identification of potent and selective 
naphthyl based antagonists. 
2. Docking simulations on a set of isoxazolylamine agonists which allowed a more precise 
analysis of the TPM8 binding site revealing which residues are responsible of ligand 
potency and which residues of ligand affinity. 
3. Blind docking simulations performed on the whole TRPM8 tetramer with a view to identify 
additional allosteric binding sites whose reliability was next assessed by mutagenesis. 
4. Selectivity studies by considering the binding sites of all members of TRPM family and 
utilizing the same database already used in the first study.  
 
Apart from the second study which was performed in collaboration with the Department of 
Pharmacy of the University of Naples Federico II, all other three studies were conducted within a 
collaboration with Dompé s.p.a. and Axxam s.p.a. 
  
 
 
 
51
3.2 TRPM8 Virtual Screening study 
 
3.2.1 Introduction. 
 
Nowadays, virtual screening plays a key role in the discovery of innovative leads and represents an 
efficient method to reduce the costs and to increase the hit rates compared to wet-lab high-
throughput screening (HTS). Notably, also virtual screening techniques can be subdivided into 
ligand-based and structure-based approaches, the former mainly based on the similarity analyses 
and the latter mostly involving docking simulations. Recent studies suggested the fruitful 
opportunity of combining both methods even though robust comparisons of such methods as well as 
of their possible combinations suffer from a lack of reliable datasets large enough to allow 
statistically significant analyses148.     
Based on these premises and considering that TRPM8 is well suited to high throughput screening 
(HTS) campaign using a calcium sensitive fluorescence dye approach149,150, the present study 
started from a HTS campaign on a highly diverse corporate library of 124,107 compounds, 
described later. With the HTS results in hand, a second part of the study exploited such an 
invaluable wealth of biological data to compare ligand-based and structure-based virtual screening 
approaches. In detail, the primary objective of the computational study involved the evaluation of 
the predictive power of the SMARTS-based pharmacophore mapping compared to well-established 
docking simulations which are permitted by the previously described development of a TRPM8 
homology model.    
 
 
3.2.2 Library generation. 
 
The compounds collection used for the first HTS campaign is composed by 124,107 synthetic small 
molecules and is a joined Dompé S.p.A. and Axxam S.p.A. corporate collections. For the assembly 
of the screening collection several computational tools were used: millions of commercially 
available compounds were screened in silico, applying a number of scientifically recognized filters 
to select a set of compounds that adhere to strict drug-like criteria: almost  90% of the library has 
zero violations of Lipinski’s Rule of Five151 for oral drug-likeness and more than 85% has zero 
violations of Oprea’s parameters for lead-likeness152. Then, several other filters were applied to 
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minimize the number of known aggregators153,154, false positives155, toxicophores156, and 
compounds containing reactive functional groups157. Particular attention was given to the choice of 
compounds with calculated favorable physicochemical and pharmacokinetic (ADMET) parameters, 
resulting in almost 80% of the library having predicted oral drug-like properties and no major 
liabilities158,159,160,161. The selection of compounds with a relatively high degree of novelty was 
performed by application of a modified version of the framework analysis proposed by Murcko162. 
Following a hierarchical fragmentation schema, progressive levels of structure abstractions were 
used to classify compounds according to their scaffolds or frameworks. Compounds were then 
clustered by framework or scaffold and compared to similarly clustered compounds currently at 
various stages of development, including launched drugs. The library was assembled in such a way 
that frameworks and scaffolds not represented in development compounds make up 63-71% of the 
library, respectively. Cluster analysis of these structural descriptors was also applied to ensure high 
chemical diversity of the screening collection. 
 
3.2.3 Initial High Throughput Screening. 
 
The first part of the study involved the HTS analysis of a highly diverse corporate library performed 
by Axxam s.p.a. and aimed to identify novel TRPM8 antagonists. In Primary Screening, all the 
124,107 compounds were tested once at 10 µM. Valid results were produced for all of the 376 
compound plates.  
The screening was evaluated for each plate both in compound addition phase (CA, when the 
compound is injected onto the cells) and subsequent target activation phase (TA, when the reference 
agonist is added at EC80 concentration to open the channel). Compounds active in CA (potential 
agonists) and compounds which exhibited an unusual and fast rise of the fluorescent signal upon 
addition (potentially auto-fluorescent) were flagged and excluded from further characterization. The 
threshold for the primary screening hit selection was calculated according to the distribution of the 
percentage inhibition of all the compounds that was centered around 8.9% with a standard deviation 
of 14.8%. The threshold was then set at 53% corresponding to [percent inhibition mean]+[3*percent 
inhibition standard deviation].  
Such a primary screening allowed the identification of 2916 compounds, corresponding to a hit rate 
equal to 2.4 %. The selected compounds underwent Hit Confirmation phase in which they were 
tested at 3 concentrations (10µM, 3µM, 1.0µM), with triplicate data points.   
  
 
 
 
53
Hence, based upon the performance at 1µM, 3µM and 10µM, a response score was computed (i.e. a 
weighted score averaging the percentage inhibition information for a compound at the three tested 
concentrations) for each compound which was used to rank the Hit Confirmation data. In this way, 
1739 compounds were selected for Activity Determination (IC50 calculation), as they showed a 
response score > 50. The percentage of the here selected compounds (1.40 %) thus represents the 
random percentage, namely the percentage of confirmed hits found in the library. This random 
value will be used in the following virtual screening analyses to evaluate their enrichment factors. 
During Activity Determination, a full dose-response curve was performed at 8 concentrations in 
triplicates. Remarkably, 49 compounds were identified as strong blockers, showing sub-micromolar 
IC50 values. 
While avoiding a systematic analysis of all confirmed hits (apart from the naphthyl analogues 
described below), Figure 3.2.1 compares the distribution for some key physicochemical properties 
for confirmed hits (blue bars) and for the complete library (red bars). The first two analyzed 
properties suggest that, on average, the confirmed hits are larger molecules as demonstrated by the 
fact that about 50% of the confirmed hits have a molecular weight greater than 350 gr/mol. This is 
reflected in the number of rotatable bonds even though the highest percentage corresponds in both 
sets to molecules with 4 rotors. The last two compared properties show that the confirmed hits are 
on average apolar molecules and this trend is clearly evidenced by both polar areas where the most 
populated bin corresponds to molecules with PSA around 50 Å2 and lipophilicity values where the 
highest percentage corresponds to molecules with log P around 4.  The precise balance between an 
intermediate PSA value and a good lipophilicity emphasizes the key role of some H-bonds (as 
confirmed by the pharmacophore model, see below) while accounting for the transmembrane 
position the TRPM8 binding site. 
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Figure 3.2.1 Comparison for some key ligand descriptors between the confirmed hits (blue bars) 
and all screened library (red bars). In detail, the comparison involves: (A) Molecular Weight; (B) 
Number of rotatable bonds; (C) Polar surface area computed as described in 13; 
 and (D) logP (14). 
 
 
3.2.4 Naphthyl derivatives. 
 
Among the TRPM8 antagonists identified by this HTS campaign, a set of five naphthyl derivatives 
(1-5, as compiled in Table 3.2.1) were selected and pharmacologically characterized as interesting 
for drug-likeness, chemical tractability and potency since it includes the most potent blocker (1). In 
particular, the monitored set includes two naphthyl derivatives the confirmed inhibition percentage 
of which is greater than 50% (1-2) plus three inactive compounds (3-5) included in this analysis to 
offer more complete structure-activity relationships. With a view to better rationalizing their 
potency, the naphthyl compounds underwent docking simulations on the hTRPM8 model. In detail, 
Figure 3.2.2 shows the putative complex for compound 1 within the TRPM8 binding site 
evidencing the key role played by the ionic interaction between the ligand’s ammonium head and 
Asp802, a role which is further substantiated by the observation that all reported amido derivatives 
were found to be markedly less potent. The naphthyl moiety is seen to engage the pocket normally 
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occupied by menthol where it can elicit pi−pi  stacking with Phe809 and Tyr745 which in turn 
stabilizes a H-bond with the ligand ether function. The heteroaromatic ring stabilizes H-bonds plus 
pi−pi  stacking with the amido group of Asn799, a kind of interaction already described for a recently 
reported set of isoxazole agonists163. Taken together, docking results emphasize that an antagonist 
has to engage (and constrain) at the same time Tyr745 and Asp802 thus interfering with the 
activation mechanism triggered by these two residues.  
 
A
B
R
NH
Z
X
 
 
Cpd R A B Z X % inh at 10 µM pIC50 
1 Cl -O-CH2 CH2 CH2 2-furanyl 101.11 7.15 
2 F -O-CH2 CH2 CH2 2-furanyl 98.18 6.54 
3 H CH2-O- CH2 C=O 3-pyridyl 7.92 < 5 
4 H CH2-O- CH2 C=O 
5-bromine 
3-pyridyl 0 < 5 
5 H -O-CH2 C=O CH2 3-pyridyl 0 < 5 
 
 
 
Table 3.2.1. Structure and TRPM8 inhibition values for the naphthyl derivatives 
identified by the HTS campaign. 
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Figure 3.2.2  Main interaction stabilizing the putative complex  
between the hTRPM8 homology model and the here reported compound 1. 
 
 
3.2.5 Pharmacological characterization of compound 1. 
 
Among the above described naphthyl analogues, compound 1, the most potent representative of the 
class, showed a good potency (middle nM range) regardless of the agonist used (pIC50 value of 7.l5 
with Cooling Agent 10, 7.17 with Icilin, 6.7 with WS12). Moreover and interestingly, compound 1 
showed an excellent selectivity profile towards other close members of the TRP channels family, 
since it is completely inactive on TRPA1, TRPV1 and TRPV4. 
To further validate its TRPM8 blocking behavior, 1 was tested in the presence of a TRPM8 
physiological stimulus, e.g. by giving cold temperatures to the cells (Figure 3.2.3). After incubation 
with increasing concentrations of 1, HEK-293/hTRPM8 cells were exposed to a temperature drop 
by using the ABI Prism® 7900HT instrument  (from 25°C to 14°C) and the Ca2+ influx was 
recorded by a Ca2+-sensitive fluorescent dye. Calculated pIC50 was 6.76, in the same range as the 
ones obtained with TRPM8 agonists (Figure 3.2.3a). 
As second orthogonal assay, TRPM8 inhibition was evaluated by manual patch-clamp. Outward 
currents were elicited upon addition of Cooling Agent 10 (50 µM)  at +40 mV, in the presence and 
in the absence of 1 (300 nM). When the compound was perfused, outward current was almost fully 
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blocked, suggesting a decrease of hTRPM8 activity (Figure 3.2.3b). After compound 1 washout, 
hTRPM8 activity was restored. 
In order to investigate its binding mode, TRPM8 blockade was finally assessed on a construct 
carrying the mutation Asp802Ala. Asp802 has been identified as a key residue required for 
activation by icilin in mammalian TRPM8 while this amino acid is not fundamental for stimulation 
by menthol164. As shown in Figure 3.2.3c compound 1 pIC50 was decreased by the mutation in the 
icilin binding site (5.2 instead of 7.2 on wt TRPM8). This finding confirms what was evidenced by 
docking results, namely that Asp802 is important for compound 1 binding and blocking behavior 
and gives a hint as to its mechanisms of action: compound 1 could block TRPM8 activation by 
competing with agonists such as menthol in disrupting the interaction between Tyr745 and Asp802. 
 
 
 
 
Figure 3.2.3.  Validation of TRPM8 antagonist compound 1 
 by using cold temperatures as stimulus (3A), by manual patch clamp (3B) 
 and by site-directed mutagenesis (3C). 
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3.2.6 In silico virtual screening: setting the scene. 
 
The second part of the study had the primary objective of comparing a docking-based approach 
with SMARTS-based pharmacophore filters. While commonly used in chemical data mining, 
SMARTS strings have been scantly exploited to encode pharmacophore models although the 
combined use of more strings should allow the selection of chemically diverse molecules which 
however satisfy well-defined pharmacophoric rules165. 
Hence, the computational studies began with the development of a reliable pharmacophore model 
based on a set of patented TRPM8 antagonists. The key elements were transformed into a set of 
SMARTS strings to filter the already experimentally screened corporate library. To further 
emphasize the potentialities of SMARTS-based filtering, the same set of patented TRPM8 
antagonists was used to screen the corporate library based on 2D molecular similarity analysis as 
expressed by ECFP6 descriptors and Tanimoto distances. Finally, a set of known TRPM8 
antagonists was used to optimize docking procedures which were then applied to the screening of 
the same corporate library. The two utilized approaches were finally compared including also their 
mutual combination. The here reported ligand-based studies were performed by the industrial 
partners.  
 
 
3.2.7 Pharmacophore development, SMARTS-based screening and similarity analyses.  
As recently reviewed, several TRPM8 antagonists have been reported mostly in patent literature. 
While showing a marked structural variability, they share some key common features (as 
schematized in Figure.3.2.1), since most antagonists possess two cyclic (usually but not necessarily 
aromatic) systems connected by a variable linker suitably decorated by H-bonding groups. 
Although not necessary for activity, several linkers are characterized by a central basic function. As 
already described in Figure 3.2.2 and confirmed by mutational analyses, docking simulations 
revealed that a TRPM8 antagonist should contact both Tyr745 and Asp802, hence the beneficial 
role of a suitably spaced hydrogen bond acceptor (HBA) which should interact with Tyr745 and a 
hydrogen bond donor system (HBD) which should interact with Asp802. The first cyclic system 
should mimic the menthol carbon skeleton, while the second aromatic ring should approach 
Asn799. In both cases, the interactions are strengthened by apolar contacts with the surrounding 
hydrophobic residues. This pharmacophore is also characteristic for some agonists such as D-3263 
developed by Dendreon now in phase I clinical trial. The so obtained general scheme was then 
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converted into a set of ten SMARTS strings which encode for the variability in length and 
flexibility of the linker as well as for the size and complexity of the ring moieties (Table 3.2.2).  
 
 
SMARTS Total Ratio 
SMARTS 
Ratio EF 
SMARTS 
Positive 
SMARTS 
Negative 
k 
value 
1 0.014 0.4 28.57 2 3 0,391 
2 0.014 0.132 9.43 177 1164 0,120 
3 0.014 0.127 9.04 10 69 0,114 
4 0.014 0.104 7.41 11 95 0,091 
5 0.014 0.093 6.66 11 107 0,080 
6 0.014 0.088 6.31 25 258 0,075 
7 0.014 0.08 5.71 24 276 0,067 
8 0.014 0.079 5.67 17 197 0,066 
9 0.014 0.063 4.48 14 209 0,049 
10 0.014 0.052 3.75 275 4961 0,039 
 
 
Table 3.2.2 Enrichment Factors and k166 values for the 10 SMARTS strings 
 related to the pharmacophoric model. 
 
 
 
The SMARTS-based pharmacophore mapping was performed using a small set of 12 known 
TRPM8 antagonists (Figure 3.2.4) which allowed a general motif formed by a hydrogen bond 
acceptor system (HBAcc) and a hydrogen bond donor system (HBDon) to be revealed.  The two H-
bonding groups can be spaced by two atoms, as in the case of 12, 5, 6 and 9, or one atom in the case 
of 7 and 8, or they can be spaced by more flexible chains such as in 2 and 3. Considering the 
constrained systems in 1, it has been argued that the cis orientation is preferred and this is consistent 
with the proposed binding mode for TRPM8 inhibitors, on the basis of the derived 3D homology 
models of the ion channel (Figure 3.2.2). All the three classes of selected chemotypes can be 
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schematized by a pharmacophore model which define the relevant common chemical pattern 
characterizing these active compounds (Figure 3.2.5) 
 
 
1 (AMGEN) 
Prous ID: 726494 
2 (BAYER AMTB) 
Prous ID: 445976 
3 (BAYER) 
Prous ID: 424573 
 
  
4 (BAYER) 
Prous ID: 424587 
5 (DENDREON) 
Prous ID: 399718 
6 (DENDREON) 
Prous ID: 399722 
 
 
7 (GLENMARK) 
Prous ID: 689868 
8 (ITALIAN CNR) 
Prous ID: 696404 
9 (JANSSEN JNJ41876666) 
Prous ID: 706061 
 
 
 
10 (JANSSEN) 
Prous ID: 688352 
11 (JANSSEN) 
Prous ID: 688356 
12 (JANSSEN) 
Prous ID: 703270 
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Figure 3.2.4. Known TRPM8 antagonists used to develop the pharmacophore model.  
 
 
 
The H-bond acceptor group is represented by direct and reverse sulphonamide, ether, ester, ketone 
and imine; the H-bond donor group is represented by amide, amine and alcohols. The spacers are 
represented by a carbon atom, and are restricted to some rules: between the H-bond acceptor and 
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the H-bond donor (SPACER 1), is allowed a linear distance of 2 or 3 atom, while more than 3 
atoms are allowed only in very flexible moieties due to a possible tridimensional arrangement; 
between the H-bond acceptor and the last ring (SPACER 2), is allowed a linear distance of 0 or 1 
atom.  This pattern which condenses the structure-activity relationships among the active hits can be 
encoded by 10 SMARTS strings. An example is shown below: 
[*R]~[#16X4&$([SX4](=[OX1])(=[OX1])[NX3;H1]),#7X3&$([NX3][SX4](=[OX1])(=[OX1])),#
8X2&$([OX2][CX3](=[OX1])),$([NX2]),$(*[NX3;H1]),#6X3&$([CX3](=[OX1])[OX2]),#6X3&$(
*=O),#8,#16,#7&H0]~[#6!R]~[#6!R]~[#6&$(*-[OX2;H1]),#6&$(*=[NX2;H1]),#6&$(*-
[SX2;H1]),#7X3&H1,#16X4&$([SX4](=[OX1])(=[OX1])[NX3;H1]),#7X3&$([NX3][SX4](=[OX1
])(=[OX1])),#8X2&$([OX2][CX3](=[OX1])),#6X3&$([CX3](=[OX1])[OX2]),#6&$(*-
[NX3;H2])]~[#6!R]~[*R] 
 
One compound is labelled as active if its percent inhibition value is greater than 50% . 
The Enrichment Factor (EF) obtained using the strings were calculated by the following equation: 
 
ratio TOTAL
ratio SMARTSEF =  
 
Where: 
inactives SMARTS  actives SMARTS
actives SMARTS
  ratio SMARTS
+
=  
 
And:                 
inactives TOTAL  actives TOTAL
actives TOTAL
  ratio TOTAL
+
=  
 
 
A second part of SMARTS-based filtering was then exploited to discard potentially unselective 
molecules. In detail, a collection of published compounds (MDDR Database) was analyzed in order 
to identify moieties directly connected to the reported mechanisms of action. With the same 
rationale used for the definition of the pharmacophore model, a total of 37 SMARTS strings related 
to the unselective moieties were defined (7 representative SMARTS can be found in Table 3.2.3). 
Once the optimal set of SMARTS string was defined, they were used to screen the corporate library 
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with a view to identify TRMP8 blockers while discarding unselective or undesired scaffolds. As 
reported in Table 3.2.4, this analysis allowed the selection of 6400 molecules including 479 
confirmed hits (i.e. with a Response Score > 50). Hence, the percentage of confirmed hits is here 
equal to 7.48%, thus giving a noteworthy enrichment factor (EF) of 5.35 compared to 
experimentally determined random hit rate. The performance of each SMARTS string is reported in 
Table 3.2.2; notably, even the worst performing filter shows a EF value markedly greater than 1, 
and for all strings the k value is greater than 0 thus confirming that the obtained results cannot be 
due to a randomly correct prediction. Table 3.2.4 shows also the analysis of the chemical variability 
of the so selected set. Indeed, the selected set shows a ratio of decorated scaffolds per active 
compound which, albeit less than that observed in the full library, is in line with that obtained by 
docking simulations (see below) and emphasizes that suitably designed SMARTS strings can yield 
reasonably diverse results which are  not heavily constrained by the exploited pharmacophore rules.  
 
 
 
 
 
Figure 3.2.5 Schematic representation of the developed pharmacophore model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RING 1 SPACER 1  SPACER 2 HBA HBD  RING 2 
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SMARTS Strings Mechanism of Action 
[#7,#8](-[#6](-[#6]-[#6](-[#7,#8]-[*R,#6!R])=[#8])=[#8])-
[*R,#6!R] Antineoplastic 
[c,n]1[c,n][c,n]([c,n][c,n]1)-[#6]-[#6](=[#8])-[#7]-[*R,#6!R] Antineoplastic 
[#16](=[#8])(=[#8])(-[#7]-[#6](-[#6]-[#7]-[*R,#6!R])=[#8])-
[*R,#6!R] Anticoagulant 
[#7&R0](-[#6&R0](-[#6&R0](-[#7&R0]-[*R,#6!R])-[*R])=[#8])-
[*R,#6!R] Anticoagulant 
[#6](-[#6](-[#7]-[*R,#6!R])=[#8])(-[#7]-[*R,#6!R])=[#8] Antineoplastic 
[#6](-[*R])(=[#8])-[#7]-[#6](-[#6](-[#6]-[#7]-[*R,#6!R])-[#8])-
[#6]-[*R] Nootropic Agent 
[*R,#6!R]-[#7!R]-[#6!R]-[#6!R](-[#7!R]-[*R,#6!R])=[#8] Anticoagulant 
 
 
 
Table 3.2.3 A collection of published compounds (MDDR Database) was analyzed in order to 
identify moieties directly connected to mechanisms of action. With the same rational used for the 
definition of pharmacophore strings, a selection of 7 SMARTS strings were presented. Through a 
sub-structural search, they were used to eliminate cross-selective compounds from the library. 
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Method Cpds Actives Hit 
rate EF 
Active 
scaffolds 
Full 
library 124107 1739 1.40 1.00 
1054 
(0.61) 
Similarity-
based 6400 349 5.39 3.85 
202 
(0.57) 
Ligand-
based 6400 479 7.48 5.34 
238 
(0.49) 
Structure-
based 6400 677 10.57 7.55 
282 
(0.42) 
Consensus 1075 126 11.72 8.37 37  (0.29) 
 
 
Table 3.2.4 Major results for the here performed virtual screening campaigns. 
 
 
 
The satisfactory flexibility of the utilized SMARTS string is clearly emphasized by the comparison 
with the results obtained by a simple 2D similarity analysis as encoded by ECFP6 descriptors and 
Tanimoto distances. The similarity screen was repeated considering each of the 12 known TRPM8 
antagonists (Figure 3.2.4) already utilized for pharmacophore development and the compounds 
were ranked by using a consensus function by which a given compound is ranked according to its 
maximum so computed Tanimoto distance. In other words, a compound is evaluated by considering 
its capacity to approximate at least one of the 12 known antagonists. Table 3.2.4 reports the 
obtained results and reveals that such a similarity search placed among the 6400 top-ranked 
compounds 349 confirmed hits which corresponds to a enrichment factor markedly lower than that 
obtained by SMARTS strings. This result can be explained by considering that such a similarity 
search does not include any kind of molecular flexibility and so it can find only those compounds 
which are similar to the 12 known antagonists. This consideration is confirmed by the lowest 
number of active scaffolds as reported in Table 3.2.4.    
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3.2.8 Structure-based virtual screening: setting strategy. 
 
 A similar strategy based on already reported TRPM8 inhibitors allowed the best docking strategy 
for screening on the TRPM8 receptor structure to be designed.  
Following a rationale similar to that utilized in the ligand-based approach, structure-based screening 
started collecting a benchmarking set composed of 50 published TRPM8 antagonists and 4950 
decoy compounds taken from the inactive compounds of  the screened library. With a view to 
identifying the most productive strategy, docking simulations involved the already published human 
TRPM8 homology model and were performed using AutoDock 4.0, Vina and LiGen.  
In detail, both benchmarking set and screened library were prepared by using the already mentioned 
automatic script of the VEGAZZ suite of programs. 
With regard to the AutoDock simulations, all calculations were performed by using the parallelized 
Gridock tool167 and had the following characteristics: (i) the search was focused on a 10 Å radius 
sphere around Asp802 so as to encompass the entire binding cavity; (ii) the resolution of the grid 
box had a spacing of 0.375 Å; (iii) each compound was docked into the grid by the Lamarckian 
algorithm; (iv) the flexible bonds of the ligand were automatically recognized and left free to rotate; 
(v) the genetic-based algorithm ran 10 simulations per substrate with a maximum number of 
generations of 27,000; (vi) the crossover rate was increased to 0.8, and the number of individuals in 
each population to 150. Docking simulations were repeated by carrying out both rapid (100,000 
energy evaluations per ligand and per generation) and exhaustive (2,000,000 energy evaluations) 
analyses and all other parameters were left at the AutoDock default settings168. Vina open-source 
program utilizes an iterated local search global optimizer algorithm which involves a sequence of 
steps consisting of a mutation and a local optimization and each step can be accepted or discarded 
according to the Metropolis criterion169. The box parameters were the same already utilized by 
AutoDock program.  Before performing docking simulations, LiGen requires the development of a 
suitable pharmacophore model by using  LiGenPocket. To this end, a rather large and very potent 
TRPM8 antagonist (a benzyloxy-phenylmethylcarbamate derivative, IC50 = 0.45 nM) not included 
in the benchmarking set was utilized with a view to avoiding bootstrapping situations and 
developing the pharmacophore as exhaustive as possible.  Docking simulations were then carried 
out adopting the best performing set of parameters as derived by previous studies and focusing the 
search on a 10 Å radius sphere around Asp802. The ligand was considered as flexible and the 
results were ranked by the LigenScore function. 
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Table 3.2.5 compares the computed enrichment factors as derived by using AutoDock, Vina and 
LiGen and considering the top 10%. Overall, the reported EF values reveal a rather low predictive 
power of all considered scoring functions except for LiGenScore, the optimization of which will be 
described below. With regard to AutoDock results, Table 3.2.5 shows that the EF values obtained 
by exhaustive docking are slightly better than those derived by fast docking, a clearly expected 
result which however cannot compensate the hugely greater computational time required by the 
exhaustive search. Similarly, Vina score shows no predictive power. Conversely and even adopting 
the default parameters, LiGenScore reveals an encouraging predictive power ranking about one half 
of the active molecules170 in the top 10%.  
Based on these results, the LiGen simulations were then optimized by tuning the arrangement and 
the extension of the box where the docking search is performed, whereas the docking parameters of 
the program were not adjusted since they were already optimized by experimental design to 
optimize virtual screening performances and a further specific optimization can result in a 
unproductive overfitting. Hence, the LiGen simulations were repeated by varying the radius of the 
considered sphere (i.e. equal to 12, 10, 8, 6.5 Å) and its center (around Asp802 or Tyr745) so as to 
take into account also a possible adjacent sub-pockets. Table 3.2.6 reports the remarkable 
enrichment factors as obtained by the best performing LiGen simulation which involved a 8 Å 
radius sphere around Asp802 and such an optimized protocol was then utilized to analyze the 
screened library. 
 
Score Function 
Enrichment Factor 
Fast docking 
Enrichment Factor 
Exhaustive docking 
AD_Intermolecular 1.01 1.31 
AD_Electrostatic 1.02 1.12 
AD_VdW-Hbond-Desolv 1.03 1.30 
Vina 1,01 -- 
Ligen 4.91 -- 
 
 
Table 3.2.5 Enrichment factors as derived by using AutoDock,  
Vina and LiGen  and considering the top 10%. 
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top % N Cpds Active EF 
1 50 18 36 
2 100 27 27 
5 250 38 15.2 
10 500 41 8.2 
20 1000 43 4.3 
 
 
Table 3.2.6 Enrichment factors as derived by using LiGen  
and focusing the search in 8 Å radius sphere around Asp802. 
 
 
3.2.9 Structure-based virtual screening: results. 
 
Such an optimized docking protocol (based on LIGEN software and using the LiGenScore 
consensus scoring algorithm) was exploited to virtually screen the corporate library and the top-
ranked 6400 compounds (a number of compounds similar to that obtained by SMART-based 
filtering) were selected and analyzed.  As evidenced in Table 3.2.4, docking-based screening 
identified 677 confirmed hits with an enrichment factor (7.55) greater than that achieved by 
SMARTS strings. Interestingly and contrary to what was expected, the docking-selected library 
shows a chemical variability as represented by a ratio of decorated scaffolds per active compound 
which is comparable to (and even slightly less than)  that obtained using SMARTS strings (0.42 vs. 
0.49). 
Among the chemotypes identified by the HTS campaign, the study describes the pharmacological 
characterization of a set of naphthyl TRPM8 antagonists. Besides including the most active 
compound found within the corporate library, the naphthyl series was selected for its chemical 
novelty, its optimal lipophilicity profile while possessing ionizable and/or polar moieties, and 
because the compounds showed an activity in the nanomolar range combined with a remarkable 
selectivity since they are completely inactive against closely related TRP members. In fact, most of 
the available TRPM8 antagonists suffer from an unsuitable selectivity profile which hampers their 
clinical applications and indeed to date only the phosphonate analogue JNJ-39267631 has advanced 
  
 
 
 
68
to clinical trials. The here reported naphthyl analogues might show a proper balance between 
potency and selectivity thus reducing unfavorable off-target effects and representing valuable 
candidates for clinical studies. From a mechanistic standpoint, mutational studies are in line with 
docking simulations and confirm the key role of Asp802. This finding is in agreement with the 
previously hypothesized activation mechanism and emphasizes that an antagonist has to interfere 
with the interaction between Tyr745 and Asp802 to induce the TRPM8 blockade. 
With regard to in silico screening campaigns, the SMARTS-based results evidence the remarkable 
potentialities of this approach which gives productive results with very reduced computational costs 
(16 minutes for virtual screening 1 million compounds on a single CPU). Moreover, the reported 
method emphasized the fruitful possibility of combining pharmacophore SMARTS strings with 
other strings encoding for unselective (anti-targets SMARTS strings can be easily identified from 
annotated databases such us MDDR) or undesired scaffolds as well as strings to screen the 
compounds according to the Lipinski rule or other ADME/Tox filters. In this way, it is possible to 
collect a library of SMARTS strings which allow a proper filtering of any database. This 
combination of filters may reduce the number of hits but greatly enhances the quality of the 
retrieved compounds, because the final goal of a screening campaign is the identification of 
valuable hits suitable for progress to the lead optimization phase. The potentiality of suitably 
combined SMARTS strings is clearly documented by the comparison with the similarity analysis 
based on the EPCF6 descriptors which, despite being based on the same set of known TRPM8 
blockers, give poorer results in terms of both enrichment factor and active scaffold variability. 
Although supported by similarity analyses of known TRPM8 antagonists, the pharmacophore 
mapping involves a subjective definition of the pharmacophoric elements whose arbitrariness is 
however minimized by the possibility of exploiting many SMARTS strings so as to cover all 
conceivable combinations of the key elements. Although one of the major concerns with the 
SMARTS strings is the poor flexibility of the so performed substructure searches, our results clearly 
indicate that the filtered subset contains the same structural variability observed in docking results. 
It should be underlined that the chemical variability obtained by SMARTS strings can be modulated 
by varying the number of utilized strings, while that observed in the docking-based results is 
unavoidably constrained by the shape and size of the explored binding site and this limit is here 
further exacerbated by the fact that computed poses are evaluated without any complex 
optimization to reduce the computational costs. Nevertheless, docking-based screening provides a 
remarkable enrichment factor in line with the preliminary benchmarking tests. Collectively, the 
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remarkable results of docking-based screening represent a relevant validation of both the TRPM8 
homology model and the used docking strategy.  
The obtained screening results allow the positive effects of combining ligand-based and structure-
based methods to be investigated. In detail, the two generated subsets share 1075 common 
compounds which represent about 1/6 of the entire subsets thus suggesting that SMARTS strings 
and docking simulations select rather different chemical spaces, a result which can be explained 
considering the different criteria by which the two methods collect their subsets. Among the shared 
compounds, there are 126 confirmed hits thus yielding an enhanced enrichment factor of 8.37. This 
means that the two methods, while covering rather diverse chemical space, can be successfully 
combined in a parallel approach which corresponds to selecting from among the compounds which 
fulfill the pharmacophore filters those achieving the most stable complexes. Remarkably, such an 
enhanced enrichment factor cannot be ascribed to the fact that it involves a restricted subset of 
1,075 molecules. Indeed, the 1,075 top-ranked molecules as obtained by docking simulations 
include 113 confirmed hits with a percentage in line with that obtained for all 6,400 top-ranked 
molecules. In other words, the consensus approach allows the selection of a rather restricted number 
of compounds which benefits from ligand-based and structure-based approaches. 
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3.3 Isoxazole derivatives as potent TRPM8 agonists. 
 
3.3.1 Introduction. 
 
As mentioned before, both peripheral and central activation of TRPM8 induces analgesic effects 
that specifically reverse the sensitization of the behavioural reflexes elicited by peripheral nerve 
injury171. These effects are produced in a range of very low concentrations of topically applied 
TRPM8 activators, whereas high concentrations of menthol were found to cause both cold and 
mechanical hyperalgesia in healthy volunteers172,173. These findings suggest the potential relevance 
of TRPM8 activators as therapeutic strategy for pain treatment.  
In this study174, 12 isoxazole derivatives have been designed and tested for their pharmacological  
properties both in F11 sensory neurons in vitro and in an in vivo model of cold allodynia. 
The experiments revealed that, when compared to menthol, some newly-synthesized compounds 
were up to 200-fold more potent, though none of them showed an increased efficacy. Some 
isoxazole derivatives potentiated allodynic responses elicited by acetone when administered to rats 
subjected to sciatic nerve ligation; when compared to menthol, these compounds were efficacious at 
earlier (0-2 min) but not later (7-9 or 14-16 min) time points.  
In order to investigate what lies under this behaviour, docking experiments have been performed on 
the hTRPM8 receptor model, revealing that newly-synthesized compounds might adopt two 
possible conformations, thereby allowing to distinguish “menthol-like” compounds (characterized 
by high efficacy/low potency), and “icilin-like” compounds (with high potency/low efficacy). 
 
 
3.3.2 Compounds design and  experimental/computational SAR analyses strategies. 
 
Given the potential role of TRPM8 agonists for the treatment of neuropathic pain conditions, 
increasing efforts in the last few years have been dedicated to the design of selective and potent 
TRPM8 ligands. To date, the most active cooling compound, icilin (Scheme 3.3.1B), is 
characterized by the presence of a central tetrahydropyrimidine-2-one ring substituted by a 
nitrophenyl and phenol moieties. Several other analogues, based on the tetrahydropyrimidine-2-one 
moiety, have been described and patented for their cooling activity175. 
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The need for a heterocyclic ring to elicit efficient interactions with TRPM8 is also witnessed by the 
isolation of the potent cooling agents alpha-ketoenamine (Scheme 3.3.1C and D) from roast malt 
extract176; however, these molecules are penalized by their great instability to oxidation, probably 
related to the reactive enamine functional group. A similar instability was also found for a class of 
aminophenols synthesized as hybrid derivatives of icilin and ketoenamines. Therefore, and in view 
of these stability issues, different heterocyclic moieties have been utilized as chemical scaffolds for 
the synthesis of new TRPM8 modulators; these include benzimidazole-based (Scheme 3.3.1E), as 
well as fused oxazole (Scheme 3.3.1F) and thiazole derivatives (Scheme 3.3.1G)177,178. 
In addition, aminoisoxazoles, in particular the 3-amino derivatives, are resistant to the typical 
degradation occurring to the isoxazole rings179, and are suitable for simple and high-yield chemical 
derivatization of the amino group. Substituted aminoisoxazole derivatives seem to include the 
minimum structural requirements for a TRPM8 ligand, as seen for menthol or icilin, such as 
hydrogen bonding groups, a compact (mainly cyclic) hydrocarbon backbone, a correct 
hydrophobic/hydrophilic balance with a log P range between 1 and 5, and a molecular weight in the 
range of 150-350 g/mol. Indeed, several structural similarities can be observed between the 
alphaketoenamine derivatives and the aminoisoxazoles (Scheme 3.3.1H) 180. 
Based on these evidence and on the known SARs for menthol (Scheme 3.3.1A) and its analogues181, 
in this study 12 new isoxazole derivatives, carrying modifications on the isoxazole ring, have been 
synthesized. These mainly involved the introduction of aminoaliphatic or aminoaromatic chains in 
position 3 and/or the introduction of a methyl group in position 5 of this scaffold ring.  
 
 
 
Scheme 3.3.1 (A-G) Molecular structures of main TRPM8 modulators: menthol (A), icilin (B), 
a-ketoenamine (C and D), benzo-fused imidazole (E), oxazole (F) and thiazole derivatives (G); 
generic structure of the newly synthesized compounds of the present study (H). 
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When tested for their ability to trigger TRPM8-induced [Ca2+]i responses in sensory neurons in 
vitro, some of these derivatives showed higher potency when compared to menthol. Thereafter, the 
most potent compounds were tested in vivo in an animal model of cold allodynia, where they 
showed strong and rapid, although short-lasting, allodynic responses.  
According to the previously resumed devices, the 12 new isoxazole derivatives synthesized bear 
substituents at position 3 and 5 of the heteroaromatic ring (Scheme 3.3.2). 
In particular aminoaliphatic (1a-e) and aminoaromatic (1f-h) chains were introduced at position 3 
for derivatives belonging to series 1, while a methyl group occupies position 5. By contrast, 
derivatives belonging to the series3 (3b and 3d) lack the methyl group in position 5. Finally, the 
derivatives 2b and 2d are isomers of 1b and 1d, due to inversion of the oxygen and nitrogen 
heteroatoms. 
To characterize their pharmacological activity as TRPM8 agonists in vitro, these new compounds 
were tested for their ability to enhance [Ca2+]i in differentiated F11 cells, as done for menthol (For 
procedure details see study reference). All tested molecules increased [Ca2+]i in a concentration-
dependent manner, although with different efficacy and potency. 
None of the tested compounds showed a higher efficacy than menthol. The compounds referred as 
1d and 1f showed the same efficacy than menthol; instead, the other ten tested compounds were less 
effective than menthol, showing the following rank order of efficacy: 
1g>3b>3d>1h>1c>1e>1b>1a>2b>2d, suggesting that longer aliphatic chains or aromatic 
substituents at the position R2 are required to retain high efficacy. 
By contrast, comparison of the potency among tested compounds was performed by normalization 
of the experimental data to the maximal value of fluorescence ratio prompted by each compound. 
Eight of the tested compounds (i.e. 1a-e, 1h, 3b, 3d) showed a significantly lower EC50 when 
compared to menthol, suggesting that aliphatic substituents at the R2 and R1 positions are involved 
in conferring high potency to the tested compounds. The compound referred as 1g showed the same 
potency as menthol; finally, the other three tested compounds were less potent than menthol, with 
the following rank order of potency:2b>2d>1f, suggesting that the introduction of an aromatic ring 
at the position R2 or the inversion of the heteroatoms at the position X, Y (Scheme 3.3.2) have 
deleterious effects on compound potency. 
As later detailed, the reported newly-synthesized molecules can be roughly subdivided into two 
groups: the first includes compounds characterized by submicromolar potency but with quite low 
efficacy (as seen for example in 1a-c derivatives), and the second includes compounds endowed 
with low potency and high efficacy (as exemplified by 1f and 1g).  
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The compound 1d appears to be the most promising compromise since it shows low micromolar 
potency combined with a very remarkable efficacy. 
 
                                        
 
Scheme 3.3.2 Representation of the synthesis procedure for all isoxazolylamine derivatives  
of the study  and classification of the substituent groups present in each compound. 
 
 
3.3.3 Computational methods. 
 
The ligands were simulated considering their neutral forms since they are the favored ones at the 
physiological pH. After a preliminary optimization using the PM6 semi-empirical method, as 
implemented in MOPAC 2009, to discard high energy geometries and to calculate precise atomic 
charges, the conformational behavior of the compounds was investigated using VEGAZZ by a 
clustered MonteCarlo procedure which generated 1000 conformers by randomly rotating the rotors. 
All geometries obtained were stored and optimized to avoid high-energy rotamers. For each ligand, 
the so obtained lowest energy structure was then exploited in the docking simulations performed by 
AutoDock4.0 using the TRPM8 model recently obtained by homology techniques [23]. In detail, 
the calculations involved a single TRPM8 monomer and the grid box was set to include all residues 
within a 15 Å radius sphere around Tyr745, whose role in ligand recognition has been confirmed by 
mutational studies (ref), in order to comprise the entire binding cavity. The resolution of the grid 
was 68×77×100 points with a grid spacing of 0.450 Å. For docking simulations, the flexible bonds 
of the ligand were left free to rotate to account for ligand flexibility within the binding cavity. Each 
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substrate was docked by using the Lamarckian algorithm as implemented in AutoDock. The 
genetic-based algorithm ran 30 simulations per substrate with 2,000,000 energy evaluations and up 
to 27,000 generations. The crossover rate was increased to 0.8, and the number of individuals in 
each population to 150. All other parameters were left at the AutoDock default settings. The best 
complexes were finally minimized to favor the mutual adaptability between ligand and receptor and 
the optimized complexes were then used to re-calculate AutoDock docking scores, VEGA energy 
scores and X Score values. All mentioned minimizations were performed using the conjugated 
gradients algorithm as implemented in the Namd 2.51 package with the force-field CHARMm v22 
and Gasteiger’s atomic charges.   
 
 
3.3.4 Computational results. 
 
To identify the structural elements involved in the interactions of the here reported isoxazole 
derivatives with the TRPM8 channel, which might provide a plausible explanation for their 
different pharmacological properties, docking simulations were performed.  
As shown in Figure 3.3.1A, the main interactions stabilizing the complex between TRPM8 and the 
most potent 1a derivative occur in a subpocket adjacent, but not coincident, with that of menthol, 
roughly corresponding to that occupied by the nitrophenyl moiety of icilin182. 
This result emphasizes the role of N799, which stabilizes an extended π-π stacking involving the 
carbamido function of the aminoacid side chain and the entire isoxazole ring. Furthermore, ligand’s 
amino group is involved in an H-bond with the D802 carboxylate, a further key residue determining 
the activity of icilin, as also demonstrated by mutagenesis183. Finally, the interaction between ligand 
and the D802 seems to be essential for agonism as it destroys the H-bond between D802 and Y745, 
which characterizes the inactive state of TRPM8 channels, thus triggering its activation184. 
These two major contacts are further stabilized by a set of hydrophobic interactions with 
surrounding apolar side chains (e.g. L749, A753 and F794). Notably, the isopropyl group of the 1a 
derivative approaches Y745 contacting the apolar residues involved in the interactions with 
menthol, while the ligand’s methyl group seems to act as a pivot which restrains the ligand pose 
within the binding site, thus maximizing its interactions (see below). Accordingly, docking results 
show that the desmethyl analogue, 3b, is characterized by a slightly different pose, in which the 
ligand slides towards F794 and loses its key H-bond with D802. Again, the isopropyl chain affords 
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the best potency presumably because it balances apolar contacts and steric hindrance, while bulkier 
groups (such as in 1b or in 1d) tend to clash against Y745 or L749. Interestingly, the isopropyl 
group corresponds to the substituent also inserted in a comparable pose by menthol, suggesting that 
this group best fits the TRPM8 cavity in that region. 
By contrast, when the N-linked group is further enlarged, as seen in the1fehderivatives, the 
resulting ligands cannot assume the above described pose and show a completely different 
arrangement in which the isoxazole ring approaches Y745, while the bulky N-linked moiety 
approaches N799. Figure 3.3.1B displays the pose of the 1h derivative showing that the isoxazole 
ring is unable to elicit both significant π-π stacking and the key H-bond with Y745. The nitrophenyl 
moiety mimics the pose assumed by the same group of icilin stabilizing a key H-bond which 
involves the nitro function and the side chain of N799, while the amino group of 1hinteracts with 
D802. However, the inability to contact Y745 as well as the steric clashes exerted with surrounding 
residues could explain its poor potency, an effect which appears to be dramatically exacerbated 
when the ligand cannot elicit H-bonds with N799 (as seen for 1f).  
Finally, docking simulations revealed that the inverted 3-methyl derivatives (2b and 2d) assume a 
different pose which could explain their poor potency. In detail, their isoxazole ring stabilizes an H-
bond between the intra-annular oxygen atom and the N799 side chain, losing the extended π-π 
stacking and, more importantly, these compounds appear to be unable to elicit the pivotal contact 
with D802. 
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Figure 3.3.1  Magnification of the binding site in TRPM8 channel. (A, B) Main interactions 
stabilizing the complex between the TRPM8 binding site and 1a (A) or 1h (B). The cartoon for the 
transmembrane helices is colored according to their orientation within the membrane bi-layer 
(gray=extracellular side; pink=intracellular side). 
 
 
3.3.5 Discussion. 
 
When tested in vitro, the compounds containing modifications only at the 3-position, particularly a 
secondary amine linked to an isobutyl (3b) or a butyl (3d) group, displayed a slightly higher 
potency when compared to menthol, whereas their efficacy was slightly reduced. The introduction 
of a methyl group at the 5-position in both these compounds (generating 1b and 1d, respectively), 
lead to a further improvement of the potency, without altering the efficacy in the case of 1b or 
inducing a small, but significant efficacy increase in the case of 1d when compared to 3d. 
Further modifications of the aliphatic chain connected with the secondary amine (consisting in an 
isopropyl or an isobutyl group in the case of 1a or 1c, respectively) prompted to similar 
improvement in the potency, but still not in the efficacy, when compared to the parent compounds 
(3b or 3d). 
The increase in potency showed by the described compounds is instead prevented by the 
introduction of an aromatic function on the groups linked to the amine at the 3-position of the 
isoxazole ring. In fact, when a benzyl group was linked to the secondary amine (1f), a dramatic 
decrease in potency was observed; furthermore, when this high electron density group was depleted 
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through the introduction of the known deactivator e NO2 (at the ortho- or para-position, as in the 1h 
and 1g derivatives, respectively) or replaced by a cyclohexyl group (1e), the potency increased by 
about 20-fold. 
In in vivo test, we observed that, similarly to menthol, the newly-synthesized 1a-d compounds also 
potentiated allodynic responses prompted by acetone exposure, suggesting that they also acted as 
TRPM8 agonists. However, when compared to menthol, 1a-d showed a distinct time-dependent 
profile. In fact, allodynic responses triggered by these compounds showed a shorter latency, being 
already evident after the first triggering stimulus was applied; in addition, 1a e 1d compounds 
ceased to elicit allodynic responses after the second or third acetone application. By contrast, 
menthol was only effective after the second acetone application, and the 1f compound failed to 
display allodynic effects at any time point after stimulus challenge.  
These observation suggests the existence of a good correspondence between in vitro and in vivo 
data, with those compounds showing the highest in vitro potency as TRPM8 agonists being 
provided of faster onset and offset in vivo effects when compared to menthol, and the lower potency 
TRPM8 agonist showing no efficacy in in vivo testing.  
About the in silico investigation, the results achieved in our docking experiments suggest valid 
structural hypothesis to rationalize the biological evidence. Indeed, the computed complexes 
suggest that the TRPM8 binding site can be roughly subdivided into two regions. The first region is 
more hydrophobic, and contains the Y745 residue playing a key role in TRPM8 activation185. Given 
the nature of the flaking residues, a  ligand can occupy such a region by stabilizing a set of precise 
hydrophobic contacts plus key H-bonds with Y745, as seen for the prototypical example of 
menthol.  
The second region is more polar as it is lined by N799 and D802 which can elicit reinforced H-
bonds and extended π-π stacking with the more potent isoxazole derivatives. When considering 
these possible polar interactions, it comes as no surprise that suitable ligands which occupy this 
second region can afford markedly higher potencies compared to ligands which are positioned in 
the first sub-cavity where at most they stabilize H-bonds with Y745. Yet, the ability of molecules to 
interact with residues of the first region appears to be an essential requisite to achieve a good 
efficacy profile, regardless of the polar contacts stabilized within the second sub-pocket. Notably, 
icilin confirms that ligands able to suitably occupy both sub-pockets can successfully combine 
potency and efficacy even though such a double occupation appears to be vastly constrained by 
hampering steric clashes exerted by surrounding apolar residues.  
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Taken together, the results obtained emphasize that the newly synthesized compounds (particularly 
1a-c) can induce TRPM8 activation in vivo. Although the TRPM8-dependent acetone test in CCI 
animals utilized in our study is a model of cold allodynia (indicative of an increased pain 
sensitivity), it should be reminded that the activation of TRPM8 channels can also mediate 
analgesic effects186.  
As a matter of fact, menthol itself, though acting as a reference compound for TRPM8 activators, 
has well-known analgesic properties187. Concentration-dependent effects of menthol at TRPM8 
receptors might provide a plausible explanation for this apparently paradoxical behaviour; in fact, 
while, as indicated previously, elevated concentration of menthol trigger TRPM8-dependent 
nociceptive behaviour in CCI mice, lower menthol concentrations induced marked analgesia in the 
same rat model of neuropathic pain. However, whether additional variables such as changes in 
TRPM8 kinetics of activation and/or desensitization, differential treatment modalities  (topical vs 
systemic administration), or model-dependent effects on TRPM8 expression levels at various sites 
contribute to the distinct pharmacological profile shown in vivo by menthol or other TRPM8 
modulators remains to be investigated. 
Despite all these uncertainties, the present results clearly suggest that presently-described 
aminoisoxazole-based derivatives display a pharmacological profile, both in vitro and in vivo, 
consistent with that of TRPM8 agonists. These molecules might be of considerable interest for 
further structural optimization and functional analysis, in order to validate their clinical utility as 
novel analgesics. 
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3.4 Accessory binding site research on TRPM8. 
 
3.4.1 Introduction. 
 
As reported so far, the TRPM8 homology model has shown to be structurally reliable and to 
perform well in terms of both ligand interaction, agonists and antagonists as well, and from a 
functional point of view. Anyway, the orthosteric binding site is not the only mechanism we have 
been interested in. The TRPM8 polymodal activation is still not completely understood as proven 
by the ever increasing interest by the worldwide scientific community; moreover, the interest in its 
allosteric modulation is becoming increasingly popular in the scientific community, as supported by 
the several reports appeared in literature.    
For the here reported study, the rationale has been based on both literature data and in house results. 
As already mentioned, several antagonists, like BCTC, SKF96365 and 1,10-phenanthroline, have 
been proved to act as allosteric modulators, shifting the voltage curve that lies under the TRPM8 
channel opening towards more positive potentials. In their mutagenesis study, Malkia and co-
workers found that, substituting the key Tyr745, only the agonist activity of menthol was lost, while 
antagonist’s desensitization was stably maintained188. This strongly suggests that not all the 
antagonists interact with the orthosteric site and thus TRPM8 should have at least one allosteric 
binding domain, by which antagonists like BCTC can change the physiological properties of the 
channel, moving the threshold for activation towards higher temperatures for native currents. 
In a recent study, Taberner and co-workers investigated the allosteric modulation on TRPM8 
through in silico calculation, first, and mutagenesis studies, later, finding the linker between the S6 
of pore module and the TRP conserved box to be a target of the channel function modulation. In 
detail, stepwise substitutions of segments in the S6-TRP box linker of TRPM8 channel with the 
cognate TRPV1 channel sequences, recently resolved by cryo-electron microscopy images189,  
produced functional chimeric channels, and identified Tyr981 as a central molecular determinant of 
the channel function. Additionally, mutations in the 986–990 region had a profound impact on 
channel gating by voltage and menthol, as evidenced by the modulation of the conductance-to-
voltage (G-V) relationships.  
Another example of allosteric antagonism came from the study of Miller and co-workers190.  They 
proved the rabbit polyclonal antibody ACC-049 to be full antagonist of TRPM8 cold and icilin 
activation, by blocking the channel pore and avoiding the cations entrance. Species-specific 
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differences were found for menthol activation, supporting, again, that there are different critical 
residues/regions within the TRPM8 channel. 
On the other hand, further motivation arose from some results obtained in my previous studies. 
Indeed, among the actives found through the previously described HTS study, a non negligible part 
of them (about 10%) were characterized by a quite hydrophilic profile, as supported by their log P 
values lesser than 2.5, which appears to be seemingly incompatible with the hydrophobic 
environment of the orthosteric intramembranous binding domain.  
While considering that the difference of potency between the molecules used for setting up the 
screening strategy (nanomolar antagonists) and the screened ones (low micromolar antagonists) is 
presumably a key factor influencing the consistent decrease of the EF values as measured along the 
two screening studies (from around 32 to 8, one fourth), the role of a secondary binding domain, in 
which part of the active molecules can interact, might be a second factors to be to explain why 
docking simulations didn’t rank most of tested antagonists in the top of the ranking. 
Based on these observations, our interest has understandably been directed to the search of a 
secondary ligand binding domain, presumably located in the extracellular part of the channel, where 
hydrophilic ligands (or, more generally non Tyr745-depending antagonists) can be conveniently 
accommodated blocking the channel through a lid mechanism on the pore entrance. 
In order to explore this possibility, a blind docking study on the whole surface of the tetrameric 
TRPM8 model has been performed. So obtained potential pockets have been selected and 
complexes analysed. The most promising area, structurally compatible with the hypothesized 
accessory domain, has been promoted to a mutagenesis experiment, whose results, unfortunately, 
did not support what was predicted in silico. 
 
 
3.4.2 Blind docking strategy. 
 
Although working on the single monomer would be much less time demanding, and, at a first 
glance, it could even be enough to explore most intra- and extra-cellular portions, especially for the 
sensor module, such an approximation could neglect suitable binding pockets located at the 
interface between two or more monomers of the channel. With a view to exploring all possible 
binding domains, the docking calculations were thus performed on the whole TRPM8  tetrameric 
structure. 
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To what concern the set of molecules used as probes and considering its early stage, the study was 
focused on known nanomolar antagonists, in order to reduce as much as possible false negative  
results, leaving the molecules from the HTS for the following steps. 
So, a dataset of ten representative antagonists was generated, by collecting several potent AMTB 
derivatives, chosen due to their marked hydrophilicity, with some more hydrophobic antagonists 
known to be independent from Tyr745, such as BCTC, CTCP, and SKF96365. 
The docking calculations were performed by using Biodock191, an in house pure stochastic docking 
program, able to produce, evaluate and classify a high number of complexes between two 
interaction partners in a rapid and efficient way. Both the ligand and the protein were kept fixed. 
For each compound thousands complexes have been screened and the most stables were clustered, 
optimized and visually analysed.  
Among the most populated and top-ranking clusters, only few had suitable features in terms of 
location, size and residues involved. In particular, two pockets stand out from the findings: a first 
one is located on the extracellular side of the sensor module while the second is located within the 
pore loop. So individuated regions were further characterized. Indeed, the obtained complexes were 
optimized by NAMD energy minimization, in order to refine the binding mode and the relative 
scores, and then the refined complexes were analyzed to highlight the most conserved patterns of 
interactions.  
 
 
3.4.3 Sensor module putative pocket. 
 
On the extra-cellular side of the sensor module domain, a calyx made by the two parallel loops 
(here loop 1 and loop 2), linking S1 to S2 and S3 to S4, respectively, hosted many molecules of the 
probe set, with remarkable interaction energies. The so arranged loops define a potential binding 
pocket with interesting chemical features.  
Loop 1, on the right of the here reported schemes, exhibits mainly polar residues, in agreement with 
the hydrophilic nature of the extracellular environment, namely His720, Lys721 and Lys722. On the 
other flank of the calyx, loop 2 exposes several aromatic amino acids, like Tyr732, deeply in the 
pocket, and Phe832, more superficially. The so framed area can be seen as a triangular pyramid, 
oriented with the top toward the membrane, with height of about 7 Ǻ and sides of 8, 8.5 and 9 Ǻ, 
approximately. On these grounds, the maximum length of the hypothetic allosteric modulators 
should be not more than 14 Ǻ, still sufficient to harbour all molecules used in this study. 
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As reported in the Scheme 3.4.1, the pharmacophore resulting from the pocket analyses should 
contain, substantially, three chemical substructures, which brings to mind those defined to develop 
the pharmacophore model for the TRPM8 antagonists (see paragraph 3.2.7) (i) an 
hydrophobic/aromatic moiety that should stabilize the complex through π-π stacking with the 
Phe832 side chain as well as through hydrophobic interaction with Leu825 aliphatic chain; (ii)  an 
H-bond acceptor to form an Hydrogen bond with imidazole function of Hys720 (circled in red), 
flanked by protonated amines of Lysine residues, that could be able to drive partial negative head of 
ligands; (iii) and a second aromatic moiety, even better if substituted in order to form an H-bond 
with the hydroxyl function of the Tyr826 or the Thr732, intended to establish a second π-π stacking, 
so stabilizing the complex. 
 
 
 
 
 
Scheme 3.4.1 Bi-dimensional representation of the putative 
 accessory TRPM8 ligand bind domain on sensor module  
and related pharmacophore model. Putative crucial Histidine circled in red. 
 
 
As example of satisfactory complexes between the putative accessory TRPM8 binding pocket and 
two representative antagonists, namely CTPC ((2R)-4-(3-chloro-2-pyridinyl)-2-methyl-N-[4-
(trifluoromethyl)phenyl]-1-piperazinecarboxamide) and a diamine derivative taken from patent WO 
2010010435 A2, are here described (Figures 3.4.1-2, respectively). 
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To what concern CTPC, the trifluoromethyl-phenyl moiety establishes π-π stacking with Tyr826, an 
interaction further stabilized by a H-bond between the hydroxyl function of Tyr826 and a fluorine 
atom. The piperazinecarboxamidic moiety establishes a well-conserved H-bond with His720, while 
the chloro-pyridyl tail stabilizes π-π stacking and apolar interactions with Phe735 and Leu825, 
further strengthened by a H-bond between pyridyl nitrogen atom and the Leu825 backbone group. 
Moreover, the complex shows a very favourable docking score which further supports how 
hydrophobic antagonists can be suitably accommodated whiten the hydrophilic environment of this 
putative pocket. 
And indeed, docking results show that also the more hydrophilic benzimidazole derivatives are able 
to successfully interact with the accessory pocket. An example of this class is offered by the 
complex for diamine derivative. The ligand phenyl ring elicits π-π stacking with Tyr826 and 
His720, which also establishes the conserved H-bond with the ether oxygen, while the oxazol-
pyridyl moiety and the charged amine establish H-bonds with Ser824 and Ser733, respectively. 
 
 
 
 
Figure 3.4.1Representative scheme of CTPC-putative sensor module binding domain interactions. 
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Figure 3.4.2 Representative scheme of  
diamine derivative-putative sensor module binding domain interactions. 
 
 
3.4.4 Pore module extracellular putative pocket. 
 
At the entry of the channel, a second putative accessory binding domain was found (Scheme 3.4.2). 
Here, the four extracellular loops, linking S5 to S6 segments of each monomer, flank each other and 
delimit the pore. Here, the exposed residues appear to be mostly involved in ions detection and 
regulation. 
The possibility that this region represents an allosteric modulation site is in line with many other 
known receptors, in which the antagonists bind the protein at the entry of the channel and physically 
blocks the ionic flow, acting as a cork, as proposed by Miller for the antibodies. Alternatively, the 
antagonist binding can lead to a refolding of the area, thus preventing  the normal ionic flow.  
In detail, the TRPM8 putative accessory binding site appears to be within the channel, a bit 
displaced in respect to the longitudinal axis of the pore. Here, three of the four monomeric 
intramembrane loops are mainly involved into framing the sub-pocket. Immediately deeper, going 
in the intracellular direction, pore module helices complete the pocket, by exposing both polar and 
apolar residues toward the pore. The putative site appears, then, to be straight, long and tight, 
allowing the ligand to enter maintaining an extended conformation.   
The top of the putative binding site is mostly characterized by polar residues, in agreement with the 
extracellular environment. Here, Asn934, Lys937 and Pro938 of the monomer A, Thr930 and 
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Thr932 of monomer B, and Tyr905 and Asn934 of monomer C frame the extracellular side of this 
putative pocket. Deeper, monomer A and B mostly contribute to complete the site with several 
hydrophobic residues, such as Val941, Phe951, Ile957, Val960 and Pro907, Phe912 respectively. 
 
 
 
 
 
Scheme 3.4.2 Bi-dimensional representation of the putative 
 accessory TRPM8 ligand bind domain within the pore module  
and related pharmacophoric model. 
 
As for the previous docking calculations, the computed complexes between this putative accessory 
binding pocket and two representative ligands, namely BCTC and the same a diamine derivative 
previously shown are here reported (Figures 3.4.3-4, respectively). 
BCTC enters the pocket with its t-butyl-phenyl ring, that seems to drive the molecule down to the 
pore attracted by the hydrophobic area at the bottom of the pocket. Here, both Phe931 and Phe951 
of monomer A stabilize the complex through π-π stacking interactions with the aromatic ring, while 
t-butyl group elicits a set of apolar contacts with the surrounding alkyl side chains. Then, the urea 
moiety establishes two H-bonds with His928 on chain A and with Tyr905 on chain B, respectively. 
Finally, the chloro-pyridyl ring interacts with Pro938 on chain A, Ile904 on chain B and Phe931 on 
chain B via hydrophobic interactions, while the pose is further stabilized by a H-bond between the 
pyridyl nitrogen atom and the ammonium head of Lys937 on chain A.  
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Again, an example of a computed complex with a more polar diamine derivative is reported. 
Similarly to the BCTC binding mode, the hydrophobic methyl-phenyl head is inserted deeply into 
the pocket, attracted by hydrophobic/aromatic residues such as Phe951, Ile957, Val 960 and 
Met964. Next, the ether oxygen atom establishes a H-bond with His928, while the ammonium head 
stabilizes a ion-pair with Glu942 on chain A. On the pocket rim, the oxazol-pyridyl moiety contacts 
Ser902 and Lys937 on chain A, and elicits a π-π stacking interaction with Phe931 on chain C. 
 
 
 
Figure 3.4.3 Representative scheme of BCTC-putative pore module binding domain interactions. 
 
 
 
 
 
Figure 3.4.4 Representative scheme of  
diamine derivative-putative pore module binding domain interactions. 
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3.4.5 Virtual screening validation. 
 
In order to select the putative accessory pocket to be promoted to mutagenesis studies for an 
experimental validation, a virtual screening campaign has been performed on both putative binding 
domains: the best performing one, as evaluated in terms of enrichment factors and skewness values, 
will be preferred. 
The database of active and decoy molecules was, then, collected by selecting 120 active molecules 
from the previous HTS study the log P value of which was lower than 2.5. To these molecules, 
11880 decoy molecules,  proved to be inactive in HTS, have been added in order to obtain a dataset 
containing 1% of active compounds. These decoys were selected according to their log P average 
value, as well as to their molecular weight and charge in order to avoid biasing conditions. 
Unfortunately, as happened for the entire HTS set of molecules used in the previously described 
virtual screening study, selected hydrophilic active molecules possess a lower potency compared to 
the molecules initially used as probe to detect the accessory binding pocket. This might reflect in a 
partial incapacity to correctly rank the 120 active compounds, but it would not represent a biasing 
problem since it will equally affect both putative pockets. 
By considering the best performing procedure as evidenced in the previous in silico virtual 
screening study, also here docking simulations were performed by the Ligen docking program and 
using the previously described benzimidazole complexes as the pharmacophoric templates. Docking 
calculations were performed in a 8 Ǻ radius sphere around the center of mass of the antagonists 
used as the templates. The LiGen score function was used to rank the resulting complexes. 
To evaluate the performances of the two screening studies and besides the skewness values, the 
enrichment factors were calculated by considering the following arbitrarily chosen percentages of 
the ranking: top 1, 2, 5, 10 and 20 %. Results of the screenings on both the sensor module and the 
pore module putative pockets are reported in Table 3.4.1 and Table 3.4.2, and the histogram plots of 
the entire distributions are reported in Figure 3.4.5 and Figure 3.4.6, respectively. 
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n (top %N) Cpds Act EF Sk 
1 120 4  (1) 4 
2 240 11 (2) 5,5 
5 600 24 (5) 4,8 
10 1200  45 (10) 4,5 
20 2400  64 (20) 3,2 
2,01 
 
 
Table 3.4.1 Sensor module-Virtual Screening evaluation. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act” stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
 
 
n (top %N) Cpds Act EF Sk 
1 120 1 (1) 1 
2 240 4 (2) 2 
5 600 12 (5) 2,4 
10 1200  22 (10) 2,2 
20 2400  40 (20) 2 
0,78 
 
 
Table 3.4.2 Pore module-Virtual Screening evaluation. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act” stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
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Figure 3.4.5 Sensor module-Virtual Screening distriburion. 
The  histogram plot reports the number of actives per cluster. 
 
 
 
 
Figure 3.4.6 Pore module-Virtual Screening distribution. 
The  histogram plot reports the number of actives per cluster. 
 
 
As clearly evincible from results in both tables and histogram plots, the best distribution was 
obtained for the docking calculation performed into the extracellular putative pocket within the 
sensor module. Especially for the lowest percentages, namely top 1 and top 2 %, the markedly 
higher EF values emphasize the greater reliability of the first binding pocket. However and even if 
it performs better than the pore module binding site, the screening results are far from the ones 
performed within the orthosteric binding site, where both EF and skewness values were higher and 
statistically more significant. On the basis of the screening results, the putative accessory pocket on 
the sensor module underwent to mutagenesis validation.  
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3.4.6 Mutagenesis study. 
 
With these results in hands, the following step was selecting the putative key residue of the selected 
accessory binding site for a mutagenesis study, performed by Axxam s.p.a along with four residues 
within the TRPM8 orthosteric binding site, selected to investigate differences in the mechanism of 
action between icilin and menthol-related compounds.  
His720 was then chosen, since it is involved in the most conserved H-bond in the generated 
complexes. It was mutated into an alanine residue, whose apolar side chain cannot preserve the 
mentioned polar interaction.  
Aim of the study was to prove for the generated mutants the activity of icilin and menthol-related 
molecules; then, the capability of selected TRPM8 antagonists to inhibit icilin- or menthol-like 
Cooling Agent 10-mediated activation was tested. 
For the first step, mutation of His720 in Ala  showed no effect on both icilin-mediated and menthol-
related compounds activations compared to the wild type response profile, meaning that this amino 
acid is not involved in agonist binding, in line with the expectations.   
Contrarily, as expected for the orthosteric residues, mutations of Asn799 and Asp802 in Ala 
completely abolished TRPM8 activation by icilin since these aminoacids are involved in the icilin 
binding. The same effect was also observed  for mutation of Tyr745Ala and for Ile746Ala 
indicating that also these amino acids play crucial roles for the icilin binding.  
In the case of activation by menthol-related compounds, all the constructs behaved similarly 
towards the tested agonists Cooling Agent 10, WS-3 and menthol confirming a similar binding 
mode. Mutations of Ile746 or Tyr745 in Ala greatly reduced or completely abolished their TRPM8 
activation while mutations of Asn799 and Asp802 which are located in the icilin-binding site 
showed any effect on neither maximal TRPM8 activation nor EC50.  
Then, the activity of selected TRPM8 antagonists has been evaluated on the TRPM8 mutants. 
Unfortunately, His720 mutation keep showing no effect on the receptor response profile, suggesting 
that is not involved in antagonist activity, even thought this was encouragingly supported by 
computational studies.  
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3.5 Computational selectivity prediction study on hTRPMs. 
 
3.5.1 Introduction. 
 
The last part of the studies on TRPM8 involved the selectivity prediction for the active compounds 
as obtained from the above described wet-lab HTS study. Indeed, it is well known that a major 
factor which hampered the clinical development of TRPM8 antagonists is their poor selectivity 
profile which render their use potentially unsafe.  
The present study was focused on the highly homologous TRPM subfamily (TRPM1-TRPM8) and 
although it includes some clear approximations which will be later detailed, it led to some 
meaningful results. The study started from the already discussed docking results on TRPM8 and, 
with regard to TRPM5, it exploited the complete TRPM5 monomer which was modelled by 
fragments as described in Chapter 4. Hence, the study can be subdivided into two major parts. In the 
first part, the sensor modules (S1-S4) of the not yet modelled TRPM members were modelled by 
using the corresponding TRPM8 domain as the template. Then, the seconds part involved analysis 
and comparison of the results obtained by docking simulations performed on the so generated seven 
TRPM sensor modules (TRPM1-TRPM7) by utilizing a dataset including all the 1739 active 
molecules as found by HTS plus 10000 randomly selected inactive molecules, thus obtaining a 
reasonably manageable dataset.    
 
 
3.5.2 Homology modeling of the sensor module. 
 
Although utilizing a homology model as the template to generate other homology models is highly 
questionable, here such a choice can be justified by several key reasons. Firstly and as reported in 
Figure 3.5.1, there is a high degree of homology at least to be concern the S2-S3 segments which 
are directly involved in ligand recognition. In detail the triad of key residues involved in the binding 
processes (Tyr745, Asn799 and Asp802) are constantly conserved in all TRPM members and the 
sole minor difference is seen for TRPM6 which bears a glutamate (Glu911) instead of an aspartate. 
The same degree of similarity is also observed in S4 (data not shown) that, despite not being 
directly involved in binding, includes some key residues involved in the channel activation as above 
described for TRPM8. Some differences are observed in S1, especially with regard to their length 
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since in four members it includes a greater number of residues showing an additional peptide of five 
conserved residues in their N-terminal tail. However, S1 has a very limited role in binding and thus 
such difference should minimally impact on docking results. Secondly, the utilized TRPM8 model 
was extensively validated by both MD and docking simulations investigating in depth both ligand 
binding and activation mechanism. Hence and while considering the potential risks in using a 
homology model as the template, the here utilized TRPM8 template seems to be accurate enough to 
assure that reliable homology models can be generated at least to be concern the appropriate 
architecture of their binding sites. Thirdly and while avoiding to trivialize the performed 
calculations, the primary objective of this analysis is to gain some insights about the factors 
governing the subtype-selectivity with the TRPM subfamily without delving a specific TRPM 
member. Hence, the introduced approximations appear to be adequate to the planned objectives and 
do not significantly undermine the reliability of the obtained global results.  
 
                                                                                            
            
 
 
Figure 3.5.1 S1-S3 sequences alignment for all TRPM members; 
key residues boxed in black. 
 
 
On these grounds the primary sequences of the sensor modules were retrieved from UniProt and 
firstly aligned by using ClustalX as reported in Figure 3.5.1 and above discussed. The amino acid 
sequences were then used to generate the corresponding homology models by using Modeller and 
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the TRPM8 model as the template.  In detail, the models were generated by Modeller9.10 using the 
default parameters and generating 20 structures for each run. Among the generated models, the best 
structures were selected according to (a) the scores computed by Modeller9.10 (i.e. DOPE and 
GA341) (b) the percentage of residues falling in the allowed regions of the Ramachandran Plot; (c) 
the agreement with the predicted secondary structure from the sequence alignment especially to be 
concern the TM helices; (d) the lack of not predicted gaps. Notice that the loops of the sensor 
modules are rather short segments and so their folding is clearly constrained by the arrangement of 
the TM helices. The so selected four-helix bundles were then completed by adding hydrogen atoms 
using VEGA. According physiological pH, Arg, Lys, Glu and Asp residues were preserved ionized, 
while His residues were considered neutral by default. The completed models were carefully 
checked to avoid unphysical occurrences such as cis peptide bonds, wrong configurations, improper 
bond lengths, non-planar aromatic rings or colliding side-chains. Finally, they were optimized by a 
final minimization made up by two phases: first a minimization without constraints until RMS = 0.1 
and then a second minimization with backbone fixed until RMS = 0.01 to preserve the predicted 
structure.  
The high degree of similarity among the modelled sensor modules is clearly documented by Figure 
3.5.2 that for clarity reports the superimposition of the pivotal segments (S2 and S3) highlighting 
the three key residues involved in ligand binding. While considering their remarkable similarity, the 
considered binding sites show some significant differences which allow them to be grouped into 
two well defined groups. As schematized in Table 3.5.1, the TRPM’s binding site can roughly be 
subdivided into two sides. A more internal side which is bears the three key residues and is flanked 
by other mostly hydrophobic residues and a more external side which is mainly characterized by 
hydrophobic residues which however show some relevant differences regarding the abundance of 
aromatic residues. In detail, Table 3.5.1 reveals that (a) TRPM3, TRPM4 and TRPM8 show only 
one aromatic residue in their external region; (b) TRPM1 and TRPM6 include two aromatic 
residues and (c) TRPM2, TRPM5 and TRPM7 include three or more aromatic residues in the more 
external side of their cavity. A careful analysis of the modelled binding site emphasizes that the 
pockets of the subtypes belonging to the third group are clearly more deepen, and while remaining 
substantially superficial binding site, they should be sterically more constrained for the hindrance 
exerted by the aromatic residues. Some slight differences are noticeable in the residues flanking the 
three key conserved residues. Indeed in most subtypes the key residues are surrounded by apolar 
side-chain but in some cases the more internal side is characterized by additional polar residues 
which can play a crucial role in determining the subtype selectivity. As examples, one may cite 
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TRPM2 which shows a second aspartate residue in that region or TRPM6 and TRPM7 which 
possess there an additional H-bonding threonine residue.        
 
 
 
 
 
Figure 3.5.2 Superimposition of TRPM1-7 S2 and S3 helices.  
Key residues are highlighted in ball and stick. 
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Subtype Key residues Internal side External side 
TRPM1 Tyr838, Asn900, Asp903 Trp899, Ile907 Tyr841, Phe845, Leu482 
TRPM2 Tyr806, Asn869, Asp872 Val873, Asp866 
Phe809, Leu810, 
Phe813, Trp868 
TRPM3 Tyr905, Asn967, Asp970 Leu971, Ile974 Leu839, Tyr908, Leu911 
TRPM4 Tyr790, Asn865, Asp868 Leu869 Trp864, Leu791, Leu794 
TRPM5 Tyr742, Asn808, Asp811 -- 
Phe743, Leu746, 
Phe749, Trp807 
TRPM6 Tyr849, Asn911, Glu914 Thr915 
Leu850, Leu853, Phe856, 
Trp910 
TRPM7 Tyr863, Asn925, Asp928 Thr829, Ile926 
Phe866, Leu867, 
Tyr870, Phe924 
TRPM8 Tyr745, Asn799, Asp802 Leu806, Phe807 Ile736, Leu750 
     
 
Table 3.5.1 Residues involved in the ligand binding domain, reported for TRPM1-8. 
 
 
3.5.3 Docking results. 
 
With the above described homology models in hand, docking simulations involved a reasonably 
manageable dataset including the 1739 active molecules as found by HTS plus 10000 randomly 
selected molecules from among the inactive compounds as found by HTS. The resulting database  
underwent to docking simulations on all the seven remaining TRPM subtypes. TRPM8 was not 
considered since these ligands were already docked in the previous study and more importantly 
their biological activity towards TRPM8 was experimentally evaluated by HTS. Docking 
simulations were performed by using AutoDock. For all receptors, the search involved a 10 Å 
radius sphere around the key (and central) aspartate residue thus encompassing the entire cavities by 
applying the computational settings already described in paragraph 3.2.8. Although Ligen 
performed better in previous docking simulations, AutoDock was here utilized since Ligen results 
are particularly dependent on the availability of validated starting complexes to derive the 
corresponding pharmacophore models. Without these initial complexes, a stochastic program like 
AutoDock should be more reliable. 
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The so obtained results of each screening were ranked and analyzed by considering for how many 
subtypes the active molecules was in the top 30%, 50% and 70%. Ideally a TRPM8 selective ligand 
should not be in the top 70% for all other TRPM members. Contrarily, a pan-selective ligand should 
be in the top 30% for all TRPM members.  
Figure 3.5.3 shows the obtained distributions and reveal a parabolic profile which should be 
indicative of a sort of binary behaviour. When considering the top 30% distribution a large part of 
compound are absent for all remaining seven members (the termed bin ‘0’) and the found 
percentages progressively decreases in the following bins. This result is clearly understandable 
since it is improbable to find active molecules when considering a so challenging percentage 
(namely the top 30%) However and as later discussed, the distribution shows a parabolic trend since 
they re-increase in the bins ‘6’ and ‘7’. On the other hand when considering the most generous top 
70% profile most compounds appear to be understandably affinitive for all subtypes and the bin ‘7’ 
is the most populated one.  
A remarkable result is offered by the intermediate top 50% and here the parabolic profile is really 
evident since ‘0’ and ‘7’ are the two most populated bins while the central bins are progressively 
less populated. As mentioned above, these results seem to suggest that the active molecules can be 
roughly subdivided into selective and pan-selective compounds and molecules which putatively 
interact with three of four subtypes represent a marked minority. While considering the small 
differences between subtypes described above, this result can be interpreted considering the high 
degree of similarity shared by all TRPM members. Stated differently, an active molecule either has 
some peculiar features which render it selective for TRPM8 or it interacts with the three key 
residues and thus it unavoidably binds all subtypes. The obtained results suggest that the TRPM8 
binding site has some distinctive structural properties which do not allow intermediate possibilities 
and which should allow the design of truly selective ligands.  
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Figure 3.5.3 Graphical distribution of actives selectivity profile. 
Actives are considered ranked within the top 30, 50 and 70 % of the set; 
 bins going from “0” to “7” account for  the TRPM8 itself  to all TRPM members together, 
respectively,  by including one more model per bin. 
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4. Computational studies concerning the hTRPM5 ion channel 
 
4.1 TRPM5 structural features. 
 
Located within the Beckwith-Wiedemann syndrome critical region-1 on chromosome 11p15.5, and 
identified in a study on genes correlated to such a disease, although it has been shown to be 
unrelated to this pathological condition, the human TRPM5 gene comprises 24 exons and predicts 
for a 1165 amino acids protein192. Within the melastatin sub-family, TRPM5 has highest homology 
with TRPM4, showing about the 42% of identity and 55% of similarity, while it is more distantly 
related to other members, such as the cold and menthol receptor TRPM8, with which the homology 
level is about 30% of identity and 45% of similarity. 
In line with the conserved structure of almost all TRP members, TRPM5 as well is thought to 
spatially arrange in large intracellular amino- and carboxy-termini and in a transmembrane domain 
composed by six TM helices (S1-S6). It is expected to assemble in a homo-tetrameric structure 
since so far there is no evidence that it can co-assemble with any other TRP monomers, and no 
different interacting proteins have been reported as well. 
The binding site for chemical agonists and antagonists has been mapped within the transmembrane 
portion, on the lateral surface of the first four helices block, as seen for the TRPM8. Actually, the 
entire site appears to be quite conserved compared to the TRPM8 one, especially for the highly 
conserved key residues Tyr742 on the S2 helix, and Asn808 and Asp811 on the S3 helix. On these 
grounds, each monomer unity is expected to be able to contact the ligand, and so four molecules 
would bind the tetrameric channel, causing conformational changes which lead to channel opening.  
Intracellular N- and C-termini brings several site expected to be involved in protein-protein 
interaction, specially along the C-terminus, were coiled-coil domains have been predicted. 
The pore channel is predicted to be lined by the transmembrane segments S5-S6 and relative linker, 
relying on the fact that mutations addressed toward aminoacids in theis area reflect into changing in 
the ions selectivity and permeability.  
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4.2 TRPM5 functional features. 
 
Studying the TRPM5 profile in taste cells introduced the idea that it is part of a phospholipase-
mediated pathway193, specially if considering that TRPM5 currents can be generated by stimulating 
Gq-coupled receptors, and their consequent PLC cascade, in many heterologous cellular type194.  
As known, PLC hydrolyzes PIP2 producing DAG and IP3, which in particular stimulates the exit of 
calcium from cytoplasmic stocks, event that, in line with the TRPM5 polymodal activation profile 
discussed later, would directly activate the channel (Figure 4.1).  
To date, this mechanism have been supported by diverse independent studies. For example, it has 
been proved that the previously mentioned PLC dependant TRPM5 triggering doesn’t happens if 
IP3 receptors are blocked or intracellular calcium is not free to move out from the stores and to 
reach the cellular membrane (calcium buffering195), or can contrarily be overstimulated, for 
example increasing IP3 level (UV-uncaging196). 
The resulting model, in which TRPM5 is activated as a consequence of the activation of other 
receptors (taste receptor or GPCRs) leading to increase intracellular calcium concentrations, is 
consistent with physiological data from taste cells and with targeted deletion of taste transduction 
molecules197,198.  
There are many ways in which intracellular calcium signal can be induced and, moreover, 
depending on the trigger, the duration time as well as the intensity may change. For example, 
calcium signal can rise and end very fast, like happens when induced by ryanodine receptors199, 
reaching  20–30 µM concentrations, or can increase slower and stays on for several seconds. 
Clearly, to better understand how TRPM5 channels can be activated by intracellular calcium, two 
fundamental aspects must be investigated: (i) the distance between TRPM5 and calcium source, the 
closer the easier to be activated, and (ii) its sensitivity to calcium. 
The first question can be quickly answered considering that both TRPM5 channels and IP3 receptor 
or PLCβ2 are known to locate across plasma membrane of the whole taste cell, condition that 
strongly supports the possibility that they are part of the same signalling path, like happens, for 
example, for the signaling components of fly phototransduction200. 
For what concern the second aspect, it might be a bit more complicated to be investigated, as seems 
to be reading the not always consistent results in literature. Among the diverse techniques for 
determination of a given receptor calcium sensitivity so far developed, the inside-out patches is in 
all probability the most accurate. Using this approach, experimental evidences attested that TRPM5 
channels are activated by intracellular calcium with an EC50 ranging from 20 to 30 µM201, and this 
value would be in line with the one measured for the activation of native channels in taste cells, that 
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is about 8 µM. Moreover, this sensitivity profile is not stable during the activation, but has been 
proved to decrease up to 80 µM, event that might be partially explained considering the decreasing 
stocks of PIP2 in the environment. All these data depict a condition in which  TRPM5 would be so 
activated only if located close to the calcium stores. 
The situation changes if approaching the measurement with the whole cell recording technique, 
from which evidences TRPM5 appears to be much more sensitive to calcium activation202, allowing 
it to respond to the stimulus even if far from its location. Several considerations can intervene to 
level this important difference, such as the “calcium-induced calcium release”, that would allow 
even really low calcium concentrations to activate TRPM5 through the release of more calcium 
from intracellular stores, making the channel able to detect not only local but global calcium 
changes as well. 
It is worth noting that TRPM5 and TRPM4, despite being the only two TRP channels activated by 
Ca2+, they are not crossed by this ion. Moreover, TRPM5 channels show little discrimination among 
the monovalent cations too, namely Na+, K+ and Cs+, that has been attributed to several residues 
along the putative pore, basing on mutagenesis studies in which changing them with the 
correspondent residues of the calcium permeable TRPV6 led to a slight but detectable calcium 
permeability203.  This further confirmed that S5-S6 linking loops of each monomer act in cation 
detecting and filtering, but unfortunately, so far, no experimental evidence has been able to reveal 
the relation between residues and ion selectivity, suggesting that multiple residues or regions might 
cooperatively contribute to this feature. 
Beside calcium-induced activation, TRPM5 was proved to respond to voltage shifts as well204, like 
happens for TRPM8 and TRPM4 members, suggesting how this event could intervene as a 
modulator of the diversely-induced channel gating205, as the cold regulation of TRPM8, TRPV1 and 
TRPM5, and the PIP2 regulation of TRPM4 and TRPM8206. Unfortunately, differently from the 
mentioned modulating system for which a good part is now clear, voltage modulation of TRPM5 is 
still quite unknown. 
TRPM5 activity is regulated by lipids as well. Several experimental evidences proved the 
phosphoinositide PI(4,5)P2 to participate in the activation of many ion channels, among which 
TRPM5, and indeed the its hydrolysis products have been proposed to underlie rundown of many 
PI(4,5)P2-sensitive ion channels207. Beside PIP2, arachidonic acid as well, probably generated in 
taste cells from DAG by the actions of PLA2-IIA, is another lipid that seems to be involved in 
TRPM5 regulation208. 
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Recently, TRPM5 was proved to respond to long-chain unsaturated free fatty acids, so being related 
to the fat taste sensing. Just to mention one example, linoleic acid was proved to depolarize mouse 
taste cells so eliciting a robust intracellular calcium rise via the TRPM5 activation209. The induced 
responses were shown to depend on G-protein-phospholipase C pathway, suggesting how G-
protein-coupled receptors are involved in the transduction of fatty acids. Moreover, mice lacking 
TRPM5 channels exhibits no preference for and reduced sensitivity to linoleic acid. 
Finally, TRPM5 was found to respond to warm temperatures, even though it is structurally more 
related to the cold-activated TRPM8 than to the heat-activated TRPV members210. Here, heat was 
speculated to intervene by shifting the midpoint for voltage-dependent activation toward negative 
voltages, contrarily to what happens for TRPM8, which goes toward more positive values. 
Nevertheless, heat is not sufficient to activate TRPM5, which even at warm temperatures still 
requires the Ca2+ contribute.  
TRPM5 is sensitive to extracellular pH level below 7.0 and is completely blocked by pH 5.9211. By 
comparison, TRPM4 is insensitive to pH levels as low as 5.4. Two residues account for most of the 
pH sensitivity of TRPM5, a glutamate in the S3–S4 linker and a histidine in the pore region. 
 
 
 
 
 
 
Figure 4.1 TRPM5 taste transduction mechanism. 
(Picture from the work of Liu and colleagues212) 
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4.3 TRPM5 expression. 
 
 
TRPM5 was first reported to be expressed in mammalian taste buds, in a subset of cells that co-
express receptors for bitter, sweet, and umami tastes. Subsequent studies showed a more wide-
spread distribution of the channel. Using a mouse in which the TRPM5 promoter drives expression 
of GFP213 or direct antibody labelling, TRPM5 expression has been detected in two distinct subsets 
of olfactory neurons, namely ciliated and microvillous neurons, in the vomeronasal organ, in the 
gastrointestinal tract, and in the respiratory system. In most of these tissues, TRPM5 is expressed in 
solitary cells. Within the gastrointestinal system, TRPM5 is expressed in the stoma, small intestine, 
and colon in sparely distributed solitary cells.  
TRPM5 is also expressed in pancreatic islets, where it is localized into insulin secreting β-cells. In 
addition, there are a few reports describing the TRPM5 expression in the central nervous system.  
 
 
 
4.4 TRPM5 physiology. 
 
As already mentioned,  TRPM5 was found to be highly expressed in the subset of taste receptor 
cells that mediate bitter, sweet, and umami taste. The corresponding taste-sensing pathways start 
activating the G protein gustducin and phopholipase C β2 followed by an intracellular cascade 
leading to membrane depolarization and ATP release. Data from electrophysiological experiments 
showed that a TRPM5-dependent current follows the increase of IP3 or Ca2+ concentrations214.  
Tastants-mediated activation of taste receptors was found to generate TRPM5-related events as 
well215, attesting how TRPM5 is crucial for normal sensing, how strongly suggested by 
experimental studies on knockout animals in which the lack of TRPM5 reflects in a considerable 
less sensitive to bitter, sweet, and umami, although preserving both sour and salty sensing216. 
Similarly to TRPM8, besides sensory tissues, TRPM5 is known to be expressed in many non 
sensory tissues as well. Just to mention few examples, duodenum and stomach cells express 
TRPM5, that it is believed to play a role in post-ingestive chemosensation217; the respiratory and 
olfactory epithelia as well present TRPM5 in solitary chemosensory cells, where it may function 
downstream of bitter receptors to detect inhaled irritants or pheromones218. 
An important role is played by TRPM5 in pancreatic β-cells, where it was found to be involved in 
insulin secretion219. In detail, rising blood levels of glucose induces its uptake into β-cells, where it 
imbalances ATP against ADP, and so blocks a specific family of ATP/ADP sensitive potassium 
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channel, with consequent depolarization of the membrane potential may be through the opening of a 
still not determined channel, probably sodium permeable. Here, voltage gated calcium permeable 
channels are gated allowing the intracellular calcium level to rise and directly acts on the insulin 
releasing from intracellular stores220. 
To date, many actors have been proposed to regulate these depolarizing currents, including TRPM4, 
TRPM2, and TRPM5, which in particular has been tested in knockout animal in vivo studies. In 
detail, in response to glucose administration, TRPM5 lacking animals showed a decrease in both 
insulin secretion and glucose clearance if compared with wild type mice221, suggesting how TRPM5 
would intervene in the only partially known genetic propensity to develop the pathology and, 
hopefully, how important it would be as target for pharmacological treatment of diabetes or 
metabolic diseases in general.  
 
 
4.5 TRPM5 pharmacology.  
 
The first field in which TRPM5 ligands, specially antagonists, have been explored is the taste 
sensing manipulation, with the aim to alterate the TRPM5-related tastes perception, may be so 
masking unpleasant sensations for both drugs and foods oral ingestion. 
To date, really few selective molecules have been discovered. Among the non selective ones, for 
example, the bitter chemical quinine was found to block TRPM5 too, with an EC50 of 50 µmol, and 
the contemporary administration of quinine with a sweetener agent was proved to silence the sweet 
response, so supporting the mentioned interaction between sweet and bitter tastes222. 
In a HTS for specific TRPM5 antagponists, triphenylphosphine oxide (TPPO) was identified223, 
reported to act with an IC50 value of 12 µmol. Contrarily, the related triphenylphosphine showed no 
effect, indicating how the oxygen atom would be crucial. TPPO appears to be specific for TRPM5, 
and no effect of TPPO on the activity of TRPA1, TRPV1, or TRPM4 was observed. 
Nicotine as well has been proved to inhibits TRPM5 channel. In a study aimed to investigate the 
consequences of the oral administration of nicotine and its metabolites, such as cotinine, they were 
found to reduce the activity of neurons in the nucleus of the solitary tract224.  
Nicotine in particular affects TRPM5 channel, decreasing the maximal whole-cell conductance and 
augmenting the rate of channel closure. Besides negatively acting on TRPM5 it also affects IP3 
receptors, as well important for sensing the sweet taste. Moreover, intracellular Ca2+-release 
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channel activity was proved to be promoted by the nicotine, while highly inhibited by quinine, and 
only modestly by caffeine, theobromine and theophylline. 
 
 
4.6 TRPM5 Homology modelling. 
 
As for TRPM8, at the time of the study and so up to now, the TRPM5 structure was not yet 
resolved by crystallographic experiments. So, the TRPM5 modelling was based on homology 
techniques by adopting a fragmental strategy, since highly homologous global templates were 
unavoidable. Such an approach tends to favour the local homologies shared with different templates 
thus allowing more reliable models to be generated. 
Human TRPM5 primary sequence was then subdivided into structural domains, namely the N- and 
C-termini, the six transmembrane helices and the five relative loops. Except for the intracellular 
domains, modelled by using the importin beta and the HCN2 pacemaker channel as the templates, 
respectively (as already done for TRPM8) all fragments were submitted to FUGUE online server 
for their homology modelling.  
As already described, FUGUE tool is able to manage more then one request per time. In absence of 
highly homologous templates, it conveniently produces many different solutions among which it is 
possible to select the most promising ones in a reasonably time. Another interesting feature is that 
FUGUE generates structurally reliable models even for rather short peptides thus rendering this on 
line tool particularly well suited for the fragmental strategy 
For each segment and among the realistic models produced by FUGUE, the preferred structure was 
chosen considering the following major conditions: (a) the predicted secondary structure from the 
sequence alignment, as obtained using ClustalX; (b) the lack of not predicted gaps; (c) the 
prediction score as calculated by the programs; (d) the helix conformation of six transmembrane 
segments with characteristic slight bend of helices containing proline and glycine residues; (e) the 
global “U” shape for the loops in which the two ends are close enough to join to adjacent TM 
segments. Then, the so selected models were completed by adding side chains and hydrogen atoms 
using VEGA. According physiological pH, Arg, Lys, Glu and Asp residues were preserved ionized, 
while His residues were considered neutral by default. After a careful visual scrutiny of obtained 
structures to avoid unphysical conditions, the segments were minimized and assembled using the 
mammalian Shaker Channel Kv1.2 (PDB: 2A79) as the template, the same used to assemble the 
TRPM8 model. First, the transmembrane helices (S1-S6) were superimposed to the corresponding 
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segments of the Shaker Channel by matching the equivalent Cα atoms. Next, the extramembrane 
loops were manually added, as their arrangement is reasonably defined by the position of 
transmembrane segments. However and as described later, their conformation was further relaxed 
by targeted molecular dynamics simulations. The superimposed fragments were then assembled by 
manually adding the connecting bonds and the so obtained model underwent an initial minimization 
until RMS = 1 to discard high-energy interactions, followed by a local minimization until RMS = 
0.05, where all atoms were kept fixed except for atoms included within a 7.5 Å sphere around the 
manually connected bonds (at the fragment ends). The completed model was carefully checked to 
avoid unphysical occurrences such as cis peptide bonds, wrong configurations, improper bond 
lengths, non-planar aromatic rings or colliding side-chains. Finally, the model was optimized by a 
final minimization made up by two phases: first a minimization without constraints until RMS = 0.1 
and then a second minimization with backbone fixed until RMS = 0.01 to preserve the predicted 
structure.  
 
 
4.7 TRPM5 optimization by  MD simulation. 
 
Differently from the TRPM8 modelling study, in which the entire tetrameric structure was 
generated by protein-protein docking starting from the refined monomer, in this study only the 
monomeric unity of TRPM5 has been considered. This is justified by considering that the 
orthosteric binding domain we were interested in is located on the intramembrane surface of the 
sensor module (S1-S4), in line with the other TRPM members,  and as such their structure is not 
influenced by the presence of the other monomers.  
For further improvement, the TRPM5 monomer underwent to a molecular dynamics simulations 
study, that allows to better refine the entire model, especially to be concern the extra- and intra-
cellular loops while the transmembrane helices which were reliably modelled by homology 
techniques were maintained fixed. Thus, the model was inserted in a cubic box (80 Å x 90 Å x 90 
Å) of water molecules and underwent a preliminary minimization to optimize the relative position 
of solvent molecules. During this minimization and the following MD run the transmembrane 
segments were kept fixed and only loops atoms are free to move. Indeed, the selected water medium 
is clearly unsuitable for TM segments and the MD run was aimed at refining the loop 
conformations. In detail, the MD run had the following characteristics: (a) Newton's equation was 
integrated using the r-RESPA method (every 4 fs for long-range electrostatic forces, 2 fs for short-
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range non bonded forces, and 1 fs for bonded forces); (b) the simulation space was stabilized by 
introducing the Periodic Boundary Conditions (90 Å × 100 Å × 100 Å); (c) the long-range 
electrostatic potential was treated by the Particle Mesh Ewald summation method (80 × 100 × 100 
grid points); (d) the temperature was maintained at 300 ± 10 K by means of the Langevin’s 
algorithm; (e) Lennard-Jones (L-J) interactions were calculated with a cut-off of 10 Å and the pair 
list was updated every 20 iterations; (f) a frame was stored every 5 ps, to yield 2000 frames (g) the  
atoms of TM segments were kept fixed. The simulations were carried out in two phases: an initial 
period of heating from 0 K to 300 K over 300000 iterations (300 ps, i.e. 1 K/ps) and the monitored 
phase of 10 ns. During the MD run, the loops show significant beneficial rearrangements as 
assessed by an increase of about 10 % of residues falling in the allowed regions of the 
Ramachandran plot (from 75.95 % to 84.25%). The so obtained last frames was finally minimized 
and utilized in the following docking simulations. All minimizations in model construction and 
equilibration were performed using the conjugated gradients algorithm. The structural reliability of 
the final model was finally assessed by several parameters such as Ramachandran Plot and side 
chain χ-space. 
 
 
4.8 TRPM5 binding site. 
 
Before starting docking simulations, the so generated TRPM5 monomer was utilized to analyze its 
binding cavity comparing it with that already described of TRPM8. Similarly to the TRPM8 
binding site, the TRPM5 ligand binding domain appears to be markedly apolar, in line with the 
transmembrane environment. Moreover, key residues involved in ligand recognition for both 
models appear to be exactly conserved. In particular, Tyr742, Asp811 and Asn808 (corresponding 
to Tyr745, Asp802 and Asn799 in TRPM5)  arrange their side-chains in a very similar way, and 
thus they should be involved in similar inter and intramolecular interactions, as already mentioned 
for TRPM5. 
However a slight difference can be noted between TRPM5 and TRPM8 binding sites. Indeed, while 
the TRPM8 pocket appears to be completely superficial and lined only by few aliphatic residues, 
such as Ile746 and Leu750, which surround Tyr745 and contribute to the hydrophobicity of this 
region,  the TRPM5 cavity appears to be slightly deeper and surrounded by a greater number of 
aromatic residues which should restrict the cavity capaciousness rendering it more affinitive for 
ligands rich in aromatic moieties. 
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4.9  QSAR validation of the TRPM5 orthosteric site. 
 
Relying on the high homology of the orthosteric binding site between TRPM5 and TRPM8, and 
considering the multiple successful studies through which TRPM8 binding domain has been  
validated, all docking calculations were focused on this site.  
As already mentioned, TRPM5 common activating role in taste sensing clearly suggests that 
TRPM5 blockers could be used as innovative taste masking agents for oral pharmaceuticals with 
unpleasant, bitter-tasting components. On this considerations, I have been mostly interested in 
TRPM5 antagonism, dealing with antagonists from the initial validation stages up to the virtual 
screening campaigns. At the date of the work, really few selective ligands were available in 
literature. Among them, it is worth mentioning the compounds reported by the patent US 7674831 
B2225 from Redpoint Bio Corporation, “Heterocyclic compounds as sweetener enhancers”, dated 
march the 9th, 2010. It describes a set of sweet enhancers developed and tested for their capability to 
improve the activation of TRPM5 in presence of endogenous gating inducers, such as ATP. Among 
the reported heterocyclic compounds, seventeen molecules showed negative percentage of 
activation, ranging from -139 to -16%, thus acting as antagonists. 
So, these molecules have been selected as training set for docking calculations aimed to validate the 
reliability of the binding site of the TRPM5 model. 
The ligand’s structure was built using the VEGA ZZ software, and the overall geometry and the 
atomic charges were optimized using MOPAC 6.0. Their conformational profile was explored by a 
MonteCarlo procedure (as implemented in VEGA) which generated 1000 conformers by randomly 
rotating the rotors. All geometries so obtained were optimized and clustered according to similarity 
to discard redundant ones; in detail, two geometries were considered as non-redundant if they 
differed by more than 60° in at least one torsion angle.  
As done for the TRPM8, all calculations about the orthosteric binding site were performed on the 
single monomer, since this region is located far from the inter-monomer interface regions, within 
the membrane. 
Although the above reported docking simulations on TRPM8 were carried out by the recently 
developed LiGen program, most of the docking simulations here described were performed by 
using Autodock 4.2 and PLANTS programs. When comparing the results obtained by the two 
pieces of software, PLANTS appeared to provide better results in terms of computed poses, 
predictive power and requested computational time. Thus and as in this docking analysis, several 
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studies were initially performed by AutoDock and then repeated by using PLANTS. For the sake of 
clarity, only the optimized results obtained by PLANTS were here described. 
In detail, PLANTS was used with default settings and without geometric constraints. The search 
was focused on a 10.0 Å radius sphere around a centroid defined by the three key residues Tyr742, 
Asp811 and Asn808 thus encompassing the entire binding cavity. For each campaign, speed 1 was 
used, 10 poses was generated for each ligand and scored by using the most exhaustive ChemPLP 
function. The so obtained best complexes were then minimized by keeping fixed the atoms outside 
a 10.0 Å radius sphere around the bound ligand. The refined complexes were then utilized the 
recalculate a set of docking scores including (a) the three PLANTS score functions, (b) the 
AudoDock ones, namely the predicted pKi, the internal (intermolecular) energy, the non-bond 
energy accounting for Van der Waals interactions plus Hydrogen bonds plus the Desolvatation 
energy, the Electrostatic interaction, (c) the X-SCORE scores, namely HP, HM and HS226, (d) the 
AMMP non-bond interaction energy, calculated with SP4 force field, (e) the VEGA ZZ scores, such 
as the MLPInS score227, accounting for the compatibility of hydrophobicity/hydrophilicity between 
ligand and protein, in its four distance related functions (linear, square, cubic or Fermi’s), the 
Electrostatic energy, with and without distance dependent dielectric function, and the non-bond 
interaction energy calculated with CHARMM force field.  
As a representative example of the obtained complexes, Figure 4.2 reports the detail of the complex 
between TRPM5 and compound 2 (2-(2-(2-Methoxyphenoxy)ethylthio)-1H-benzimidazole; -136% 
of activation). It is interesting to observe that the key Tyr742 residue stabilizes pi−pi stacking 
interactions with the ligand benzimidazole which also contacts Asp811. The methoxyphenoxy 
moiety approaches Asn808 with which it elicits H-bonds. Finally the complex is further stabilized 
by a rich set of hydrophobic contacts involving both aliphatic and aromatic side chains.   
Similarly the ligands extracted by the minimized complexes were utilized to compute a set of 
representative ligand-based descriptors. Overall, these descriptors represent the starting point for a 
multivariate QSAR studies by canonical regression techniques, aimed to develop a model, the 
predictive power of which can indirectly confirm the reliability of the obtained model thus allowing 
the activity on unknown antagonists to be predicted. 
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Figure 4.2 Representative scheme of the Cpd2-TRPM5 complex; 
 Compound 2 is visualized in ball and stick; key residues are underlined; 
 hydrophobic residues are reported in violet. 
 
 
 
In this study, the QSAR analyses can be subdivided into two steps since the first part involved the 
development of correlative models by including only ligand-based descriptors, while, in the second 
step, the developed equations exploited all available descriptors. The equations generated in the first 
phase have two major objectives. On one hand, the comparison of the statistics for the best 
equations obtained in the two steps should reveal the effective contribution of the docking 
simulations. Ideally, the equations obtained in the second phase should show significantly better 
statistics; if not, docking simulations would lose a large part of their relevance. One the other hand, 
ligand-based equations can be seen as fruitful tools to filter huge databases so focusing docking 
simulations only on the most promising datasets. 
Considering the small size of the dataset, the developed equations have to include at most two 
variables, to avoid overfitting conditions. To be concern the first ligand-based study, the best 
equation was obtained combining (i) the number of the flexible torsions (FlexTors) of the 
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compound and (ii) its molecular weight (MW). The equation and its statistical parameters are here 
reported, followed by the dispersion plot of the distribution (Eq.1, Figure 4.3): 
 
 
Eq. 1                                pInhib =    2.6332 + 0.0954*FlexTors – 0.0038*MW 
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Figure 4.3 Linear regression for the pInhib predicted with the correlative equation Eq.1  
 
 
As indicated by the signs in the equation, flexible torsions are predicted to positively contribute, 
suggesting how the ligand can preserve its flexibility within the pocket, a results easily explainable 
considering its superficiality. Again, the second term suggests that, despite being not so deep, the 
binding site has however well-defined and constraining spatial requirements since small ligands 
perform better. 
The statistics of the Equation are not really satisfactory, a poor result which emphasizes the scarce 
predictive power of these ligand-based descriptors and invites to involve also docking scores, in 
order to improve the robustness of the model. And indeed, combining both ligand and docking 
descriptors led to much better predictive equations, among which the best performing one is here 
reported (Eq 2, Figure 4.4). It was obtained with (i) the number of the flexible torsions, thus 
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confirming the role of ligand flexibility, and (ii) the scoring function HM_score228,  which is one of 
the three scoring components generating by the well-known X-Score function and which accounts 
for steric hindrance, H-bonds, and hydrophobic interactions, the last one weighted by a value, HM, 
that accounts for the compatibility of the ligand apolar atoms with the environment of the pocket. 
Correlative equation and distribution plot are here reported: 
 
 
Eq.2                           5.4302 - 0.8914*HM_Score + 0.0709*FlexTors 
 
                            r
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Figure 4.4 Linear regression for the pInhib predicted with the correlative equation Eq.2 
 
 
In this case, the statistics of this docking-based equation are consistently higher than those of the 
previous model, as evidenced by their r2 and q2 values. This result affords an encouraging 
confirmation  for the reliability of the here generated TRPM5 homology model, and allow us to 
move to the following step of the validation process, namely the virtual screening test. 
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4.10 TRPM5 virtual screening. 
 
Once the reliability of the main binding site was encouragingly validated by testing its capability to 
correctly interact with representative ligands, the following step was to further assess the TRPM5 
performances in a virtual screening study. Indeed, successful results of the so developed screening 
strategy would represent a further validation of the reliability of the TRPM5 homology model and 
clearly could be applied in screening campaigns on large databases. 
To this end and similarly to what was already described for TRMP8 (see 3.2.8 ) a database of 
known antagonists was collected from patent literature. In detail and besides the 17 compound 
already used in QSAR analyses, antagonists came from four different patents, namely US 0259875 
A1229, US 0306030 A1230, US 0033393 A1231 and US 7723075 B2232. They included (a) 10 triaryl-
substituted imidazole derivatives from the first patent, (b) 5 dimethoxyphenyl-acetohydrazide 
derivatives from the second, (c) 65 acetohydrazide derivatives from the third and (d) 3 
heterogeneous derivatives from the fourth patent. In total, 100 active compounds were collected and 
jointed to 9900 putative TRPM5 inactive molecules, selected from among the compounds screened 
in the HTS experiment for their activity toward TRPM8 and proved to be inactive ligands in order 
to reach the already described percentage of 1% of active compounds. Albeit questionable, the 
choice of the here utilized decoys was supported by the high homology between the two receptor 
binding sites, and, however, it was due to usual lack of experimental published data about inactive 
molecules. Clearly, inactive compounds were selected with a physicochemical profile similar to that 
of the active ones to avoid biasing conditions. 
As above mentioned all docking simulations started by using AutoDock 4.2 and then were 
performed by PLANTS obtaining markedly better results. Also here AutoDock 4.2 produced 
enrichment factors so close to the random (best obtained EF = 1.56) not to give a glimpse of room 
for improvement even exhaustively changing the docking parameters. By contrast and since from 
the first run performed with default parameters, PLANTS afforded EF values almost double 
compared to those obtained by AutoDock. Hence, PLANTS was definitively adopted for this 
screening campaign by gradually varying the available parameters especially to be concern the 
scoring function and the protein region on which the docking search was focused. The best results 
were thus obtained by using the PLP95 scoring function and focusing the search on a 8 Ǻ radius 
sphere centred on the carboxylic carbon atom of Asp811. Ligands were considered as flexible while 
all protein residues were kept fixed. Although PLANTS allows the flexibility of some selected side 
chains to be considered, this would increase the required computational time so as to render the 
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simulations unsuitable to screen large databases. The simulations were carried out at speed 1 level, 
to guarantee more detailed calculations, and 1 pose was computed for each ligand.  
Although PLANTS calculates the simple total Score function as well as several weighted scores 
(e.g. by the rotatable bonds and by the molecular weight) in order to harmonize the values with the 
unavoidably different physicochemical properties of the ligands within the database, the best results 
were produced by the simple total score. 
In detail, the arbitrarily chosen enrichment factors (namely, top 1, 2 , 5, 10 and 20%) were 
evaluated. The Skewness factor was also considered and visualized by the histogram plot of the 
entire distribution (Table 4.1, Figure 4.5). 
 
 
n (top %N) Cpds Act EF Sk 
1 100 6 (1) 6.00 
2 200 10 (2) 5.00 
5 500 28 (5) 5.60 
10 1000 52 (10) 5.20 
20 2000 65 (20) 3.25 
2.3 
 
 
Table 4.1 Virtual screening evaluation, molecules ranked per PLP95 Total score. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act”stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
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Figure 4.5 Virtual screening ranking per PLP95 Total score. 
The  histogram plot reports the number of actives per cluster. 
 
 
Table 4.1 shows remarkable results, especially for the Top 1% enrichment factor and this value is 
extremely relevant because it suggests that such a screening strategy can conveniently tackle the 
problem of early recognition. The richest cluster is the fifth, hosting 8 active compounds, however, 
it rises among other rich clusters, in line with the expectations. Notably, in the top 15% of the 
distributions, the simulations ranked 57 active compounds out of 100, more than one half (Figure 
4.5). This encouraging result clearly emphasizes the reliability of both the here generated homology 
model and of the utilized docking strategy, and promotes them to be used in the virtual screening 
studies with promising perspectives. 
 
 
4.11 Correlative equations versus virtual screening. 
 
In the previous screening analysis the ligands were ranked by simply using the PLANTS scores 
without any further mathematical processing. For the preliminary QSAR validation, two notable 
predictive models were however developed and therefore they can be interestingly exploited also to 
rank the screened database with a view to comparing the screening performances of these predictive 
equations with that of a “standard” virtual screening campaign. Moreover and since the first 
equation includes only ligand-based descriptors, it is possible to investigate whether they can be 
effective in screening analyses. Such a study should reveal the concrete role played by docking 
simulations and if it is possible to hugely reduce the computational costs by screening the databases 
by pure ligand-based methods. 
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Thus, the first correlative equation (Eq. 1) including only ligand descriptors was utilized to predict 
the activity (pInhib) of all 10000 molecules and the corresponding metrics were calculated. 
Hopefully (for docking supporters) the obtained results (Table 4.2, Figure 4.6) show that this first 
correlative equation not only not enrich the set, but does even worse than random.  
 
 
n (top %N) Cpds Act EF Sk 
1 100 1 (1) 1 
2 200 0 (2) 0 
5 500 4 (5) 0.8 
10 1000        6 (10) 0.6 
20 2000 11 (20) 0.55 
0.1 
 
 
Table 4.2 Virtual screening evaluation, molecules ranked per pInhib predicted with Eq. 1. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act”stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
 
 
 
 
 
 
Figure 4.6 Virtual screening ranking per pInhib predicted with Eq.1. 
The histogram plot reports the number of actives per cluster. 
  
 
 
 
116
This very poor result may be due fact that also the starting equation showed rather poor statistics 
and thus a second ligand-based equation including three descriptors and showing better statistics 
was tested (Eq. 3). Even though such an equation may be questionable when considering the low 
number of compounds, it could yet perform better in screening campaigns. However, the 
distribution of actives appears clearly to be randomly dispersed among all the bins even in this 
second test, revealing the complete unsuitability of these ligand-based models in virtual screening 
(Table 4.3, Figure 4.7) Clearly, part of this failure can be due to the unavoidable differences 
between training set and screened database. Moreover it should be emphasized that ligand-based 
pharmacophore models can be really effective in virtual screening (as seen for SMARTS-based 
study on TRPM8) because they are able to catch the structural features characterizing the active 
molecules. Conversely, it is very improbable that simple physicochemical descriptors can be able to 
suitably discriminate between active and inactive compounds even when combined in multivariate 
models.   
 
 
Eq. 3                    1.999 + 0.1011*Hb Acc + 0.0556*Torsions – 0.0746*Heavy Atoms 
 
R2 = 0.69  Q2 =0.54  SE = 0.161  F = 8.87  P = 2.26e-03 
 
 
n (top %N) Cpds Act EF Sk 
1 100  1 (1) 1 
2 200 1 (2) 0.5 
5 500 1 (5) 0.2 
10 1000        7 (10) 0.7 
20 2000 17 (20) 0.85 
0.1 
 
 
Table 4.3 Virtual screening evaluation, molecules ranked per pInhib predicted with Eq. 3. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act”stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
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Figure 4.7 Virtual screening ranking per pInhib predicted with Eq.3. 
The  histogram plot reports the number of actives per cluster. 
 
 
The results enhance when docking scores are involved in the study. Since the calculation of X-
Score for all screened database was unfeasible, the second QSAR model was modified by including 
the PLP Total Score instead of the HM_score so obtaining a new equation with slightly worse 
statistics (r2 = 0.68).  
Table 4.4 reports the EF values of this structure-based model, showing that they are notably better 
than those obtained by first equations but a bit worse than those generated by canonical virtual 
screening strategy (Table 4.4, Figure 4.8). This result can be still explained considering that the 
molecules used to derive the equation have different and limited properties compared to the 
screened library thus emphasizing that QSAR equations have a very restricted efficacy when 
dealing with large and heterogeneous datasets.  
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n (top %N) Cpds Act EF Sk 
1 100 4 (1) 4 
2 200 7 (2) 3.5 
5 500 10 (5) 2 
10 1000 26 (10) 2,6 
20 2000 41 (20) 2,05 
1,42 
 
 
Table 4.4 Virtual screening evaluation, molecules ranked per pInhib predicted with Eq. 2. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act”stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
 
 
 
 
 
 
Figure 4.8 Virtual screening ranking per pInhib predicted with Eq.2. 
The  histogram plot reports the number of actives per cluster. 
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5. Computational studies concerning the hTRPV4 ion channel 
 
5.1 TRPV4 structural features. 
 
Ion channel TRPV4 was individuated by screening expressed sequence tag databases for sequences 
with similarity to TRPV1 and TRPV2, already individuated by expression cloning. It was initially 
indicated with different names by the different groups who cloned it, such as OTRPC4 (OSM-9-like 
TRP channel 4)233, VROAC (vanilloid receptor–related osmotically activated channel)234, TRP12235 
or VRL-2 (vanilloid receptor–like channel 2)236.  
The human TRPV4 gene is located on the long arm of chromosome 12 at position 24.1 and predicts 
for a 871 amino acids protein. Within the TRPV family, it shows higher homology with TRPV1 and 
TRPV3 members, with 40.3 % and 36.3 % of identity and 57 % and 52.7 % of sequence similarity, 
respectively. By contrast, the homology with other members sensibly decrease, till 25% of identity 
and 37.5% of similarity with TRPV2.  
Like most of TRPs, TRPV4 is expected to arrange in a tetrameric functional channel, and so far, 
even though it shares high homology with other TRPV sequences, there is no evidence for 
heteromeric assemblies with other TRPV monomers. In line with the other elements of the sub-
class, both N- and C-termini are located in the cell and the transmembrane portion is organized in a 
six membrane spanning segments (S1–S6), linked by five loops (L1-L5), the last of which, 
connecting S5 to S6, partially enters the membrane (Figure 5.1). About this segment, the 
determination of several the bacterial potassium channel structure, namely KcsA 237, KirBac1.1238 
and KirBac3.1239, has been of great help in better understanding the general structure of these 
channels, confirming, inter alia, that they presents a four-fold symmetry around the central pore 
region. 
The big intracellular N-terminus represents more than half of the entire TRPV4 sequence, and 
branches (i) three ankyrin repeat domains (ARD1–3), (ii) four sites predicted to receive a protein 
kinase C (PKC)–phosphorylation, (iii) a cAMP-dependent phosphorylation site, and (iv) two 
additional PKC regions located immediately after the ARD3 domain.  
With regard to the channel core, the central domain is expected to consist of six transmembrane 
spanning helices and relatives linking loops, the last of which, between TM5 and TM6, partially re-
enters the membrane and together with S5 and S6 is predicted to build up the pore module of the 
channel. As for other members of this class of receptors, TRPV4 transmembrane domain is 
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predicted to undergo to post-translational glycosylation240, and a protein kinase C phosphorylation 
site is predicted to remain immediately after the helix 2, in the intracellular environment. 
As mentioned, TRPV4 channel, as TRPVs in general, shows a three-dimensional structure very 
similar to the bacterial KcsA K+ channel. Relying on  structural information of the latter, the pore 
loop domain is expected to be made by a series of non polar residues arranged in a short alpha helix 
followed by few residues more which role is to manage the ion selectivity, operating as a filter. 
Mutagenesis studies addressed in this region found several residues to affect both selectivity and 
permeability. Among these residues, Asp672, Asp682 and, although it is not that clear how, Met680 
have showed to sensibly  weaken calcium channel crossing. 
Finally, TRPV4 C-terminus is predicted to starts from around position 712 up to 871 and is thought 
to bring the docking site on which at least two proteins, namely calmodulin241 and microfilament-
associated protein 7242 are expected to land on.  
 
 
 
 
Figure 5.1 Schematization of monomeric TRPV4 structure.  
Interesting point such as important residues or sites are highlighted.  
(Figure takrn from Plant and Strotmann243) 
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5.2 TRPV4 functional features.  
 
Similarly to the highly homologous TRPV1 and TRPV3, TRPV4 has a specific permeability and 
conductance profile, clearly different from the other vanilloid members, especially concerning Ca2+ 
permeability. 
 The reversal potential in normal extracellular solutions is positive close to 0 mV. The outward 
rectification results from a block by extracellular Ca2+. Lowering the extracellular calcium 
concentrations increases inward currents and leads to a loss of rectification in calcium-free 
solutions244.  
TRPV4 is a non-selective cation channel, only slightly permeable to calcium, with a preference for 
sodium of about two times245. It is also crossed by other divalent cations, such as magnesium, 
strontium and barium, with a ratio compared to the sodium of  2–3, 9, 0.7–7, respectively246,247. 
Lower is the discrimination level among monovalent cations, for axample potassium, cesium and 
litium permeability has proved to range from 0.9 up to 2, respect to the sodium248.  
Unfortunately, all these experimental evidences still have not found a completely clear correlation 
with the structure of the channel.  
 
 
5.3 TRPV4 polymodal activation.  
 
Considering its wide expression in many unrelated tissues and the nature of its receptor family, the 
variety of the physical and chemical stimuli activating TRPV4 comes as no surprise. It likely acts as 
a polymodal sensor protein with specified functions, depending on the cell type and on the co-
expressed proteins pattern profile. Different chemicals stimuli, such as diacylglycerol and phorbol 
esters as well as arachidonic acid and epoxygenase metabolites, interact with the protein and gate 
the channel. Besides them, physical stimuli as well, such as mechanic stress, temperature and 
osmotic pressure, are able to activate it. 
With regard to chemical stimuli, the first ligand discovered to activate TRPV4 was the synthetic 
phorbol ester, 4α-phorbol 12,13-didecanoate (4α-PDD)249, found to be able to activate TRPV4 at 
relatively modest concentrations (EC50 about 0.2 µM), with good specificity, since so far it was 
proved not to activate any other TRPV channels.  
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Since 4α-PDD is a metabolically stable non-protein kinase C–activating ligand, it was speculated 
that it might bind itself TRPV4. Moreover, recent studies have demonstrated that other 4α-PDD 
analogues can activate the channel with a potency depending on their apolarity250.  
Initially, experimental studies aimed to investigate the ability of protein kinase C-activating phorbol 
esters to activate TRPV4 demonstrated that they actually were able to do it, but quite slightly. Only 
in a second time, performing the same studies at higher temperature, TRPV4 was demonstrated to 
be potently activated by phorbol esters as well as by mechanical stimuli251. In detail, at 37 °C, sub-
µM concentrations of phorbol myristate acetate were proved to be enough for activating TRPV4 in 
a PKC-dependent manner, obtaining an effect similar to that induced by 4α-PDD, and suggesting 
how TRPV4 channel might be someway strictly related to signaling pathways underlying the 
induction of PKC. 
TRPV4 main binding domain is reasonably expected to be within the four helices sensor module, in 
line with the other TRPs channels. Moreover, this speculation is further supported by the 
individuation of a YS motif similar per both nature and position to that one of the known main 
binding site of TRPV1 channel252. In detail, two residues, namely Tyr556 and Ser557, located on 
the third transmembrane segment, close to the intracellular side, have been so selected and 
studied253. In particular, coherent results came from mutagenesis studies in which changing on 
Tyr556 was proved to completely cancel the responsiveness to 4αPDD, but not to arachidonic acid,  
suggesting how diverse paths would underlie the chemical-mediated TRPV4 activation254.  
Beside phorbole esters, arachidonic acid (AA) and related epoxyeicosatrienoic metabolites (EET) 
generated via the cytochrome P450 epoxygenase pathway, namely 5,6-EET and 8,9-EET, were 
found to activate TRPV4255. This represented the first evidence for endogenous ligands. 
Concerning the mechanical stimuli, TRPV4 was firstly cloned while investigating on its capacity to 
respond to hypo-osmotic cell swelling, behaviour that once confirmed proposed it as a potential 
mechano-sensitive channel256, probably acting as controller in all volume related processes.  
To support this speculation, several studies have been conducted, for example, by applying fluid 
shear stress across the apical surface of TRPV4-expressing cells257, and the resulting TRPV4 
activation confirmed its capacity to respond to mechanical stimuli as well, even if this process was 
proved to be strictly temperature-dependant.  
Two principal mechanisms have been proposed to explain how TRPV4 detects and reacts to this 
kind of stimulation: (i) direct mechanical activation and (ii) indirect activation through other 
transduction pathways. Indeed, cell swelling leads to the activation of both the phospholipase C 
(PLC)/diacylglycerol (DAG) and the phospholipase A2 (PLA2)/arachidonic acid (AA) transduction 
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pathways, able to modulate TRPV4 activation. TRPV4 knockout mice demonstrated that the 
inhibition of PLA2 or cytochrome P450 epoxygenase activity reduced the swelling-induced 
activation of TRPV4, while application of the EET metabolites or inhibition of EET hydrolysis 
enhanced both the swelling and AA-induced activation of TRPV4.  
Hypotonicity-induced nociception has also been described as a TRPV4-mediated process258. 
TRPV4 is highly sensitive to changes in extracellular osmolarity. Reductions in the extracellular 
osmolarity result in increases in [Ca2+]i and membrane currents, whereas osmolarities above 300 
mosmol/L decrease both [Ca2+]i and currents in those cells displaying spontaneous activity259.  
Beside cell suffering and osmotic pressure, temperature has been related to TRPVs activation, in 
particular for TRPV1–4 members, which have been shown to be activated by warm to noxious 
temperatures. It has been demonstrated that temperature dependency may involve a shift of the 
channel’s voltage dependency to more physiologically relevant voltage ranges. Elevating the 
temperature induces a left shift in the voltage sensitivity, thus activating the channel. Cold-activated 
TRPs show a complementary right shift in the voltage sensitivity with cooling. 
 
 
5.4 TRPV4 expression. 
 
TRPV4 is widely express in many different tissues. It is present in kidney260, in the heart, 
endothelium, brain, liver, placenta, lung, trachea, and salivary glands261. TRPV4 mRNA is also 
present in airway smooth muscle262 and in the substantia nigra pars compacta263.  
In the kidney tubules, TRPV4 expression is localized to constitutively or conditionally water 
impermeable (antidiuretic hormone-sensitive) segments, where it is mainly localized to the 
basolateral membrane264. Moreover, TRPV4 is highly expressed in pancreatic Islet of Langherans, 
as well as in testis seminiferus ducts and prostate. In other different tissues TRPV4 is still expressed 
albeit in lower concentrations. In female breast and reproductive system it is expressed in 
endometrium, ovary and placenta. Lower level are detected into blood and immune system, as in 
lymphatic and tonsil germinal center cells. TRPV4 has been found in skeletal and smooth muscles, 
as well as in skin and adipose issues, but with markedly lower abundance. 
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5.5 TRPV4 physiology. 
 
Its ubiquitous expression combined with its polymodal activation makes TRPV4 an important actor 
in many unrelated physiological processes. Directly involved in osmoregulation, TRPV4 is 
expressed in the cerebral circumventricular, which is responsible for the osmotic balance 
controlling it by levelling water intake/excretion. TRPV4 plays an important role in regulating the 
osmotic balance in kidney, as well.  
TRPV4 is highly present in epidermal keratinocytes, which role is to monitor temperature changes, 
so contributing to warmth perception. TRPV4 might also play a role in regulating thermogenesis, 
since it is expressed in neurons of the pre-optic and anterior hypothalamus which are involved in 
thermoregulation and contain specialized warm- and cool-sensitive neurons also activated by hypo-
osmolarity265. 
Activation of TRPV4 after damaging the stratum corneum of the skin accelerates epidermal barrier 
recovery, probably by stimulating lamellar body exocytosis and intracellular lipid bilayer formation 
in keratinocytes of the stratum granulosum. Moreover, TRPV4 can act as humidity sensor in the 
skin by regulating transcutaneous water loss. 
 
 
5.6 TRPV4 related pathologies.  
 
TRPV4-related channelopathies are directly or indirectly involved in several diseases, specially 
skeletal dysplasies, such as mild brachyolmia or spondylomethaphyseal dysplasia (SMD). Hence, 
TRPV4 proved to be a promising target for the pharmacological treatment especially for liver 
pathologies as well as pancreatic, respiratory and cardiovascular diseases. 
Certainly, one of the most interesting pharmacological implication of TRPV4 is in the treatment of 
the type II diabetes. Located in pancreatic β-cells, known to decrease in number in patients affected 
by type II diabetes  as a consequence of the deposition of amyloid in the pancreatic islets266, TRPV4 
was proved to be activated by physical changes induced by islet amyloid polypeptide (hIAPP), and 
someway leading to β-cells apoptosis beginning. 
Moreover, TRPV4 has recently been proposed as a target for pharmacological treatment of 
inflammation diseases, such as arthritis, inflammatory bowel diseases and interstitial cystitis, since 
it is co-expressed with Protease activated receptor 2 (PAR2) within a subset of primary sensory 
neurons. Activation of PAR2 by several inflammation mediators induces sensitization of TRPV4-
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expressing cells to mechanical and osmotic stimuli267. Several TRPV4 knockdown animal models 
have shown that TRPV4 mediates such an increased sensitivity in response to PAR2 activation.   
 
 
5.7 TRPV4 ligands. 
 
Up to date, many TRPV4 agonists have been developed. This is not surprising when considering the 
studies performed in the last years to characterize the structure-activity relationships of the well-
known TRPV4 agonists such as 4α-PDD and the arachidonic acid metabolites, further supported by 
exhaustive mutagenesis studies. For example, only to mention a class, several phorbol esters has 
been developed by Nilius and Appendino groups by exploring substitution on esterification pattern 
on ring moiety and varying the length of the aliphatic chains268. Among many findings, this work 
led to identify 4α-PDH, with shorter chains made by only 6 carbon atoms, which is a five time more 
potent agonist than 4α-PDD (EC50 equal to 0,07 and 0.37 µM, respectively). 
Oppositely, the TRPV4 antagonists are not so abundant. To date, only a relatively limited number 
of TRPV4 antagonists have been developed, and most of them are relatively unspecific269. Thus, the 
well-known voltage-dependent blockers, ruthenium red (RR), Gd3+ and La3+, which inhibit inward 
but not outward TRPV4 currents, show similar actions on other TRPV channels. Similarly, citral oil 
from lemongrass blocks transiently TRPV4 in a micromolar range, but also modulates other 
channels in sensory neurons, such as TRPV1-3, TRPM8 and TRPA1270. 
However, it is worth mentioning a series of molecules patented by GSK (GlaxoSmithKline) which 
are derivatives based on a diazabicyclo[2,2,1]hept-2-yl chemotype. These compounds show 
structural similarities to the TRPV4 agonist GSK 1016790A25, and can be regarded as 
conformationally-constrained analogues of this compound. Unfortunately, no structure-activity 
relationships have been reported for these TRPV4 antagonists rendering them unamenable for 
rational correlative studies. Nevertheless, the conserved substructure in common with several 
agonists suggest that they can bind in the same binding site. This means that these molecules can be 
used in docking simulations to assess the reliability of a homology model as performed in the here 
reported final virtual screening study.  
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5.8 Computational studies: setting the scene. 
 
The above mentioned scarcity of well-characterized TRPV4 antagonists rendered the validation of 
the here generated TRPV4 homology model, and especially of its ligand binding domain, truly 
difficult. In particular, the scarcity of known antagonists prevented detailed and validating QSAR 
analyses to be carried out. Trusting the truly reliable results afforded by fragmental approach for the 
TRPM8 and TRPM5 members, the same approach was here employed also to generate the TRPV4 
homology model which was preliminarily validated by docking a small set of ten known phorbol 
ester agonists. Although the dataset was not enough to perform QSAR studies, the relevance of the 
found stabilizing interactions and the agreement of these contacts with the available SAR studies 
provided a preliminary validation of the TRPV4 homology model. With these results in hand, the 
last part of this study involved a virtual screening campaign as performed by utilizing a dataset 
including 130 known antagonists taken from patent literature and 12870 suitably chosen decoy 
molecules.  
 
 
5.9 TRPV4 homology modelling and optimization. 
 
At the time of the study, TRPV4 (and no member of TRPV subfamily) was not experimentally 
resolved. Nevertheless, in march 2014, Liao and co-workers reported  determined the three-
dimensional structure of the rat TRPV1  as resolved by single particle electron cryo-microscopy 
(cryo-EM)271. This finding, albeit far from the exhaustiveness of the X-ray resolved structures, 
represents a notable starting point for a better understanding of TRPV channels, and, as described 
later, a good test bench for the human TRPV1 homology models. However, since the here reported 
study on TRPV4 was carried out prior of this findings, homology modelling was performed by 
fragments. 
Due to the low homology degree with the available templates, fragmental multi-template approach 
was, indeed, the preferred modelling strategy, since it allows a more reliable model to be generated, 
exploiting local homologies. In order to streamline the modelling studies and as successfully done 
for the TRPM5 model, only the monomeric structure of the TRPV4 was generated, since the study, 
was focused on the main ligand binding domain, which is located on the lateral surface of the sensor 
module (S1-S4), in line with the other TRP channels. On these considerations, the modelling of 
both termini were avoided. 
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The precise subdivision of the TRPV4 sequence in the structural segments with in particular the 
identification of the key TM helices was performed by carefully aligning the TRPV4 sequence with 
that of the other TRPV members. With these alignments in hand, FUGUE was used to generate the 
starting models for each segment. Due to the already mentioned low homology with the available 
templates, this modelling study was a really challenging task and some long segments were 
subdivided into more subfragments and modelled separately. Nevertheless and since the general 
protocols for both homology modelling and model optimization have already being described, 
please refer to paragraph 4.6 and 4.7, respectively, for the computational details. 
 
 
5.10 TRPV4 binding site. 
   
Before starting docking simulations, the so generated TRPV4 monomer was utilized to characterize 
its binding cavity, analysing the involved residues at the light of what was reported in literature. By 
analogy to TRPV1 channel, for which a YS motif in the S2–S3 linker was shown to be involved in 
the binding with its reference agonist, the capsaicin, a highly conserved (and correspondent) YS 
motif on the S3 helix of TRPV4, namely Tyr556 and Ser557, was hypothesized as the core of the 
TRPV4 orthosteric ligand binding domain. This consideration was further corroborated by 
mutagenesis studies showing the Tyr556 mutations induce the loss of channel activation mediated 
by 4α-PDD.  
The so defined region is located in the transmembrane region, close to the intracellular 
environment, on the opposite side respect to the pore of the channel, similarly to what was observed  
in the TRPM5 and TRPM8 models. The putative pocket evidently hosts both Tyr556 and Ser557, 
along with Tyr553 and several apolar residues, such as Phe554, Ile555, Ile561 and Leu584. 
Analysing the arrangement of the involved residues, two main regions can be clearly individuated. 
The two tyrosine residues and the serine confer a strong polar nature to a small sub-pocket, beside 
which, instead, apolar residues line a more hydrophobic  and more extended region. The disposition 
of these residues brings to mind the “internal/external” distribution described for the TRPM 
members (see paragraph 3.5.2). 
On these grounds, the phorbol esters are expected to accommodate its polar functions close the YS 
motif, while the aliphatic chains should be inserted into the hydrophobic region (Figure 5.2). 
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Figure 5.2 TRPV4 ligand binding domain residues disposition. 
Key residues are circled in red. 
  
 
5.11 Docking studies. 
 
As mentioned before, preliminary docking calculations involved a small set of phorbol esters (Table 
5.1), which were built using VEGAZZ software. Ligand’s conformational analyses have been 
performed similarly to what was already described (see paragraph 4.9 for the computational 
details). Once available both protein and ligands, docking calculations were performed in a 10 Ǻ 
radius sphere centred on the key Tyr556. Considering the successfully docking campaigns 
performed on TRPM5, the PLANTS docking program was utilized. Ten poses were generated for 
each ligand and scored by using the most exhaustive ChemPLP function. The so obtained 
complexes were analyzed considering both the computed scores and the expected contacts. The 
selected best complexes were then minimized keeping fixed all atoms outside a 10 Ǻ radius sphere 
centred around the bound ligand and the docking scores were finally recalculated. 
In line with the expectations, Figures 5.3-4 clearly show that the parent compound 4α-PDD 
arranges its polar functions toward the YS motif, establishing two H-bonds with Tyr556 and Tyr553 
with the two hydroxyl functions carried by the seven member aliphatic ring. Besides these pivotal 
interactions, the carbonyl group of one ester tail forms another H-bond with Ser557, confirming the 
relevance of both YS residues. The complex is further stabilized by several hydrophobic 
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interactions between Phe554, Ile555, Val558, Ile561 and Leu584 and the two aliphatic tails of the 
ligand. (Figures 5.3 and 5.4).   
 
Compound R1 R2 R3 EC50 (µM) 
1 (αPDD) n-COC9H19 n-COC9H19 αOH 0.37 
2 n-COC3H7 n-COC3H7 αOH 22.47 
3 (αPDH) n-COC5H11 n-COC5H11 αOH 0.07 
4 n-COC7H15 n-COC7H15 αOH >50 
5 n-COC8H17 n-COC8H17 αOH >50 
7 n-COC13H27 n-COC13H27 αOH 2.83 
8 H n-COC9H19 αOH 0.45 
6 COCH3 COCH3 αOH >50 
9 n-COC9H19 n-COC9H19 βOH 0.40 
10 n-COC9H19 n-COC9H19 H >50 
 
Table 5.1 Chemical structure of the docked 4α-PDD derivatives. 
 
  
 
 
 
130
 
Figure 5.3 Representative scheme of the TRPV4-4α-PDD complex.  
 
 
 
 
Figure 5.4 TRPV4-4α-PDD complex.  
Key Tyrosine and Serine residues are underlined and reported in light blue; 
 hydrophobic residues are reported in violet. 
 
 
4α-PDD 
Tyr556 
Ser557 
Tyr553 Phe554 
Phe592 
Leu584 Val558 
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The docking results for the 4α-PDD derivatives are in clear agreement with the reported activity. In 
detail, the simulations allow for two main considerations. First, docking results emphasize the key 
role played by the hydroxyl group in 4 which is involved by two key H-bonds thus explaining why 
the deoxygenated analogue is inactive. As an aside, docking results confirm that the 4β-PDD 
epimer is able to rearrange and to retain the key H-bonds also supported by the close carbonyl 
function. Second, the good activity of compound 8 which bears only one ester tail is clearly 
understandable considering that docking results suggest that the key role of this ester group is to 
elicit H-bond with Ser557, a role which is clearly maintained by the simple hydroxyl function. 
Finally, it is more difficult to rationalize the fluctuating dependence of activity on chain length 
which appears to be due to steric hindrance and chain fitting and in which the apolar contacts with 
the mentioned hydrophobic residues play a key role.   
Beside agonists, a preliminary docking study has been also conducted with some representative 
antagonists. In detail, this study involved a set of sulphonamide derivates, among which a 
dichlorophenyl derivative, RN-1734272 (IC50 2.3 µM),  is here reported in complex with TRPV4 
(Figure 5.5) as well as capsazepine, well-known TRPV1 antagonist recently proved to be also a 
TRPV4 inhibitor (Figure 5.6), and the nanomolar HC-067047 derivative273 (Figure 5.7). 
When compared to above described complexes for agonists, all analyzed antagonists are 
characterized by their ability to interact only partially with the YS motif, establishing an unique H-
bond with only one of the two key residues. More in detail, RN-1734 and HC-067047 contact only 
Ser557, capsazepine interacts with only Tyr556 while all ligands stabilize pi−pi stacking with 
Tyr556. Moreover, all computed complexes are further stabilized by a set of hydrophobic 
interactions that ligand’s hydrophobic groups elicit with aliphatic side chains within the TRPV4 
binding site. Analysing the complexes and considering the differences in potency (micromolar for 
RN-1734 and capsazepine, and nanomolar for HC-067047), one might speculate that the polar and 
pi−pi interactions are mandatory for the activity which in turn increases with the number of 
hydrophobic interactions, which can be reasonably related the size and lipophilicity of the 
compounds.  
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Figure 5.5 RN-1734 structure (upper) and TRPV4- RN-1734 complex (below). 
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Figure 5.6 Capsazepine structure (upper) and TRPV4-Capsazepine complex (below). 
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Figure 5.7 HC-067047 structure (upper) and TRPV4- HC-067047 complex (below). 
 
 
5.12 Virtual screening studies. 
 
Once the TRPV4 ligand binding domain has been analyzed by docking simulations and similarly to 
what was already done for the previous TRPM members, the successive computational study 
involved a virtual screening campaign, performed in order to further validate the reliability of the 
model, by testing its capacity to discriminate between active and inactive compounds. 
As already detailed in paragraph 3.2.8, to which the reader is invited to refer for all the 
computational details, a library of 130 structurally different TRPV4 antagonists was collected by 
selecting compounds from several patents, mostly acyclic 1,3- and 1,4-diamine derivatives from 
US0259965A1274 and US0105259A1275, as well as amino azepine derivatives from 
US0293477A1276 and US0124619A1277.  
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As already mentioned, the virtual screening strategy requires that these 130 actives are dispersed 
among inactive molecules, which also in this case come from the inactive ligands of the previously 
described HTS study on TRPM8. In order not to bias the results, putative decoys were selected if 
they fulfilled several physicochemical property ranges, which were determined by analysing the 
active compounds.   
Once again, we had to speculate that TRPM8 decoys would also be inactive toward TRPV4, a 
choice that is indeed justified by the lack of available data about TRPV4 inactive compounds. In 
order the guarantee the statistical significance of the study, the 130 active ligands were jointed to 
12870 decoys, obtaining a 13000 molecule dataset in which the percentage of active molecules 
correspond to 1%. 
Docking calculations were, then, performed using PLANTS, testing all three scoring functions, in 
order to maximize its performances. Calculations were focused on the previously described binding 
site, namely in a 10 Ǻ radius sphere, centred on Tyr556 and had the same docking characteristics 
already described in paragraph 4.9.  
For every simulations, the generated complexes were scored according to different functions and 
ranked from best to worse. Indeed and besides the Total Score value, three normalized values of 
each scoring functions were considered. In detail, the total scores were normalized per (i) the 
rotatable bonds, (ii) the cubic root of molecular weight, (iii) the cubic root of heavy atoms. The 
cubic root function is applied to obtain a smoothed normalization thus avoiding an excessive 
overestimation of the smallest molecules, while the normalization per rotatable bonds is an indirect 
way to account for entropic factors by penalizing too flexible ligands. Virtual screening 
performances were, than, evaluated by calculating the EF and the Skewness values.  
The results for the all three scoring function are reported in Table 5.2,  which shows the EF values 
as calculated in the top 1, 2, 5, 10 and 20 % of the set, by ranking molecules according to all three 
Total Scores and their mentioned normalized values. While the normalized scores reveal worst EF 
values, the obtained results afford an overall encouraging validation of the predictive power of the 
here modelled TRPV4 model. Best performing score is the PLP simple Total score, which 
performances are reported in detail in Table 5.2. Clearly appreciable even by the histogram plot 
itself, the screening produced really remarkable results (Table 5.3, Figure 5.8). In more detail, the 
best performing results are especially obtained within the smallest top ranked clusters, namely 1, 2 
and 5% of set. For example in the Top 5% the screening places more than a half of the total actives, 
reaching the impressive EF values of almost 13.5 in the top 2%. Even if only a very small part of 
the screened molecules are effectively promoted to the experimental stages, the results obtained in 
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the Top 1% of the distribution mean that it is possible to decuple the odds to find an active 
compounds respect to the random. The goodness of the screening is further supported by the 
remarkable Skewness value of 3.5, which emphasize the predictive power of both homology model 
and docking protocol as assessed in the entire distribution. 
With these gratifying results in hand, the model as well as the entire screening strategy could be 
reasonably exploited to screen large databases, looking for new hits. 
 
 
ChemPLP Total score ScoreRotors ScoreHA ScoreMW 
1 3.84 2.30 0.76 0.76 
2 4.23 1.53 0.38 0.76 
5 4.15 2.76 1.07 1.23 
10 2.76 2.53 1.69 2.15 
20 2.2 1.96 1.46 1.42 
PLP Total score ScoreRotors ScoreHA ScoreMW 
1 10.76 8.46 3.07 3.84 
2 13.46 9.23 2.69 3.07 
5 10.3 7.53 3.84 2.15 
10 6.76 4.6 2 2.3 
20 3.8 2.92 1.46 1.69 
PLP95 Total score ScoreRotors ScoreHA ScoreMW 
1 6.92 2.30 1.53 2.30 
2 8.07 2.69 1.92 3.07 
5 7.38 3.23 2.76 2.61 
10 6.38 3.00 2.84 3.53 
20 3.76 2.38 2.30 2.73 
 
 
 
Table 5.2 Virtual screening evaluation  for ChemPLP, PLP, PLP95  scoring function and their 
wheightings.  EF reported are calculated in the top 1, 2, 5, 10 and 20 % of the set. 
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n (top %N) Cpds Act EF Sk 
1 130 14 (1.3) 10.76 
2 260 35 (2.6) 13.46 
5 650 67 (6.5) 10.3 
10 1300 88 (13) 6.76 
20 2600 99 (26) 3.80 
3.5 
 
 
 
Table 5.3 Virtual screening evaluation, molecules ranked per PLP Total score. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act”stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichement factor values; 
“Sk” the Skewness value of the entire distribution. 
 
 
 
 
 
 
 
Figure 5.8 Virtual screening ranking per PLP Total score. 
The  histogram plot reports the number of actives per cluster. 
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6. Computational studies concerning the hTRPV1 ion channel 
 
 
 
6.1 TRPV1 structural features.  
 
TRPV1 was cloned in 1997 by Caterina and co-workers within a research project on somatic 
sensory and pain278. This finding represented a significant improvement for the understanding of 
molecular mechanisms involved in the transduction of noxious thermal and chemical stimuli by 
sensory neurons. Originally described as a receptor for capsaicin and related natural irritants (the so 
called vanilloids), TRPV1 is indeed involved in detecting different noxious stimuli, such as heat, 
acids, negatively charged pollutants and endogenous pro-inflammatory molecules. 
Located on chromosome 17p13, hTRPV1 gene encodes a 839 amino acids protein. Beside the 
complete channel, two splice variants lacking residues in the N-terminus domain are known, 
namely TRPV1b and VR.5’sv279. The former protein shows no sensitivity to heat, low pH or 
capsaicin and was proved to interact with TRPV1 channel, so acting as a down-regulator280. 
Similarly, the second variant does not respond to TRPV1 agonists but interacts with TRPV1 and 
definitively inhibits the gating281. 
In line with other TRP channels, TRPV1 is homologous to the voltage gated potassium channels 
(Kv), with which it is expected to share the three-dimensional arrangement, made by N- and C-
termini located in the cellular environment, and a transmembrane domain composed of six segments 
(S1-S6), with a pore-loop defined by S5-S6 and relative linking loop. TRPV1 as well assembles in a 
functionally active homotetrameric channel. 
Like other TRPV channels, the N-terminus contains six ankyrin repeats, whose structure has been 
determined via high resolution x-ray crystallography282. Similarly to what already described for 
TRPV4, the pore loop is expected to arrange in a short helix and a selectivity filter, partially 
entering the plasma membrane283. Here, several residues have been individuated as important for 
the response to diverse stimuli, as discussed later; phosphorylation sites as well have been found 
along the intracellular loops as well as in the S5-6 segments. 
A motif common in all TRPs channels, namely the TRP box, is predicted to locate in the C-
terminus region, where is thought to arrange in an α-helix parallel and close to the membrane, on 
the intracellular side. 
As already mentioned in the previous chapter, an important improvement has been recently 
achieved in the knowledge of TRPV structure, in general, and more specifically for the TRPV1 
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member, with the resolution of the rat TRPV1, via electron cryo-microscopy technique with a 3.4 Å 
resolution 284. While confirming many predicted structural elements, such as the TRP box location 
and arrangement or the spatial architecture of the first four ankyrin repeats, this study provided 
novel information, such as, for example, that the last two ankyrin domain are actually involved in 
channel assembly, or that several sub-region of the N-terminus are involved in connecting the 
ankyrin repeats to the segment S1, which in turn contacts the last two ankyrin on the following 
monomer, further stabilizing the tetramer.  
 
 
6.2 TRPV1 functional features.  
 
TRPV1 channel shows no selectivity among monovalent cations, resulting almost equally 
permeable to sodium, potassium, cesium, lithium and rubidium, while its permeability to divalent 
cations appears to be much higher, as reported by Ahern and colleagues studies, in which capsaicin 
mediated TRPV1 gating showed for calcium and magnesium values five and ten times bigger than 
sodium permeability, respectively; similar ratio was reported for heat-mediated channel 
activation285. 
Protons were proved to enter the cell easily passing through TRPV1 channel286, that it is also 
permeable to polyvalent cations as well, albeit a little less, via a “pore dilation” mechanism10. 
So far, diverse mutagenesis studies attested the involvement of several amino acids in the process of  
ion selection. Clearly, most of them are located in the pore-forming loop, but others are surprisingly 
located in the transmembrane helices, specially in the last segment. 
About the pore region, there is a well conserved sequence motif “TIGMG” which is typical of 
TRPV channels and is highly similar even to that of the bacterial KcsA channel, that is 
“TVGYG”287. Beside this sequence, other amino acids are involved in regulating both cations 
passing and channel gating. As a general rule, neutralization of acid residues or replacement of 
neutral residues with basic ones induce a reduction of permeability as seen in D646N, E648A or 
Y671S, the last one leading to a loss of calcium-mediated desensitisation288. 
Deeper in the membrane, Ile679 plays a crucial role in permeation, as proposed by electron cryo-
microscopy, which showed that it represents the narrowest point along the ion path. Comparisons of 
the position of closed and open states reveals that Ile679 forms a hydrophobic seal able to impede 
the permeation of hydrated ions when the channel is close, but, at the same time, rearrangements 
occurring in the activated state remove this cap, allowing the ion permeation. 
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6.3 TRPV1 polymodal activation.  
 
TRPV1 receptors are activated by vanilloids like capsaicin, inducing the influx of calcium and 
sodium, and thus depolarizing the cell. At very ineffective low concentrations, capsaicin can 
however sensitize TRPV1 receptors to protons and heat. Similarly, protons sensitize TRPV1 to 
capsaicin and heat.  
Vanilloids binding site is expected to be in transmembrane sensor module, far from the pore 
channel, and this is supported by the fact that, when added extracellularly, membrane-nonpermeant 
derivatives of capsaicin are inactive. Moreover, mutagenesis studies revealed that three residues, 
namely Tyr511, Ser512 and Tyr550, are crucial for the capsaicin activation. In detail, mutations of 
one of the first two residues abolished capsaicin response, but not activation by heat or protons, 
while mutating Tyr550 only reduces the capsaicin sensitivity of the channel289.  
TRPV1 is a major heat sensor in peripheral sensory neurons that innervate the body. Thermal 
activation of these neurons shows a temperature threshold of about 42 °C although this can be lower 
during inflammation. The TRPV1 regions responsible for heat activation have not been yet 
completely established. Mutational studies involving pore region and C- or N-termini show that all 
these regions influence the temperature responses of TRPV1.  
TRPV1 is known to act not only in thermal-related pain conditions, but it maintains a low activity at 
physiological temperature as well. This role is fundamental for body thermal regulation, as pointed 
out in clinical studies in which diverse TRPV1 blockers were related to high fever side effect290. 
Moreover, at room temperature and physiological pH, TRPV1 acts as a voltage-gated outwardly 
rectifying channel, resulting activated by depolarizing voltage itself291. 
In addition, TRPV1 sensitivity to heat and capsaicin is modulated by variations in proton 
concentrations within the range of pH 6–9292,293. The potentiating effect of pH on capsaicin 
activation is related to both an increased affinity for capsaicin and an enhanced channel gating. 
Generally speaking, the effect of protons on TRPV1 can be explained considering the neutralization 
effect of the acidic residues lining the pore. Thus, Glu648, located between the selectivity filter and 
the S6 mediates the agonist effect of protons, without affecting pH modulation27
.
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6.4 TRPV1 expression. 
 
TRPV1-expressing tissues can be divided into two categories: neuronal and non neuronal tissues. 
For what concern the first group, TRPV1 has been detected in the most part of both somatic and 
visceral sensory neurons and only in small/medium size fibers of dorsal root, trigeminal and vagal 
ganglia1. These neurons form non- or thinly-myelinated branches, named C or Aδ fibres, directed 
toward almost all organs in the human body.  
TRPV1 is also present within the CNS, particularly expressed in the preoptic area of the 
hypothalamus, where it acts as body temperature downregulator294. Moreover, TRPV1 also 
intervenes in generating postsynaptic long-term depression when activated by endogenous 
anandamide,  specially in the nucleus accumbens295. 
Besides neurons, TRPV1 is additionally expressed in diverse non-neuronal cells, where its 
activation induces a rapid rise in intracellular Ca2+ levels. Among these tissues, one may mention 
the endothelium, the immune cells (lymphocytes, dendritic cells and mast cells), keratinocytes, the 
smooth muscle cells and the urothelium, thymocytes and macrophages. 
In more detail, TRPV1 activation in perivascular sensory fibers was attested to reflect into 
neuropeptide CGRP- mediated vasorelaxation of resistance arteries296. TRPV1 expression was also 
detected in arteriolar smooth muscle in skeletal and thermoregulatory tissues30, where it is 
speculated to manage the blood flow with a still not completely understood mechanism.  
Taste buds are surrounded by TRPV1 containing peptidergic nociceptors from the trigeminal nerve 
that are responsible for the burning sensation typically induced by capsaicin containing foods by a 
calcium mediated transmitter release. Once reached the brain, this information can be interpreted as 
reward or threat and so the substance can be ingested or rejected. TRPV1 expression has also been 
reported in bladder urothelium, where the it regulates bladder contractions by mediating urothelial 
ATP release in response to stretch297. Finally, several studies have reported expression of functional 
TRPV1 in human keratinocytes298.  
 
 
6.5 TRPV1 physiology. 
 
One of the most important implications of TRPV1 channel in physiological processes is, surely, the 
detection of temperature increasing. In sensory peripheral neurons, it is known to transduce not only 
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thermal nociception due to noxious temperature (reasonably intended major than 42 °C) but 
physicochemical stimuli as well, generating the perception of local ‘burning’ heat.  
Moreover, TRPV1 has a remarkable physiopathological role in inflamed tissues, in which even 
lower temperatures were proved to elicit a painful sensation (so called thermal hyperalgesia), as 
demonstrated in a knockout animals based study, in which mice lacking TRPV1 did not exhibit the 
expected sensitization to warm temperatures exposure of  injured or inflamed tissues299. 
Beside noxious heat sensing, both central and peripheral TRPV1 expressing neuronal tissues have 
recently been implicated in controlling the physiological body temperature too. 
Pain sensation is augmented by the acidic extracellular pH during ischemia or inflammation. On 
these grounds, it has been found that protons only activate the channels when they are added from 
the extracellular solution, suggesting that the proton-active gate is on the extracellular part of the 
molecule15. Lowering the pH causes sigmoidal increases in the current. This current has a reversal 
potential close to zero millivolts, suggesting that, at neutral pH, protons do not carry much of the 
current in buffers containing physiological concentrations of sodium and calcium. 
Finally, TRPV1 is thought to intervene in the transduction process of osmotic information in the 
CNS. Hyperosmotic-induced cell volume diminution leading to the augmentation of the membrane 
conductance was proved to be balanced by ruthenium red in functional TRPV1 expressing mice; 
while, contrarily, it was not detected in knockout animals300. 
In addition, in TRPV1 knockout mice, the consume of water under systemic hyperosmotic 
challenge was attested to be much less than in the normal animals, so introducing TRPV1 in thirst 
induction process too301. 
 
 
6.6 TRPV1 ligands.  
 
Besides CAPS.like molecules, TRPV1 was proved to be both stimulated or silenced by diverse  
amphiphilic compounds. Among these, can be mentioned the resiniferatoxin, a highly irritant 
diterpene twenty time more potent than CAPS302, quinazolinone303, evodiamine304 and 17-β-
estradiol305, as well as long acyl and amide chains bringing chemicals, such as anandamide306, 
olvanil and omega-3 polyunsaturated fatty acids are known to gate TRPV1307. Other natural TRPV1 
agonists are 12-hydroperoxyeicosatetraenoic acid (12-HPETE) and N-arachidonoyl dopamine 
(NADA)308.  
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Piperine from black pepper, eugenol from  loves and zingerone from ginger have also been shown 
to activate TRPV1309. Moreover, gingerols from raw ginger, and shogaols, possessing a vanillyl 
moiety, can also activate the channel. 
Considering the various anatomical/physiological contests in which TRPV1 channel is implicated, 
the possibility of making it a target for the pharmaceutical treatment of several important 
pathological conditions clearly appears as a great goal. 
To date, two opposite approaches are mainly walked for antagonize TRPV1 channel in diseases: (i) 
an indirect approach, which involves TRPV1 agonists and aims to the activation/desensitization of 
the channel, and (ii) a classical direct approach involving TRPV1 antagonist. 
The first method lies of the fact that, somewhat surprisingly, capsaicin is able to attenuate painful 
sensations, long desensitizing TRPV1 after the brief activation. According to this, it is used, for 
example, for treating osteoarthritis and rheumatoid arthritis as well peripheral neuropathy pain.  
About the second method, capsazepine, setup by modifying the chemical structure of the agonist 
capsaicin, is the first reported TRPV1 antagonist, even if later was proved to be not selective.  
As a competitive antagonist, it locates in the capsaicin-binding site and thus impedes the channel 
activation. Unfortunately, capsazepine was not considered a good candidate for therapeutic use, 
because not selective, metabolically instable and affected by a bad  pharmacokinetic profile.  
Nevertheless, the SAR of capsazepine was used as starting point for developing new generation of 
TRPV1 blockers, that can be broadly divided in (i) competitive or (ii) non-competitive antagonists.  
The first class is the most studied and populated one. It accounts for compounds that binds to the 
agonist binding site and locks the TRPV1 channel in a closed state. The most part of competitive 
antagonists developed so far can be divided into two sub-classes, (a) classic and (b) non-classic 
antagonists.  The first class hosts molecules which have in common a carbonyl group that acts as H-
bonding donor or acceptor, brought as thiourea, urea, cinnamide, ester or amide. This class of 
molecules we have mostly been interested in, in particular, we explored the pattern of interactions 
with TRPV1 binding site of a series of thiadiazole derivatives as well as several propanamides 
derivatives, reported to effect with nanomolar activity (see later).  
On the other side, non-classic TRPV1 antagonists brings a carbonyl group which is either present as 
a part of heterocyclic ring or is unrecognizable. Among them the quinazoline or benzimidazole 
analogues appear structurally different from capsazepine but still retain the key binding elements. 
Finally, non-competitive antagonists have been individuated as well. They are pore blockers 
binding allosteric sites. To date, this class is much more attractive from the therapeutical point of 
view, since these molecules would act specially against pathologically-over-activated TRPV1 
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channels, minimizing the rise of side effects. About these, so far, really few molecules have been 
improved in terms of selectivity, aspect that afflicts the most part of the purified toxins from which 
drug development of this class of molecules usually starts.  
 
 
6.7 TRPV1 homology modeling. 
 
At the time I started working on human TRPV1 channel, immediately following the previously 
described TRPV4 study, the mentioned experimental resolution of the TRPV1 structure by cryo-
EM technique was not yet disclosed. So, once again, homology techniques represented the only 
available approach to model the TRPV1 three-dimensional structure. 
However, here a different strategy was applied relying on the high sequence homology between 
hTRPV1 and hTRPV4, namely 40.3% of identity and 57.0% of similarity, the latter even higher 
when considering only the transmembrane region (67% of similarity). Indeed the previously 
generated homology models (TRPM5 and TRPV4) were constructed by using a fragmental 
approach which gave rather encouraging results (as discussed in the previous chapters) but required 
a significant amount of computational effort which renders such a strategy unsuitable when the 
study would require the generation of many receptor models. On the other hand, the study 
performed on TRPM8 ligand’s selectivity indicated that the use of a homology model as the 
template to generate other homology models, while being questionable on a theoretical basis can 
afford encouraging results at least when there is a notable homology between the two involved 
proteins. Clearly, the study performed on TRPM8 was a first attempt which deserves additional 
confirmations. In this context, the TRPV1 appears to be an interesting case study, considering the 
really encouraging results obtained by the here presented TRPV4 homology model which should 
allow a proper modeling of the TRPV1. Hence and while considering that using a homology model 
as the template may generate an output model which is affected by an excessive and risky similarity 
with the template inheriting its structural weakness and uncertainties, an overall homology approach 
using TRPV4 as the template was adopted 
Therefore, MODELLER 9.14 was here utilized, since, as described in chapter 2, it allows reliable 
models to be generated when used in robust homology conditions. In more detail, the 
transmembrane portion of  the TRPV1 primary sequence has been modelled. Alignment first, then 
model generation were performed with default settings and ten output homology models were 
produced, in order to consider different solutions among which the most reliable one can be chosen. 
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As expected, the output models were rather similar, showing the predicted overall folding in 
agreement with secondary structure predicted by sequence alignment, a reliable arrangement of the 
sensor module and in particular of the key residues without relevant unpredicted gaps. Based on 
these remarkable preliminary evaluations, the choice of the most reliable models was carried out by 
considering structural parameters as well as MODELLER score functions. Indeed and  for each 
generated output model MODELLER computes two scoring functions, namely DOPE and GA341. 
In detail, DOPE assessment score parameterizes the model conformational energy as calculated by 
the program during the model refinement and thus the lower the better. It is a not absolute score, 
since it can only be used to rank models calculated from the same alignment. GA341 assessment 
score goes from 0 (worst) to 1 (native-like), and so the higher the better. It is a transferable score 
which can be used to compare models obtained by different calculations. For this reason, GA341 
should be preferred to evaluate the model reliability considering its general meaning. 
Besides MODELLER scores, the percentage of residues falling in the allowed regions of the 
Ramachandran Plot and of the side chain χ-space were evaluated to describe the correct 
conformation of both the backbone and the side chains. For all models, χ-space percentage  values 
were higher than 95% (Table 6.1), and thus all models can be seen reasonably satisfying to be 
concern the conformation of the side-chains.  
With these data in hands, a careful model evaluation was performed in order to select the structures 
with which docking simulations can be performed. Indeed and considering the potential weakness 
above described for the here exploited homology modeling, focusing all docking simulations on 
only one generated model (even though the seemingly most reliable one) would represent a 
tremendous approximation able to undermine the reliability of all following simulations. On the 
other hand and at the light of the general similarity among the output models, running docking 
calculations on all the ten models would be uselessly onerous and probably redundant. On these 
grounds, a three step selection strategy aimed at progressively reducing the number of the filtered 
models was setup. In detail, (i) the first filter was based on structural quality and MODELLER 
scores and allows five models to be selected, then (ii) the second step was based according to 
similarity analysis among the before selected models in order to individuate the three most 
representative structures, as evaluated by a pair-wise RMSD analysis (Table 6.2), and finally (iii) 
the last step involved docking calculations on a representative set of 30 known antagonists and was 
based on the correlations between the resulting docking scores as computed for each generated 
complex and the experimentally activity values. This last step allows the selection of the best 
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performing TRPV1 homology model on which the following docking simulations will be 
performed. 
As described above for χ-space percentage values, also Ramachandran plots, while showing a 
greater variability, reveal rather similar and satisfying results for all generated models, as seen in 
Table 6.1. Hence, the first filter was based on the MODELLER scores and in particular the 
selection was based on GA341 score choosing the five models with highest GA341 values (namely 
model 1, 3, 5, 8, 10). Gratifyingly the selected models revealed also very low DOPE score values 
and remarkable Ramachandran plots. Thus, models 1, 3, 5, 8, 10 have been selected and compared 
in terms of similarity by a pair-wise RMS analysis as performed by matching backbone atoms only 
(see table 6.2).  By using this similarity analysis, three models were selected by considering (a) the 
structure with the lowest RMSD mean (model 5) which should represent a sort of average structure 
accounting for most structural diversity exhibited by the compared models; (b) the two structures 
with the highest RMSD means which should represent two so different structures as not to be 
properly represented by the previous average model (models 3 and 10). Fortunately, the comparison 
of models 3 and 10 shows a very high RMSD value, thus suggesting that they effectively should 
represent two relevant (and not redundant) extreme structures in this comparison. 
The so selected three TRPV1 homology models were completed by adding hydrogen atoms and 
carefully checked to avoid (and fix) unphysical situations. Next, they were refined by an the 
optimization phase, that was pursuit by the same three steps strategy already used for the previous 
models,  combining energy minimizations with suitably targeted MD simulations. Please refer to 
paragraphs 4.6 and 4.7 for all the computational details. 
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Output model DOPE score GA341 score Ram. 
Plot 
χ 
space 
 
1 -26894.78 0.78807 80.39 98.04 
2 -27244.13 0.56092 81.18 95.29 
3 -27002.02 0.55980 81.96 97.82 
4 -27066.26 0.52961 83.53 97.82 
5 -26898.42 0.74333 80.39 96.71 
6 -27113.99 0.51953 78.40 96.20 
7 -27290.32 0.49000 77.90 98.66 
8 -27667.22 0.69363 81.40 96.20 
9 -26843.68 0.47999 82.24 95.87 
10 -26982.94 0.67185 79.97 97.90 
 
 
Table 6.1 Homology models structural analyses.    
 
 
 
 Model 1 Model 3 Model 5 Model 8 Model 10 
Model 1 -- -- -- -- -- 
Model 3 2.71 -- -- -- -- 
Model 5 1.45 1.78 -- -- -- 
Model 8 1.37 1.98 2.25 -- -- 
Model 10 2.23 2.45 1.78 2.53 -- 
Means 1.94 2.23 1.82 2.03 2.25 
 
 
Table 6.2 Pair-wise RMSD analyses; values are expressed in Armstrong. 
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6.8 Preliminary docking simulations. 
 
The so refined three homology models were finally tested and filtered by assessing the capability of 
their ligand binding domains to correctly interact with a set of known antagonists. 
To this purpose, a set of thirty CAPS-like antagonists was generated by collecting known molecules 
from literature and patents, including 23 heterocyclic molecules from the patent EP 2604599 A1310, 
and 7 1,3,4-thiadiazole heterocyclic derivatives from the recent study of  Rebolledo and co-
workers311, all having IC50 values within the micromolar range. The ligand’s conformational profile 
was explored by using the VEGA ZZ software, as described in paragraph 4.9.  
Relying oh the remarkable results obtained in the previous docking studies and considering the high 
homology between TPRV4 and TRPV1, docking calculations were also here performed by 
PLANTS, using a computational protocol similar to that applied for the previous models and 
detailed in paragraph 4.9. In detail, calculations were focused on a 12 Å radius sphere centred 
around the centroid defined by the Cα atoms of the key residues Tyr511 and Ser512. So, one pose 
per compound was generated and scored by all three implemented functions. The obtained 
complexes were evaluated without any post-docking refinement, in line with the idea to optimize a 
docking strategy to be applied in virtual screening campaigns, in which approaches involving post-
docking selection/optimization/rescoring procedures are clearly unfeasible. Besides the three 
PLANTS total scores also the already mentioned normalized values were considered, in order to 
harmonize the scores to the set of molecules in use.  
With these data in hand, a comparison of the correlations between the experimental IC50 values and 
the computed scores for the three selected models was performed. All resulting correlative values 
(expressed by the Pearson coefficient, r) are reported in table 6.3. 
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ChemPLP Total score ScoreRotors ScoreHA ScoreMW 
Model 3 -0.22 0.11 -0.46 -0.24 
Model 5 -0.33 0.09 -0.53 -0.33 
Model 10 -0.05 0.14 -0.34 -0.15 
 
    
PLP Total score ScoreRotors ScoreHA ScoreMW 
Model 3 -0.17 0.12 -0.44 -0.22 
Model 5 -0.62 0.06 -0.62 -0.44 
Model 10 -0.12 0.13 -0.34 -0.17 
 
    
PLP95 Total score ScoreRotors ScoreHA ScoreMW 
Model 3 -0.44 0.08 -0.55 -0.36 
Model 5 -0.49 0.07 -0.62 -0.43 
Model 10 -0.24 0.13 -0.45 -0.25 
 
 
Table 6.3  Pearson coefficient r values reported are calculated for model 3,8 and 10,  
correlating compound activity with ChemPLP, PLP, PLP95 scoring function and their weightings. 
 
 
Table 6.3 clearly shows that model 5 affords the best results reaching quite remarkable r values,  
almost independently from the score used, and giving its best correlation with PLP Total score. 
Apart from the normalized ScoreRotors values which show unsatisfactory results for all score 
functions and all models, there are no significant differences between the correlations produced by 
total and normalized scores (which are even better in some cases) thus indicating that the reported 
results are not markedly biased by structural differences within the considered dataset. It is worth 
mentioning that the model affording the best docking results is the model chosen in the similarity 
analysis since it showed the lowest RMSD mean value and thus it should represent a sort of average 
of the compared models. This results may have a general meaning suggesting that the model with 
lowest RMSD mean effectively represents a structural centroid able to account for most structural 
variability and as such able to properly accommodate most ligands. The obtained results are 
particularly interesting especially when considering both the number of simulated compounds as 
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well as the roughness of the unrefined complexes, for which it is reasonable to expect notable 
improvements if refined by post-docking optimization strategies. On these grounds, the Model 5 
was selected and promoted to the following docking simulations.  
 
 
6.9 Detailed docking simulations. 
 
With a definitive model in hand, a deeper docking analysis was performed by considering visually 
inspected and refined complexes in order to collect a set of docking-based descriptors to be 
involved in multiparametric QSAR studies. The so derived correlative equation would provide both 
a further validation of the reliability of the homology model and a useful tool for unknown 
molecules in provisional studies. 
In detail, the mentioned visual filtering is based on a detailed analysis of the ligand domain, whose 
main features come from mutational studied reported in literature. The key YS motif, namely 
Tyr511 and Ser512, is located on the segment S3, decentred toward the intracellular environment. It 
exposes the side chains on the external surface of the S1-S4 bundle, toward a flank of the sensor 
module. As for all other studied TRPs, the binding region is actually more an exposed surface than 
a real pocket, on which the ligands would land rather than fit. Besides the YS motif, several other 
residues characterize the binding site, and are arranged parallel to the membrane giving it a “C” 
shape, with the open side toward the center of the channel. On the rim, three polar residues, namely 
Tyr487, Ser510 and Glu513, delimit the left side of the binding region, conferring it a rather polar 
character. In the other regions, the binding site is mostly characterized by hydrophobic residues 
such as Met514, Phe507 and Ile564 and appears to be markedly extended especially in the right 
side. 
Interestingly, the Thr550 residue which proved to be important, albeit not crucial, for the activity of 
capsaicin by the mutagenesis studies, is located on the S4 segment, a bit far from the YS motif, with 
a distance (about 14 Ǻ between both hydroxyl functions) which does not completely exclude it from 
the interacting site. In detail, it is possible to delineate a region along the S4 helix and lined by 
Tyr554 and Tyr555, which connects the YS motif to Thr550, a region in which ligands can be 
stabilized by intermolecular stacking interactions.  
In order to deeper investigate these structural features, a pilot docking was performed using the 
reference agonist, Capsaicin. Fifty different poses were generated in order to exhaustively explore 
all binding modes permitted by such a binding site. 
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Docking calculations were performed by PLANTS, focused on the same region already selected for 
the previous docking simulations, and the same settings were applied. All generated poses were 
clustered and the so identified different binding modes were visually inspected.  
As expected, in most poses capsaicin fitted a binding site perpendicularly to the membrane axis, 
orienting its hydroxy-3-methoxyphenylic moiety toward the Ser512, with which hydroxyl group 
establishes a first H-bond, while the amide function elicits a second H-bond with the hydroxyl 
group of Tyr511 which in turn stabilizes pi−pi stacking with the ligand aromatic ring along with 
Phe507. Finally the carbon chain stabilizes apolar contacts with Met 514 as well as with the carbon 
skeleton of the side chain of Arg447, while the ligand double bond can elicit weak pi−pi stacking 
with the aromatic moiety of Tyr554 and Tyr555 which also contribute with apolar contacts (Figure 
6.1). 
Interestingly, a second binding pose, almost equally scored and significantly represented among the 
computed poses, was individuated. In more detail, Capsaicin is arranged parallel to the membrane 
axis and, despite being differently harboured, the YS motif are engaged in interactions almost 
superimposable to that already seen for the previous binding mode. The aliphatic chain is inserted 
between Tyr554 and Tyr555 with which it can stabilize the already described pi−pi stacking, and 
approaches Thr550, without in fact contacting it (Figure 6.2).  
In order to further investigate the described dual binding modes, the already used thirty CAPS-like 
antagonists set was re-docked in the ligand binding domain, producing 20 poses per ligand by still 
using the best performing PLP score. The so generated complexes were then visually analysed and,  
interestingly, the two major binding modes already seen for capsaicin were maintained for all the 
tested antagonists, thus suggesting that this dual binding mode involves all ligands regardless of 
their intrinsic activity. Hence, the best complexes of each binding mode (henceforth named BM1 
and BM2) were selected for each compound, generating two sets of 30 complexes. As already done 
in the previous filtering step, correlative studies were performed to compare the two binding modes, 
thus selecting that offering the better performances at least for the considered classes of molecules. 
Table 6.4 reports the Pearson coefficient r values obtained correlating the PLP docking scores with 
the experimental activity IC50 values, for the two monitored binding mode. 
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Figure 6.1 Capsaicin-TRPV1 complex, binding mode 1. 
Capsaicin is reported in ball and stick; key YS residues are underlined; 
 
 
 
 
 
Figure 6.2 Capsaicin-TRPV1 complex, binding mode 2. 
Capsaicin is reported in ball and stick; key YS residues are underlined; 
Thr512 
Tyr511 
Capsaicin 
Capsaicin 
Thr512 
Tyr511 
Phe507 
Phe507 
Tyr555 
Tyr554 
Tyr555 
Tyr554 
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PLP Total score ScoreRotors ScoreHA ScoreMW 
BM1 -0.69 -0.11 -0.40 -0.61 
BM2 -0.23 -0.04 -0.12 -0.22 
 
 
Table 6.4 Pearson coefficient r values calculated per BM1  and BM2, correlating compound 
activity with PLP scoring function and their normalized values. 
 
 
Table 6.4 clearly shows that BM1 performs markedly better than to BM2, in all computed score 
values. As seen in previous analysis, the best result was obtained by the PLP simple Total score, 
with a r value equal to  -0.69. As expected, the correlation obtained using refined (and rescored 
complexes) performs better than those obtained by unrefined results (as compiled in Table6.3). 
However, the differences between refined and unrefined complexes are not so significant even 
considering that here all results show a coherent binding mode.  Therefore one may suppose that 
refining the complexes and discriminating between BM1 and BM2 might not markedly enhance the 
poor correlations as derived by Models 3 and 10. Also for this reason, the following simulations 
were kept focused on Model 5. 
Next, BM1 selected complexes were involved in a wider multi-parametric QSAR analysis, with a 
view to deriving correlative equations including both docking-based and ligand-based descriptors. 
Considering the relatively low number of considered molecules, it would be statistically appropriate 
not to involve more than three independent variables to derive robust correlative equations, 
avoiding overfitting conditions. 
The best equation derived (Eq.1) involved the PLP Total score, and suggests that a good TRPV1 
antagonists should be flexible and of limited size. 
 
 
Eq. 1          3.5319 – 0.0558 PLP_TotalScore - 0.1008 HeavyAtoms + 0.1049 FlexTorsions 
            r
2
 = 0.82  q2 =0.74  SE = 0.160  F = 37.55  P = 2.06e-09   
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As done within the study on the TRPM5 channel, a correlative equation was derived using only 
ligand-based descriptors. This equation has the key objective to reveal the effective role of docking 
simulations; not to mention its possible use in a pre-docking screening study. 
Best performing ligand-based equation (Eq. 2) is in line with the previous one confirming the 
positive role of flexibility and the detrimental effect of molecular size (here described by radiuses of 
gyration). Remarkably, the docking score is here replaced by the total number of H-bonding groups, 
an easily understandable result considering the pivotal role of the H-bonds interactions stabilized 
with the YS motif. However, Eq. 2 shows markedly worse statistics and this result emphasizes the 
key role of docking simulations and indirectly affords a positive validation for the here generated 
and selected TRPV1 homology model. 
 
 
Eq. 2           8.9328 – 0.5282*Gyr_rad + 0.0910*FlexTorsions + 0.3261*HbTot 
  
r
2
 = 0.58  q2 =0.44  SE = 0.243  F = 11.90  P = 4.32e-005                 
 
     
6.10 TRPV1 virtual screening. 
 
Once the predictive power of TRPV1 ligand binding domain for the selected TRPV1 model has 
been positively assessed by docking simulations and the binding mode BM1 was proved to be more 
predictive at least for the considered antagonists, the following model validation involved a virtual 
screening campaign, aimed at further validating the reliability and the predictive power of the 
model, by testing its capacity to discriminate between active and inactive compounds. 
By applying the same computational protocols as detailed in paragraph 3.2.8, a library of 130 
antagonists was made up by collecting potent compounds (nM activity) in literature. In detail, 74 
sulfonylaminophenyl derivatives coming from the work of Kim and co-workers312 were jointed to 
56 2-thio pyridine propanamides analogues from the work of Ha and co-workers 313. 
The resulting 130 molecules were dispersed among 12870 inactive molecules, which also in this 
case were taken from the inactive ligands of the previously described HTS study on TRPM8, 
obtaining a 13000 compounds set with the percentage of active molecules corresponding to 1 %. 
Once again, in order not to bias the results, putative decoys were selected if they fulfilled several 
physicochemical property ranges, which were determined by analysing the active compounds.  
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For the sake of completeness and while best results in previous docking simulations were obtained 
when using PLP score function, docking calculations were performed by PLANTS program, 
involving all three implemented scoring functions and their related normalized values. 
Moreover, in order to focus the obtained poses only on the best performing BM1, docking 
calculations were addressed in a 8Å radius sphere around the centroid defined by the Cα atoms of 
the key residues Tyr511 and Ser512. Such a sphere is large enough to encompass the entire BM1 
region but not to involve the upper region around Thr550.  
Table 6.5 reports all computed EF values and clearly shows that PLP scoring function, and in 
particular, the Total score affords the best result (Table 6.6). More importantly, the performed 
virtual screening campaign proved successful as clearly evincible from the histogram plot (Figure 
6.3) as well as from the very high EF values as obtained in the lowest thresholds (Top 1% and 2%) 
which indicate that such a screening strategy can be conveniently utilized also in the really 
challenging early recognition. 
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CHEMPLP Total score ScoreRotors ScoreHA ScoreMW 
1 6.15 3.07 1.53 0.76 
2 5.38 1.53 1.53 0.76 
5 4.30 2.92 2.61 1.38 
10 2.92 2.69 2.00 2.15 
20 2.46 2.19 1.76 1.50 
     
PLP Total score ScoreRotors ScoreHA ScoreMW 
1 12.30 8.46 3.84 9.23 
2 9.61 5.76 4.23 6.53 
5 6.30 4.00 3.84 4.61 
10 5.69 4.15 3.23 5.00 
20 3.69 3.07 2.15 3.26 
     
PLP95 Total score ScoreRotors ScoreHA ScoreMW 
1 10.7 7.69 3.07 3.84 
2 8.07 5.38 2.30 2.69 
5 7.23 5.35 4.15 2.92 
10 3.84 5.00 3.15 2.84 
20 3.42 2.73 2.73 2.30 
 
 
Table 6.5 Virtual screening evaluation of model 8,molecules ranked per   
ChemPLP, PLP, PLP95 scoring function and their normalized values.  
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n (top %N) Cpds Act EF Sk 
1 130 16 (1.3) 12.30 
2 260 25 (2.6) 9.61 
5 650 41 (6.5) 6.30 
10 1300 74 (13) 5.69 
20 2600 96 (26) 3.69 
3.2 
 
 
Table 6.6 Detail of the virtual screening evaluation on model 8,  
molecules are ranked per PLP Total score. 
 “Cpds” reports  the number of molecules hosted in the considered subset; “Act” stays for the  
actives compared to the expected one in parenthesis; EF reports the Enrichment factor values; 
“Sk” the Skewness value of the entire distribution. 
 
 
 
 
 
Figure 6.3 Virtual screening on model 8, molecules ranked per PLP Total score. 
The  histogram plot reports the number of actives per cluster, each cluster contains 130 cpds. 
 
 
Finally and to further support the here adopted filtering strategy to select the homology model by 
which the docking simulations are carried out, virtual screening calculations were also performed 
with the same settings on model 3 and 10 as well. The simulations were performed applying the 
same computational procedures as previously described for the selected model even though only the 
best performing PLP scoring function was utilized.  
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Table 6.7 compiles the EF values obtained with total scores and relative normalized values and 
reveals that Model10 affords relevant results even though however worse than those provided by 
the best model, and once again best EFs values are generated by the Total score. Differently, Model 
3, while still enriching the set, never reached EF values higher than 4. Overall, these last results 
emphasize that the selected best model is the best performing one, thus confirming the reliability of 
the here described selection strategy. 
 
 
 
Model 3 Total score ScoreRotors ScoreHA ScoreMW 
1 3.07 1.53 0.76 1.53 
2 2.60 0.76 0.76 0.76 
5 2.61 2.46 1.38 1.07 
10 2.92 1.76 1.46 2.84 
20 2.23 1.84 1.65 2.57 
     
Model 10 Total score ScoreRotors ScoreHA ScoreMW 
1 7.69 3.07 1.53 3.07 
2 6.15 1.53 2.30 2.69 
5 4.46 2.76 2.00 3.23 
10 4.46 2.92 2.84 3.23 
20 3.04 2.23 1.69 2.30 
 
 
 
Table 6.7 Virtual screening evaluation  of model 1 and 3, molecules ranked per PLP scoring 
function and its weightings. EF reported are calculated in the top 1, 2, 5, 10 and 20 % of the set. 
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Conclusions 
 
Even though the present Thesis involves four similar but rather unconnected case studies and some 
specific conclusions are already reported at the end of each chapter, the reported results allow for 
some relevant general considerations. Firstly, the homology modeling by fragments, which was 
initially developed to support the generation of “problematic” GPCR models, has now leaved the 
GPCR world, where the reasonable richness of resolved structures allows reliable models to be 
generated for most GPCRs, and offers its notable potentialities to the modeling of clearly more 
complicated ion-channels. Specifically, the here reported results afford convincing confirmations 
that such an approach can be conveniently exploited to model complex transmembrane proteins 
provided that an even far protein with the same topology has been resolved to assist the final 
assembly. By this way, it is possible to properly account for the local homologies while fulfilling 
the overall folding imposed by the final template and while avoiding to generate models which are 
forcedly constrained to comply to the structure of the available template. The here reported results 
provide further remarkable confirmations for the reliability of the already modeled (and exploited) 
TRPM8 model, while the here generated TRPM5 and TRPV4 models afford results (despite 
obtained in a validating preliminary phase) in line with those of TRPM8 further emphasizing the 
reliability of the fragmental approach. Not to mention that the described targeted strategy to model 
TRPV1 suggests that previously generated homology models can be then exploited to assist the 
modeling of highly homologous proteins still obtaining encouraging results but with a significant 
saving of the required computational efforts. 
The second consideration involves the character of the described computational studies. While 
avoiding dangerous oversimplified scenarios, the computational studies can be roughly subdivided 
into two groups. In the first ones, the simulations involve a restricted number of compounds which 
are deeply analyzed by using really sophisticated and time demanding computational strategy which 
are able to produce a rich arsenal of information concerning not only the predicted activity but also 
the kinetic profile and the mechanism of action. Such a wealth of data can be used to rationally 
optimize new ligands and to delve the specific factors influencing the biological profile. These 
studies are rarely amenable for large libraries and typically performed within academic 
environments. The second group includes industrial driven projects which usually involve very 
huge databases of compounds which are analyzed often using ligand-based chemoinformatics 
methods. Such in silico approaches imply a set of reasonable and necessary approximations which 
  
 
 
 
159
permits to conveniently deals with the large data involved. Clearly, the results which can be derived 
by these simplified strategies are less informative and basically allow the discrimination between 
active and inactive compounds, a kind of result which represent the major goal of a virtual 
screening campaign. While conducted in an academic environment, the here presented studies 
substantially belong to the second group since they were aimed at developing homology models and 
computational strategy amenable for virtual screening analyses of huge libraries of compounds. 
Nevertheless, they were designed and performed with a view to pursuing an acceptable compromise 
in which introduced approximations and exhaustiveness of structure-based simulations are 
modulated to yield reliable results with a still bearable computational effort. While requiring further 
confirmations the results obtained for TRPM5, TRPV1 and TRPV4 emphasize that it is possible to 
reach convenient compromises by which the unavoidably introduced approximations does not 
undermine the predictive power of the obtained models.  
In this regard, one may clearly understand the attempt, here performed in some cases, to compare 
and combine structure-based and ligand-based strategies for virtual screening campaigns. As 
detailed in Chapter 3, virtual screening studies are assisting to the historic duel between structure-
based and ligand-based approaches even though more recent trends tend to synergistically combine 
the two methods. The results obtained by the TRPM8 simulations emphasize the remarkable 
potentialities in combining more different methods to generate improved enrichment factors. 
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